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ABSTRACT 
 
Immunotherapy for renal cell carcinoma (RCC) has yielded some clinical responses. 
However this approach frequently fails, possibly due to inefficient migration of T-cells to 
tumour tissue or immunosuppressive mechanisms within the tumour environment. To 
aid development of T-cell therapy for RCC I investigated how T-cells are recruited to this 
tumour, which T-cell subsets infiltrate, and how they function.  
Analysis of the expression of all 19 chemokine receptors on matched TIL and PBMC 
demonstrated that CCR5, CXCR3 and CXCR6 were expressed at significantly higher levels 
on tumour-infiltrating T-cells than memory T-cells in PBMC, suggesting a role for these 
receptors in recruitment to RCC. Immunohistochemistry showed the corresponding 
ligands were present in RCC, and transwell assays confirmed the ligands induce 
migration of TIL. I demonstrated Foxp3+CD25hiCD127low Tregs were enriched within the 
tumour, and also expressed high levels of CCR5, CXCR3 and CXCR6, as well as CCR6. 
They lacked expression of IL-2 and IFN-γ post-stimulation, consistent with a regulatory 
phenotype. Functional characterisation of Foxp3- TIL demonstrated they can function ex 
vivo, however their high expression of the inhibitory molecule PD-1 may indicate 
exhaustion in vivo. Double positive CD4+CD8+ T-cells were also enriched in TIL and had a 
similar functional profile to CD8 T-cells. 
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1. Introduction 
The aims of this work are to investigate the phenotype and function of T cells infiltrating 
renal cell carcinoma (RCC), and to determine their mechanism of homing to the tumour 
site. The introduction will therefore begin by introducing RCC and discussing both 
current treatments and the need for better therapies for advanced stage disease. It will 
address the possibility of using the immune system, particularly T cell-based therapies, 
to treat RCC. A pre-requisite for effective treatment of tumours by T cells is their ability 
to home to the tumour site, therefore there will also be review of the mechanism by 
which T cells are recruited to different tissues, and the current understanding of T cell 
homing to cancers. 
 
1.1. Renal cell carcinoma 
In the UK kidney cancer is the 8th most common cancer in men and the 9th most common 
in women, and accounts for over 2% of deaths from cancer (Cancer Research UK 2008). 
90% of kidney malignancies are renal cell carcinomas, which originate from the renal 
parenchyma (made up of the cortex and medulla) (Figure 1) (Chow et al. 2010). Due to 
the preponderance of renal cancers being RCCs, this study focuses on this cancer type. 
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Figure 1: The kidney 
RCC arises in the renal parenchyma, which is made up of the cortex and the medulla. 
Picture taken from CancerStats Report – Kidney Cancer UK (Cancer Research UK 2008) 
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1.1.1. Pathology 
Malignant RCC can be divided into subtypes based on histology. The subtypes differ in 
prognosis and disease progression, and diagnosis of the subtype can inform treatment 
choices. Clear cell RCC (ccRCC) is the most common form of the disease, accounting for 
75% of RCC cases. It arises from the proximal tubules of the kidney and is characterised 
by cells with clear cytoplasm. The next most common subtype is papillary RCC, 
accounting for 10% of cases. Papillary RCC itself is sub-classified into Type I and Type II, 
the latter of which is associated with more aggressive disease and a worse patient 
outcome. 5% of RCCs are of the chromophobe type, which along with papillary type I 
have a better prognosis than ccRCC. Collecting duct RCC is rare and accounts for 1% of 
cases and carries a poor prognosis. The remaining cases consist of unclassified tumours 
and very rare subtypes: Xp11 translocation RCC, medullary carcinoma, RCC associated 
with neuroblastoma and mucinous, tubular and spindle cell carcinoma (Lopez-Beltran et 
al. 2006). 
 
The staging of RCC tumours is classified using the TNM system, with T1-4 describing the 
size and spread of the primary tumour, N0-2 describing the number of regional lymph 
nodes involved and M0-1 detailing whether there are distant metastasis (Greene et al. 
2011). Metastases are most common in the lung, followed by bone, liver and brain 
(Ritchie and Chisholm 1983). Fuhrman grading is also used as a description of the size 
and irregularity of the nucleus and the nucleolar prominence, and is a good predictor of 
prognosis (Fuhrman et al. 1982). 
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According to the British Association of Urological Surgeons (BAUS), in 2009 39.2% of 
patients were diagnosed at stage T1, 15.5% at T2, 27.3% at T3 and 17.5% at T4 (Fowler 
2010). Survival rate is linked to the stage of the tumour, with patients diagnosed with 
stage one having a 75% 5-year survival rate, stage 2 a 63% survival rate, stage 3, 38% 
and stage 4, 11% (Guinan et al. 1995). 
 
1.1.2. Epidemiology 
In the UK kidney cancer accounts for 2-3% of all cancers diagnosed. Incidence varies 
worldwide, with Europeans and the North Americans more likely to have the disease, 
and lowest incidences of disease in Asians and South Americans. In all populations men 
are more likely to be diagnosed with RCC than women, with a male to female ratio of 
incidence of approximately 2:1 (Curado et al. 2011). 
 
In the late 20th century incidence of RCC was rising, but in recent years rates have 
plateaued and may be declining (Curado et al. 2011;Levi et al. 2008). This could, in part, 
be due to increased early detection of RCC while it is at a low grade, however survival 
rates for all stages of the disease are improving (Chow and Devesa 2008;Kane et al. 
2008). 
 
1.1.3. Aetiology 
There are a number of risk factors described for RCC. Smoking is one of the most 
studied, and male smokers in particular have an increased risk (50%) of developing RCC 
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(Hunt et al. 2005). Obesity is another clear risk factor, and is estimated to be a 
contributory factor in 30-40% of RCC cases in the USA and Europe (Calle and Kaaks 
2004). The relationship is dose-dependent, with the risk of RCC increasing in proportion 
to body mass index (Adams et al. 2008). 
 
A number of other risk factors have been suggested but have not been studied as 
thoroughly. Hypertension, renal disease, history of childbirth and occupational exposure 
to the chemical trichloroethylene have all been suggested to increase RCC incidence 
(Chow et al. 2010). The effect of diet has also been investigated with inconclusive 
results, however alcohol consumption has an inverse relationship with risk of 
developing the disease, with a 28% decreased risk in people consuming ≥ 15 grams of 
alcohol a day (Lee et al. 2007). 
 
There are also a number of hereditary genetic conditions that can predispose people to 
developing RCC, and these account for approximately 3% of cases (Verine et al. 2010). 
The most well studied of these genetic diseases is von Hippel-Lindau (VHL) disease 
which is estimated to affect approximately 1 in 36000 live births in the UK. It is an 
autosomal dominant disease associated with a mutation in the VHL gene (Maher et al. 
1991). As VHL is a tumour suppressor gene patients have an increased risk of 
developing various cancers, including ccRCC (Lonser et al. 2003). Up to 40% of patients 
develop RCC and it is thought the majority would go on to develop this tumour if they 
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did not first succumb to other complications (Levine et al. 1983;Maher et al. 1990;Malek 
et al. 1987).  
 
74 % of sporadic ccRCC cases also have loss of function of both VHL alleles, highlighting 
the importance of this gene in the disease pathology (Banks et al. 2006). VHL is part of a 
ubiquitin ligase complex that binds to hydroxylated hypoxia inducible factor α (HIFα) 
and targets it for degradation (Pugh and Ratcliffe 2003). HIFα is normally only active 
under hypoxic conditions, where it is stabilised as it is no longer hydroxylated. It can 
then translocate to the nucleus and induce transcription of genes for angiogenesis and 
cell growth and survival, for the chemokine CXCL12 and its receptor, and for pH control. 
It also induces genes that alter glucose metabolism resulting in the Warburg effect, 
which ultimately supports the generation of new cells (Semenza 2003;Struckmann et al. 
2008;Vander Heiden et al. 2009). If VHL is mutated HIFα is constitutively active 
resulting in pseudo-hypoxic conditions and inappropriate activation of angiogenic and 
cell proliferation pathways (Baldewijns et al. 2010;Semenza 2003), which promote 
tumour development. 
 
HIFα is involved in a complex signalling pathway with many upstream factors. Other 
genetic disorders associated with RCC such as Birt-Hogge-Dubé syndrome, hereditary 
leiomyoma RCC and hereditary paranglioma syndrome also alter other components of 
the same signalling pathway and also predispose sufferers to RCC, highlighting the 
7 
 
importance of the pathway in control of cell proliferation and tumour suppression 
(Baldewijns et al. 2010;Verine et al. 2010). 
 
1.1.4. Treatment 
1.1.4.1. Current 
Recommendations for treatment of RCC vary between countries. As the patients for this 
study were all treated in a UK NHS hospital, the following section focuses on guidelines 
given by the National Institute for Clinical Excellence (NICE) in the UK. 
 
Surgery (full or partial nephrectomy) is considered the best option for RCC, and studies 
on stage 1 patients show it results in a greater than 90% cure rate (Lattouf et al. 2009). 
Even in stage 4, metastatic patients, cytoreductive surgery is considered as it eases 
disease burden and can improve quality of life (Wood 2003). Other methods of reducing 
tumour size such as radiofrequency ablation and cryotherapy are occasionally used for 
early stage tumours, particularly if patients have multifocal or bilateral tumours, as 
there is a better preservation of nephron function with these techniques (Kunkle and 
Uzzo 2008). 
 
As RCC becomes more advanced, surgery is less likely to be curative and other treatment 
options are considered. Unfortunately chemotherapy has little efficacy in treating RCC 
(Yagoda et al. 1995) and so alternatives have been investigated. Immunotherapies using 
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interleukin-2 (IL-2) and interferon-α (IFN-α) have been used in the past, and although 
they have high toxicities and so were only indicated for use in fit patients, 10-20% of 
advanced RCC patients had a partial or complete response (Basso et al. 2009;Hutson 
2011;Oudard et al. 2007;Reeves and Liu 2009). In fact, to date IL-2 treatment is the only 
curative therapy reliably documented for RCC with multiple metastasis. However due to 
the high toxicities associated with these therapies, the tyrosine kinase inhibitor (TKI) 
sunitinib is increasingly being used as a first-line therapy for metastatic RCC (mRCC) 
(NICE 2009). 
 
Sunitinib targets vascular endothelial growth factor (VEGF) receptors and platelet 
derived growth factor (PDGF) receptors (Mendel et al. 2003), both of which are involved 
in pathways downstream of HIF activation (described earlier). Blockade of these 
receptors is thought to halt tumour growth by inhibiting the angiogenesis required for 
tumour cell survival. Sunitinib and another tyrosine kinase inhibitor (TKI), sorafenib, 
have also been shown to reduce the proportion of regulatory T cells (which correlate 
with a poor prognosis – see sections 1.3.6.3 and 1.4.3.2) in the peripheral blood and 
tumours of RCC patients (Adotevi et al. 2010;Desar et al. 2011), thereby potentially 
enhancing anti-tumour immunity. However eventually the tumour evolves to overcome 
this inhibition, as evidenced by the fact that patients on sunitinib eventually progress 
(Finke et al. 2011). Nevertheless it is one of the most successful treatments for mRCC, 
with a phase III trial showing improved response rate of 33% compared to 6% for IFN-α, 
and progression free survival of 11 months compared to 5 months (Faris and 
Michaelson 2010). 
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Recently a second TKI, pazoponib, has been recommended for use as a first-line therapy 
for RCC and its efficacy is currently being compared to sunitinib in a clinical trial (NICE 
2011). 
 
1.1.4.2. Future 
Due to the lack of curative therapy for late stage RCC much work is still being carried out 
on potential treatments.  
 
TKIs are a promising area of research and in addition to sunitinib, sorafenib (inhibitor of 
Raf, VEGF receptors, PDGF receptor β and the c-kit receptor) has been shown to have 
some efficacy in RCC (Escudier et al. 2009). Inhibitors to mTOR (which is upstream of 
VEGF) – temsirolimus and everolimus - have also shown some efficacy in RCC. A 
monoclonal antibody that affects the same pathway by neutralising VEGF, Bevacizumab, 
has also been investigated and appears to improve the length of progression free 
survival (Basso et al. 2009). 
 
Further preliminary studies looking at using TKIs as adjuvants or neoadjuvants to 
reduce tumour burden and improve survival have taken place with some success (Bex et 
al. 2009;Thomas et al. 2009;Wood and Margulis 2009), and ongoing trials are 
investigating this further (Sciarra et al. 2011).Combining therapies such as bevacuzimab 
and IFN-α (Escudier et al. 2007;Rini et al. 2008) or using TKIs as radiosensitisers 
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alongside radiotherapy (Taussky and Soulieres 2009) have also had modest success and 
may warrant further investigation. 
 
Other techniques being tested include high intensity frequency ultrasound (HIFU) for 
early stage patients (Caballero et al. 2010) but further study is required to determine its 
efficacy compared to existing treatments. 
 
Finally immunotherapies are the subject of much research and various clinical trials 
have been performed using a range of approaches. These will be discussed in section 
1.4.3, p41. 
 
1.2. The immune system 
The immune system has evolved from basic mechanisms of defence seen in plants and 
insects against pathogens, into a complex adaptive system in higher mammals capable 
not only of distinguishing between self and non-self, but also of recognising abnormal 
cells such as cancer. It is comprised of an array of specialised cells working in concert to 
protect against external and internal threats, and self-regulating to avoid inappropriate 
inflammation and tissue damage. 
 
The immune system can be divided into innate and adaptive immunity. This project 
focuses on T cells, which are a branch of the adaptive immune system. Other aspects of 
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immunity will be discussed briefly, however this introduction will focus on T cell 
immunity. 
 
1.2.1. Innate immune system 
The innate immune system represents the most ancient type of immunity. Organisms 
from plants to mammals share the ability to produce antimicrobial peptides (defensins) 
that can kill bacteria (Ganz 2003), and carry receptors that stimulate a reaction in 
response to detection of pathogens (Hoffmann et al. 1999). 
 
In humans the epithelium and mucus membranes offer a first line of defence against 
pathogens. However in case of a breach, macrophages patrol the body and destroy 
pathogens by phagocytosis (Aderem and Underhill 1999). Macrophages, along with 
other immune cells, are able to distinguish between self and non-self using pattern 
recognition receptors. One example of a class of pattern recognition receptor is the Toll-
like receptors (TLRs), which can trigger cytokine and chemokine release upon 
activation, thereby promoting inflammation at the site of infection and recruiting more 
innate cells such as neutrophils and dendritic cells (Kawai and Akira 2011).  
 
1.2.2. Adaptive 
A significant function of the innate system in humans is to activate a second branch of 
the immune system: adaptive immunity. Adaptive immunity alone is not sufficient to 
protect against pathogens as the initial response can take days, however it does provide 
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key advantages. After the first challenge by a particular pathogen, immunological 
memory is generated allowing a much more rapid secondary response if the same 
pathogen invades again, and rapid clearance of the danger. In addition the adaptive 
system allows very specific recognition, with each adaptive immune cell carrying an 
antigen receptor recognising a particular peptide. There is a vast repertoire of receptors, 
and this diversity allows recognition of pathogens that have evolved to evade the innate 
immune system by avoiding or hiding expression of conserved molecular patterns 
recognised by innate receptors. The greater specificity of the adaptive system also 
allows greater selectivity, and may be a key mechanism in gut immunity where it is 
advantageous to permit survival and growth of beneficial bacteria while concurrently 
patrolling for pathogenic organisms (Lee and Mazmanian 2010). 
 
The adaptive immune system consists of B and T lymphocytes that originate from the 
common lymphoid progenitor in the bone marrow. Each lymphocyte expresses one 
receptor specific for one antigen. When a naive lymphocyte recognises its antigen and 
receives appropriate stimulatory signals, it proliferates to create a clonal population. 
Once the danger has been resolved, a small proportion of the clonal cells, so-called 
‘memory’ lymphocytes are maintained in case of re-infection. 
 
1.2.2.1. B cells 
B cells recognise antigen using a surface bound immunoglobulin protein, and function to 
kill extracellular pathogens. They do this by releasing soluble immunoglobulin (known 
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as antibodies) upon activation, of the same specificity to their surface receptor. 
Antibodies are then able to bind to the pathogens and either neutralise their function or 
opsonise them for ingestion by phagocytes. Bound antibodies can also act as a receptor 
for the first protein of the complement system with subsequent activation of the 
complement cascade that can lead to destruction of the pathogen.  
 
1.2.2.2. NK and NKT cells 
Natural killer (NK) cells recognise cells under physiological stress (for example infected 
cells or tumour cells) and kill them by releasing cytotoxic granules and producing 
cytokines upon activation. NK cells can be activated by stimulation via their activating 
receptors or by failing to receive signals through their inhibitory receptors (Hamerman 
et al. 2005). NKs are normally described as innate immune cells, however recent 
evidence has shown they have some features of adaptive immunity, including the ability 
to persist after stimulation and display enhanced function upon re-challenge (Vivier et 
al. 2011). 
 
NKT cells are lymphocytes that express both NK receptors and an αβ T cell receptor 
(TCR). However, unlike T cells, NKTs have a very restricted TCR repertoire, all of which 
recognise lipids presented by the MHC-like molecule CD1d. They are able to activate DCs 
and rapidly release cytokines upon stimulation, which in turn influence and regulate the 
type of T cell response that occurs (Godfrey and Kronenberg 2004). 
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1.3. T cells 
 
1.3.1. Introduction 
In contrast to B cells, T cells migrate to the thymus where they mature and undergo 
selection processes to ensure they are capable of recognising self-major 
histocompatability complex (MHC) molecules and do not respond strongly to self-
antigens (Klein et al. 2009). B cells, on the other hand, remain in the bone marrow, 
which is where pro-B cells develop into immature B cells by completing initial 
immunoglobulin gene (VDJ) rearrangement to form and express complete IgM 
molecules, before migrating to peripheral lymphoid organs where they mature into 
naive B cells that express both IgD and IgM. In common with B cells, T cells also have cell 
surface antigen receptors, known as T cell receptors (TCRs). The majority of T cells carry 
TCRs with α and β chains, and they recognise peptides bound to MHC molecules. All T 
cells also express the CD3 complex, which is associated with the TCR and is required for 
TCR expression and signalling (Reinherz et al. 1982). Most T cells also express either the 
CD4 or CD8 co-receptor, which associate on the T-cell surface with the TCR and bind to 
invariant sites on the MHC molecule that is presenting the antigen ligand, thereby 
improving the strength of the interaction and the T cell response (Ledbetter et al. 1981). 
T cells are known as either CD8 or CD4 T cells, accordingly.  
 
T cell gene rearrangement occurs in the thymus. The β chain (in common with the 
immunoglobulin heavy chain) is encoded by three gene segments: the variable (V) 
segments, the joining (J) segments and the diversity (D) segments (Davis 1990). The α 
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chain (in common with the immunoglobulin light chain) is encoded by V and J segments. 
Initially the β chain rearranges (Saint-Ruf et al. 1994), firstly, by D to J gene segment 
rearrangement, followed by V to DJ rearrangement. It is then expressed alongside a 
surrogate α chain and CD3 (Mallick et al. 1993). At this stage CD4 and CD8 are both 
expressed (Petrie et al. 1990). β gene rearrangement then stops and the α gene is 
rearranged by V to J rearrangement. α gene rearrangement and expression continues 
until a successful αβ TCR is produced which survives positive selection in the thymus 
(Petrie et al. 1993). T cells then lose either CD4 or CD8 before undergoing negative 
selection, which ensures T cells don’t recognise self-antigens strongly. T cells are then 
able to enter the circulation. 
 
The repertoire of different αβ TCRs is vast as the variable (V) regions of the TCR are 
encoded in the genome in segments, and undergo gene rearrangement in order to form a 
complete coding sequence. There are multiple copies of the V gene segments for both 
the α and β chains, and variation can also arise at the junctions between gene segments 
and from different pairings between the α and β chains to make a complete TCR. This 
results in a potential diversity of up to 1015 different TCRs (Davis 1990). 
 
 
1.3.2. The major histocompatability complex 
The MHC, also known as human leukocyte antigen (HLA) in humans, plays a key role in 
antigen presentation. Prior to presentation antigen processing must occur, whereby 
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protein antigens are degraded into short peptide fragments that then bind to MHC 
molecules for subsequent presentation on the cell surface and interaction with specific 
TCRs. 
 
In order to prevent pathogens evolving so that the MHC is unable to present peptides 
derived from their proteins, the MHC complex has itself evolved to be both polygenic 
and polymorphic. Everyone inherits multiple MHC class I genes (HLA-A, B and C) and 
MHC class II genes (HLA-DR, DP and DQ), which bind peptides differentially. In addition, 
within the human population there are hundreds of different alleles for each gene, 
resulting in huge variation in the exact MHC molecules, and therefore exact peptide 
binding specificities, within the population (Horton et al. 2004). 
 
There are two classes of MHC molecules, MHC I and MHC II, which bind different 
peptides and are specialised for presenting peptides to different subsets of T cells. 
 
1.3.2.1. MHC I antigen processing 
MHC I molecules are expressed by every nucleated cell. They bind peptides of 8-10 
amino acids in length and present them to a subset of T cells known as CD8 T cells. They 
bind peptides derived from proteins synthesised within the cell, which will include those 
from intracellular pathogens such as viruses, allowing killing of the infected cells upon 
recognition by T cells (Falk et al. 1990;Rotzschke et al. 1990). Proteins generated in the 
cytoplasm are degraded into peptides by the proteosome, before being transported into 
17 
 
the endoplasmic reticulum (ER) by transporter associated with antigen processing 
(TAP) proteins. MHC I proteins are formed in the ER, and only complete their folding 
upon binding of a peptide. They are then transported to the cell surface (Rock et al. 
1994;Townsend et al. 1989;Townsend and Trowsdale 1993;Yewdell and Bennink 1989). 
 
1.3.2.2. MHC II antigen processing 
MHC II molecules bind longer peptides and are recognised by the CD4 subset of T cells. 
They are expressed primarily by cells of the immune system, but their expression can be 
induced in other cell types, including tumours (Steimle et al. 1994). They bind peptides 
generated from extracellular proteins, or proteins within intracellular vesicles of cells 
(Rudensky et al. 1991). They are therefore important in presentation of bacterial 
antigens. Extracellular proteins are taken up into the cell by endocytosis, into vesicles 
called endosomes. These endosomes then fuse with lysosomes. The proteins are 
gradually degraded into peptides by enzymes. MHC II is released from the ER and is 
transported to the endocytic vesicles, during which time the peptide binding groove is 
occupied by a protein called invariant chain (Ii). Once inside a new type of vesicle is 
formed, with both endosomal and lysosomal characteristics, known as the MHC class II 
compartment (MIIC) (Calafat et al. 1994). Within the MIIC Ii is cleaved to leave a small 
fragment — class II associated invariant chain peptide (CLIP) bound to the MHC 
molecule. HLA-DM, a protein closely related to the other MHC II molecules, then 
catalyses the release of CLIP and the binding of other peptides to the MHC II molecule 
(Denzin and Cresswell 1995;Roche and Cresswell 1991). 
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1.3.2.3. Cross-presentation 
Proteins can be released from one cell and taken up by neighbouring cells through 
endocytosis, thereby entering the MHC II antigen processing pathway and being 
presented on MHC II molecules. Less obviously, such extracellular proteins enter the 
MHC I pathway. Dendritic cells (DCs) (see section 1.3.3.1, p19) are important in 
initiating a CD8 T cell response as they present co-stimulatory molecules required to 
correctly activate the T cells. Therefore if a virus does not infect DCs, or if CD8 T cell 
immune recognition is required of protein signatures from other threats (e.g. cancer), 
DCs need to have a mechanism to take up the proteins and present them on MHC I. 
Normally endocytosed proteins do not enter the MHC I pathway to avoid killing of 
bystander cells which may have taken up viral particles when an infected cell was killed, 
but certain DC subsets are able to perform this function by fusing phagosomes with the 
ER and hence bringing together TAP and MHC I molecules with exogenous peptides 
(Guermonprez et al. 2003). 
 
1.3.3. Antigen presenting cells 
While many cells can express MHC I and MHC II, in order to activate a naive T cell 
expression of co-stimulatory molecules that bind the CD28 receptor on T cells, namely 
CD80 and CD86, is required by the cell presenting antigen at the point of TCR:MHC 
interaction. Macrophages and B cells can both act as professional antigen presenting 
cells (APCs) and are able to up-regulate co-stimulatory molecules upon stimulation 
(Janeway, Jr. 1992). In fact the B cell immunoglobulin receptor enhances uptake of 
antigen and subsequent presentation on the B cell’s MHC molecules, meaning that even 
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at low concentrations of antigen, if an antigen-specific B cell is present T cells can be 
activated (Lanzavecchia 1985). 
 
However, mature dendritic cells are the most effective APC and constitutively express 
co-stimulatory molecules once they have matured (Heufler et al. 1988;Inaba et al. 1990). 
 
 
1.3.3.1. Dendritic cells 
Immature DCs migrate to peripheral tissues where they patrol the site by taking up 
pathogens by phagocytosis and extracellular fluid by macropinocytosis (Sallusto et al. 
1995). If the immature DC encounters a danger signal, for example by ligation of a TLR, 
it matures, up-regulating chemokine receptors for migration to the lymph nodes (Dieu et 
al. 1998), increasing expression of MHC molecules (Cella et al. 1997) and up-regulating 
co-stimulatory B7 molecules (CD80 and CD86) (Caux et al. 1994;Rescigno et al. 1998). 
Once in the lymph node they produce the chemokine CCL18 to attract naive T cells and 
prime the antigen specific T cells to differentiate into the appropriate subset of effector 
T cell (Adema et al. 1997;Liu and MacPherson 1993). However, the receptors for this 
chemokine are not known (Chang et al. 2010;Schutyser et al. 2005).  If an immature DC 
does not encounter a danger signal, or is exposed to IL-10, it will still home to the lymph 
node at the end of its lifespan, where it will present antigen in the absence of co-
stimulatory molecules, thereby inducing anergy in CD8 T cells and a an anergic or 
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regulatory T cell (Treg) phenotype in CD4 T cells (Jonuleit et al. 2000;Steinbrink et al. 
1999) (Figure 2). 
 
1.3.4. T cell signalling 
When a T cell recognises an MHC:ligand complex, CD4 or CD8 associate with the TCR 
resulting in a signalling cascade that, through the successive phosphorylation of 
immunoreceptor tyrosine-based activation motifs (ITAMs) and Zap-70, activates the 
phospholipase C (PLC) pathway (Denny et al. 2000;Visco et al. 2000). This results in an 
increase in intracellular calcium concentration, which in turn activates the transcription 
factor NFAT. It also causes the activation of protein kinase C, which activates the 
transcription factor NFκB (Jordan et al. 2003). Finally a MAP kinase pathway is initiated 
that activates Fos, a component of the transcription factor AP-1. However, in the absence 
of a co-stimulatory signal from a DC, AP-1 will not be fully formed, and IL-2 expression 
will not occur (Jain et al. 1992). Signalling through CD28, the receptor for the B7 co-
stimulatory molecules, is required for the induction of a second MAP kinase pathway 
that activates Jun, the other component of AP-1 (Kempiak et al. 1999). The three 
transcription factors then translocate to the nucleus where they activate transcription of 
genes for cell proliferation and differentiation. 
 
The cell surface molecule CD45 is also involved in the signalling pathway as it de-
phosphorylates the inhibitory tyrosine residues on Lck and Fyn (the Src tyrosine 
kinases) that are constitutively phosphorylated in naive T cells (Cahir McFarland et al. 
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1993). This allows them to become activated and phosophorylate ITAMs, initiating the T 
cell signalling cascade. 
 
CD45 itself has different isoforms as a result of alternative splicing, and these isoforms 
are differentially expressed depending on the stage of T cell differentiation (Trowbridge 
and Thomas 1994). Naive T cells express the CD45RA isoform, whereas effector or 
memory T cells lose CD45RA expression and gain CD45RO (Akbar et al. 1988). However 
some T cells regain CD45RA expression when they reach a late stage of differentiation, 
and are designated EMRA (effector memory RA) T cells (Di et al. 2011). 
 
 
1.3.5. T cell differentiation 
Once a naive T cell has encountered its antigen it differentiates into an effector T cell. 
After the initial immune response, a small proportion of these cells resist apoptosis and 
persist as either effector memory (TEM), CD8+ effector memory RA T cells (TEMRA) or 
central memory (TCM) T cells. These can be distinguished by their phenotype, as TCMs 
express the lymph node homing receptor CCR7, which is absent on TEMs. TEMs patrol 
peripheral tissues and are able to function immediately upon antigen recognition, 
whereas TCMs sample the lymphoid environment and differentiate into effect cells upon 
stimulation (Sallusto et al. 1999). TCMs have the greatest proliferative potential, followed 
by TEMs and finally TEMRAs (Geginat et al. 2003). 
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It is unclear whether all effector T cells have the capacity to develop into memory T cells, 
or if just a subset are capable of doing so. Single naive T cells have been demonstrated to 
have the capacity to produce both effector and memory T cell progeny; therefore T cell 
fate is not decided prior to their first division (Stemberger et al. 2007). However it is 
unclear at what stage after their first division T cell fate is determined (Gerlach et al. 
2011). 
 
1.3.6. T cell subsets 
1.3.6.1. CD8 T cells 
CD8 T cells, often referred to as cytotoxic T lymphocytes (CTLs), recognise peptides 
bound to MHC I via their TCR. Their main function is to recognise virally infected cells, 
and as such upon binding of the TCR to the MHC complex, they initiate killing of the 
infected cell. This mechanism of direct killing means they may also be of use in fighting 
cancer. 
 
CD8 T cells function by releasing cytotoxic granules upon stimulation. These granules 
contain perforin, which forms pores in the target cell membrane, and granzyme, which is 
a trypsin protease that enters the target cell through the perforin pores and induces 
apoptosis (Heusel et al. 1994;Kagi et al. 1994). In addition activated CD8 T cells express 
Fas ligand, which binds the Fas receptor expressed on the target cells, thereby inducing 
apoptosis (Rouvier et al. 1993). Upon activation CD8 T cells also produce the effector 
cytokines interferon-γ (IFN-γ), and tumour necrosis factors (TNF), which activate 
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macrophages, up-regulate MHC molecules and promote T cell survival and proliferation 
(Barber et al. 2006;Kasahara et al. 1983). 
 
1.3.6.2.  CD4 T cells 
CD4 T cells are also known as T helper cells, as their principal function is to activate and 
promote the responses of other immune cells. Naive CD4 T cells differentiate into 
different functional subsets. The two major effector subsets are designated Th1 and Th2. 
Regulation of differentiation into either the Th1 or Th2 subset is dependent on both the 
antigen dose (Rogers and Croft 1999) and the cytokines present (Figure 2). Production of 
IL-12 or the type 1 interferons induces a Th1 phenotype by activating the transcription 
factor STAT4 (Cho et al. 1996;Manetti et al. 1993). This induces the expression of IFN-γ, 
which stabilises the phenotype by inducing expression of the transcription factor T-bet, 
which up-regulates the IL-12 receptor and IFN-γ production (Lighvani et al. 2001). Th2 
differentiation, on the other hand, is regulated by IL-4, which induces expression of 
STAT6 (Zhu et al. 2001), which in turn up-regulates the transcription factor GATA-3. 
GATA-3 down-regulates IFN-γ and up-regulates IL-4, thereby inducing a Th2 phenotype 
(Ferber et al. 1999).  
 
Th1 T cells activate macrophages through their expression of CD40 ligand or TNFα, to 
initiate fusing of their intracellular phagosomes with lysosomes. This is crucial in the 
case of infection of vesicles with bacteria, and results in the pathogens’ destruction. Th1s 
also produce the effector cytokines IL-2 and IFN-γ, which augment the CD8 T cell 
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response by promoting their activation and up-regulating MHC I expression on APCs. In 
common with CD8 T cells, some CD4 T cells also express Fas ligand. Th1s can also 
activate some B cells to produce opsonising antibodies (Abbas et al. 1996;Mosmann and 
Coffman 1989).  
 
Th2 cells produce IL-4 and in common with Th1 cells, function to activate B cells (Abbas 
et al. 1996;Mosmann & Coffman 1989). B cell activation by Th2 cells results in B cell 
production of neutralising antibodies and defence against extracellular pathogens. 
 
Due to their ability to promote a cytotoxic T cell response, Th1 T cells are considered to 
me more beneficial than Th2s in tumour immunity. 
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Figure 2: Naive CD4 T cells differentiate into different functional subsets 
Immature DCs migrate to tissues where they sample the local environment, before homing to lymph nodes. If the DCs do not encounter a danger 
signal within the peripheral tissue, or if they are exposed to inhibitory cytokines such as IL-10, they do not up-regulate co-stimulatory molecules, and 
will induce a regulatory or anergic phenotype in the T cells they subsequently interact with in the lymph node. 
If a DC does encounter a danger signal in the tissue it will up-regulate the co-stimulatory B7 molecules CD80 and CD86, which enable them to 
activate T cells to become effector cells. CD4 T cells will then differentiate into Th1, Th2 or Th17 T cells, depending on the cytokines and antigen dose 
present at the time of stimulation.  
The transcription factors and cytokines expressed differ between these subsets and regulate their function. 
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1.3.6.3. Regulatory T cells 
Regulatory T cells (Tregs) are a third subset of CD4 T cells. In humans Tregs can either 
arise in the thymus (natural, or nTregs), or be induced from peripheral naive CD4 T cells 
in response to transforming growth factor β (TGF-β) signalling (iTregs) (Chen et al. 
2003;Qin et al. 1993;Sakaguchi et al. 2008). nTregs are selected for in the thymus by 
their recognition of self-antigen, but instead of being deleted are directed down a 
separate differentiation pathway so they become regulatory (Jordan et al. 2001).  
 
Tregs can suppress CD8 and CD4 T cell proliferation and function, preventing 
inappropriate immune responses which would otherwise cause autoimmune disease 
such as rheumatoid arthritis (Behrens et al. 2007;Sakaguchi et al. 1995) and colitis 
(Sakaguchi et al. 1995;Takahashi et al. 2006). However, immunosuppressive activity 
may also affect anti-tumour T cell responses in cancer patients (Fujimoto et al. 1975). 
 
Defining Tregs 
The ‘classic’ Tregs, nTregs and iTregs, are now defined as CD4+CD25+CD127lowFoxP3+ 
cells (Griffiths et al. 2007;Liu et al. 2006). Early studies on Tregs often used the 
CD4+CD25hi phenotype as a marker of Tregs, as this does not require intracellular 
staining, and these cells have been shown to be functional in suppressing CD4+ T cell 
proliferation in response to stimulation by antibodies to CD3 and CD28 (Cesana et al. 
2006;Dannull et al. 2005). However, CD25 is also upregulated on effector T cells after 
activation, (Ortega et al. 1984) which means additional markers are required for more 
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accurate identification of Tregs. The Foxp3 transcription factor is critical for Treg 
development, and transduction of CD4+CD25- T cells with Foxp3 induces Treg 
phenotype and function (Fontenot et al. 2003;Hori et al. 2003). In addition, mutations in 
FOXP3 lead to autoimmune disease, as seen in immunodysregulation, 
polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) patients, indicating the 
vital role of Foxp3 expressing cells in immune regulation (van der Vliet and 
Nieuwenhuis 2007). Therefore it can be argued that Foxp3 is a better marker of Tregs 
than CD4+CD25hi. Nevertheless Foxp3 can also be transiently expressed on activated 
CD4 and CD8 cells so one cannot assume that every Foxp3+ T cell is a Treg (Ahmadzadeh 
et al. 2007;Gavin et al. 2006). CD127 expression is consistently low on Foxp3+ T cells 
and is useful as an additional marker, although it is transiently down-regulated upon T 
cell activation (Liu et al. 2006). Therefore the combination of the phenotypic markers 
CD4+CD25+ CD127lowFoxP3+, combined with functional studies, present the most 
accurate method of defining a Treg population. 
 
Other types of regulatory T cells have been identified and they may also have a role in 
cancer immunosuppression. T regulatory cells 1 (Tr1) cells have strong 
immunosuppressive properties, and can be induced in vitro through exposure to IL-10. 
However more recent studies suggest IL-27 is the main inducer of this T cell phenotype (Pot 
et al. 2009).Tr1s do not express Foxp3, and produce IL-10, TGF-β and IL-5, some IFN-γ 
and almost no IL-2 or IL-4 (Bacchetta et al. 1994;Groux et al. 1997;Roncarolo and 
Gregori 2008). They are important regulators of immunity and are thought to prevent 
autoimmune disease (Groux et al. 1997) and allergies (Akdis et al. 2004). Their 
29 
 
generation is promoted by squamous cell carcinoma of the head and neck tumours 
(Bergmann et al. 2008). In addition, some CD8 T cell subsets can have regulatory 
properties. CD8ααTCRαβ T cells can kill activated T cells in experimental autoimmune 
encephalitis and CD8+CD122+ regulate CD4 T cell mediated colitis through IL-10 
expression (Endharti et al. 2011;Tang et al. 2006). 
 
Function of classic Tregs 
As with effector T cells, Tregs must be activated through their TCR in order for them to 
carry out their suppressive function, however subsequently they can suppress not only 
cells of the same antigen specificity, but also cells specific for different antigens, by a 
mechanism known as bystander suppression (Karim et al. 2005;Masuyama et al. 
2002;Takahashi et al. 1998). The mechanism of Treg immune suppression is unclear, but 
is likely to be multifaceted.  
 
Tregs express high levels of the IL-2 receptor (CD25) and it has therefore been 
suggested they act as an IL-2 sink, depriving effector T cells of the IL-2 they require for 
function (Pandiyan et al. 2007). Furthermore, mice lacking a functional IL-2 receptor 
develop autoimmune disease (Suzuki et al. 1995;Willerford et al. 1995) and the genes 
for IL-2 and CD25 are regulated by Foxp3 itself (Wu et al. 2006), suggesting IL-2 and its 
receptor are vital for effective Treg function. However CD25 is not required for 
suppressive function of Tregs in vitro (Fontenot et al. 2005), although it is required for 
Treg survival and maintenance (Fontenot et al. 2005;Setoguchi et al. 2005).  
30 
 
As with the IL-2 receptor, cytotoxic T-lymphocyte antigen 4 (CTLA-4) is also controlled 
by the Foxp3 transcription factor and is upregulated when Foxp3 binds its target (Wu et 
al. 2006). It binds to CD80 and CD86, thereby competing with CD28 and reducing co-
stimulation. Its deficiency also causes autoimmune disease, improves anti-tumour 
immunity and decreases suppressive activity of Tregs (Wing et al. 2008). CTLA-4 
expression does not simply produce a negative signal affecting the T cell expressing it. 
Murine studies have shown that whereas a CTLA-4 knockout has lethal 
lymphoproliferative disease and disregulated immunity, a mouse with both CTLA-4 -/- 
and CTLA-4+/+ bone marrow will be completely normal (Bachmann et al. 1999). 
Therefore CTLA-4 regulates cells extrinsically, i.e. CTLA-4 expressed by one cell can 
affect its neighbours. It has recently been demonstrated that CTLA-4 can remove the co-
stimulatory molecules CD80 and CD86 from APCs by trans-endocytosis, thereby limiting 
their capacity to stimulate a T cell response (Qureshi et al. 2011). In addition, binding of 
CTLA4 to CD80 and CD86 on DCs has been shown to trigger tryptophan catabolism in 
these cells, which suppresses T cell proliferation (Munn et al. 2004). 
 
There is controversy over whether cell-cell contact is required for Treg mediated 
immune suppression. The majority of evidence suggests Tregs are incapable of 
suppressing CD4 T cell proliferation in vitro when separated from the proliferating cells 
by a semi-permeable transwell membrane, but need direct contact to exert their effect 
(Longhi et al. 2006;Sojka et al. 2008;Strauss et al. 2008;Zaiss et al. 2007). Mechanisms of 
action that require cell-cell contact include killing of target cells via granzyme and 
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perforin (Cao et al. 2007), and up-regulating cyclic AMP in target cells, which suppresses 
their proliferation and cytokine gene expression (Bopp et al. 2007). 
 
However, other studies indicate that Tregs have a definite, although lessened effect 
through a transwell (Gad et al. 2004;Longhi et al. 2006;Strauss et al. 2007). IL-10 and 
TGF-β have been proposed as soluble mediators of immune suppression. Tregs can 
secrete TGF-β and IL-10 and these can inhibit T cell function in inflammatory bowel 
disease and endothelial cell inflammation (Asseman et al. 2000;He et al. 2010;Read et al. 
2000). IL-10 does not appear to be required for immune suppression in every disease 
scenario (Suri-Payer and Cantor 2001), whereas knocking out TGF-β results in fatal 
autoimmune disease in mice (Marie et al. 2006). Studies in mice have identified a third 
cytokine, IL-35, that is highly expressed by Tregs and suppresses T cell proliferation in 
vitro and in vivo (Bardel et al. 2008;Collison et al. 2007). A recent study using human 
Tregs showed IL-35 was required in order for Tregs to reach their maximum level of 
suppression. Transwell assays also suggested the IL-35-mediated suppression was 
contact-independent (Chaturvedi et al. 2011). 
 
1.3.6.4.  Th17s  
Th17s are another subset of effector CD4 cells, which are characterised by their 
production of IL-17 and expression of the transcription factors RORγt and STAT3 (Chen 
et al. 2007). TGFβ and IL-6 are both required for Th17 differentiation, with IL-1β, TNF-α 
and IL-23 having roles in amplification and stabilisation of the cells (Bettelli et al. 
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2006;Veldhoen et al. 2006). Analogous to the relationship between Foxp3 and Tregs, 
expression of the transcription factor RORγt induces CD4 differentiation into Th17s 
(Ivanov et al. 2006). In fact, Th17s appear to arise from the same cell lineage as Tregs, 
and the differentiation of a CD4 T cell into a Treg or Th17 depends on the relative 
expression of the transcription factors Foxp3 and RORγt, and on the cytokines present. If 
TGF-β is present at low concentrations, it may upregulate the IL-23 receptor which in 
turn helps stabilise a Th17 phenotype. At high concentrations, TGF-β upregulates Foxp3, 
which in turn inihibits RORγt expression. However if pro-inflammatory cytokines such 
as IL-6 and IL-21 are also present, upregulation of Foxp3 by TGF-β will be reduced and a 
Th17 differentiation will become more likely (Zhou et al. 2008). The cells are pro-
inflammatory and provide defence against extracellular pathogens (Ye et al. 2001), 
although they also mediate autoimmune disease (Langrish et al. 2005). 
 
The contribution of Th17s to anti-tumour immunity is controversial. Th17s negatively 
correlate with Tregs, known to adversely affect prognosis (Bettelli et al. 2006). A study 
on mice has shown that transgenic CD4 T cells with Th17 bias were better at causing 
tumour regression than Th1 cells, although they also induced autoimmune disease 
(Muranski et al. 2008). A study on human ovarian carcinoma patients found Th17 
infiltration of the tumour to be negatively correlated with Treg infiltration and positively 
correlated with better prognosis, suggesting their function is anti- and not pro-tumour. 
The Th17 cells were associated with CXCL9 and CXCL10 expression and the study also 
suggested that the IL-17 and IFN-γ produced by Th17s were inducing production of 
these chemokines. CD8 T cells that infiltrate the tumour express CXCR3, the receptor for 
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these chemokines. Thus, production of CXCL9 and CXCL10 may be aiding recruitment of 
anti-tumour CD8 T cells (Kryczek et al. 2009a). Further study is required to determine 
whether Th17 infiltration of tumours always has positive consequences. 
 
 
 
1.4. Immunotherapy for Cancer 
Methods of harnessing the immune response in order to treat cancer were first used 
over a century ago, well before the interaction between the immune system and cancer 
was fully understood. Although the phenomenon of cancer regression coinciding with 
infection was first observed in the 1700s (Hoption Cann et al. 2002), it was William 
Coley who first refined a technique involving the injection of bacterial toxins as a 
therapy for tumours (Coley 1916).  
 
In recent years, immunotherapy has once again attracted much interest as a cancer 
treatment. It now appears that the immune system surveys the body for cancerous cells 
and often eliminates them before they are clinically apparent. However natural selection 
results in some tumour cells evolving mechanisms to evade the immune response. This 
is highlighted from studies in mice, where tumours grown in immune deficient mice are 
more immunogenic upon transplant into immunocompetent animals, as the tumours 
have not developed mechanisms to avoid detection and destruction by immune cells 
(Shankaran et al. 2001).  
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Research now focuses on boosting the immune system to overcome the tumour immune 
evasion mechanisms. Various strategies are being explored and these will be discussed 
below. If successful, research into immunotherapies could result in a treatment that 
would be specific for tumours, work systemically and provide long lasting protection 
against recurrence. 
1.4.1. Immunotherapy strategies 
1.4.1.1. Innate immunity 
As immune responses often commence with activation of the innate immune system, 
some therapies target TLRs to create a ‘danger signal’ to prompt a full immune response. 
Coley’s toxins are likely to have worked in this manner, and in modern medicine Bacillus 
Calmette Guérin (BCG), made with extracts from bacteria, is used to treat bladder cancer 
(Morales et al. 1976). One of the bacterial wall peptidoglycans in the vaccine has been 
shown to activate TLR2 and TLR4, which initiates the production of inflammatory 
cytokines, thereby encouraging activation and recruitment of immune cells (Tsuji et al. 
2000). 
 
1.4.1.2. Antibodies 
The innate immune system is also involved in antibody-based cancer therapies. 
Antibodies such as rituximab, which binds CD20 and is used to treat B cell non–
Hodgkin’s lymphoma and chronic lymphocytic leukaemia, and trastuzumab (Herceptin), 
which binds HER2/neu and is used in the treatment of breast cancer, are both thought to 
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work in part by opsonising cells for cytotoxic killing by NK cells, in a process called 
antibody-dependent cellular cytotoxicity (ADCC) (Barok et al. 2007;Beum et al. 
2008;Eischen et al. 1996). Rituximab can also activate the complement cascade to aid 
tumour cell killing (Cragg et al. 2003). 
 
Antibodies can also function by affecting cell signalling. Trastuzumab binding down-
regulates the HER-2 receptor (a member of the epidermal growth factor receptor 
(EGFR) family) thereby inhibiting signalling and subsequent tumour cell proliferation 
(Nahta et al. 2004). Alternatively, as in the case of Bevacizumab which binds VEGF, the 
antibody can act in a neutralising role by blocking interactions between receptors and 
ligands, that would otherwise signal for cell proliferation (Wang et al. 2004). 
 
1.4.2. T cell immunotherapy 
Another promising area of cancer immunotherapy is the utilisation of T cells. T cells 
have an advantage over antibodies because they recognise antigens derived from all 
cellular compartments (see sections 1.3.2.1-1.3.2.3) and are therefore not restricted to 
those antigens expressed on the cell surface. 
 
A variety of approaches have been tried to harness the power of T cells to fight cancer. 
One of the most successful treatments has been adoptive cell transfer (ACT). ACT using 
donor lymphocytes is successfully used in the clinic for chronic myeloid leukaemia 
(CML) patients who have relapsed following bone marrow transplant. However as 
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tumour-specific T cells are not isolated prior to transplant, graft-versus-host disease 
(GVHD) is a significant side effect (Collins, Jr. et al. 1997). ACT has also successfully been 
used to prevent and treat post-transplant lymphoproliferative disorder (PTLD). PTLD is 
caused when EBV, a virus which is normally asymptomatic and controlled by the 
immune system, is reactivated in bone marrow transplant patients, causing extreme 
lymphoproliferation. Infusion of EBV specific T cells derived from the donor and 
expanded in vitro, can effectively prevent and treat this disease (Rooney et al. 1998).  
 
ACT has also been used in solid tumours, with particular success amongst melanoma 
patients. In this case, tumour-specific T cells taken from resected malignant tissue were 
expanded in vitro before re-introducing them into the patient. Initial attempts achieved 
an objective response rate of 34% (Rosenberg et al. 1994). Further study has revealed 
that tumour infiltrating lymphocytes (TIL) that have been cultured for a shorter time 
and therefore are less differentiated, with longer telomeres, will persist longer in the 
patient and be more effective (Robbins et al. 2004;Rosenberg et al. 1994;Zhou et al. 
2005). In addition, conditioning patients with total body irradiation and/or 
chemotherapy to deplete their lymphocyte compartment increased response rates to up 
to 72%, by facilitating greater expansion of the infused cells in vivo and removing the 
regulatory T cells which otherwise hamper the response (Antony et al. 2005;Dudley et 
al. 2008). However there is significant toxicity associated with this combined therapy 
approach. Techniques currently being investigated to reduce the T cell differentiation 
status also promise to increase the response rate still further (Klebanoff et al. 2011). 
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In order to enhance T cell therapy further, genetic transfer of TCRs is being explored, 
where a high affinity TCR specific for a tumour antigen is cloned and transduced into 
patient T cells (Schmitt et al. 2009). Alternatively, where MHC restriction is a concern or 
MHC molecules have been down-regulated, patients T cells can be engineered to express 
a CAR (chimeric antigen receptor) which usually consist of a tumour-specific antibody 
fragment coupled to the CD3ζ chain (Thistlethwaite et al. 2005). 
 
Another approach to activate a T cell response is to use vaccines. These can be with 
tumour cells with an adjuvant to activate DCs which in turn stimulate a T cell response 
(Thompson and Dessureault 2007). Alternatively DCs themselves can be cultured ex vivo 
and pulsed with peptide for the tumour associated antigen (TAA), so they present this to 
T cells once re-introduced into the patient (Gilboa 2007). 
 
1.4.2.1. Tumour associated antigens 
In order for a TAA to be useful it needs to have certain features to ensure T cells will 
respond efficiently and specifically. Ideally TAAs should be derived from proteins that 
are only expressed by the tumour, vital to tumour cell survival (so tumours don’t evolve 
to evade an antigen specific T cell response), widely expressed in many patients’ 
tumours and not targeted by immunological tolerance. TAAs fall into five broad 
categories. Mutated self-proteins, such as BCR-ABL which is formed from a fusion 
protein made when chromosomes translocate in CML (Bocchia et al. 1996), are good 
targets as there should be no immune tolerance to them and they are only expressed in 
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the tumour cells. Over-expressed self-proteins, for example Her2 in breast cancer 
(Peoples et al. 1995), can be good targets, however T cell tolerance or expression on 
normal tissues can limit their usefulness. T cell tolerance can also be a problem when 
targeting lineage specific antigens, such as melanoma antigen recognised by T cells 1 
(MART-1), which is expressed in melanoma but also in melanocytes and the retina 
(Kawakami et al. 1994). Another class of TAA are aberrantly expressed self proteins, 
which are normally only expressed in immune-privileged sites such as the testes or 
placenta. RAGE and PRAME are cancer testes antigens which can also be expressed by 
tumours (Pellat-Deceunynck et al. 2000). 5T4 is an example of an oncofoetal antigen 
aberrantly expressed in some cancers (Griffiths et al. 2005). 
 
1.4.2.2. Tumour Immune evasion 
As they grow tumours evolve to evade and suppress the immune response. One way in 
which tumours can do this is by down-regulating MHC I expression, thereby hiding from 
T cell recognition. Loss of antigen processing machinery such as TAP also prevents 
antigen presentation by the tumour (Garcia-Lora et al. 2003). Tumours often express 
HLA-G in place of MHC I and II. HLA-G interacts with its ligand on NK cells, sending an 
inhibitory signal to prevent them killing the tumour cell (Lin et al. 2007;Tajima et al. 
2003). Tumours also frequently have a loss of co-stimulatory molecules, thereby causing 
T cell anergy (Tirapu et al. 2006). T cells are also inhibited by tumour overexpression of 
gangliosides (which are glycosphingolipids) as they inhibit T cell proliferation and APC 
function, and can promote apoptosis (Jales et al. 2011;McKallip et al. 1999).  
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The programmed death 1 (PD-1) protein is expressed by T cells upon activation, 
however if it then binds either of its ligands, PD-L1 or PD-L2, T cell function becomes 
impaired and T cells become anergised (Barber et al. 2006;Freeman et al. 
2000;Latchman et al. 2001). Various tumours express the PD-1 ligands (Wang et al. 
2011b). Mouse studies have shown blocking PD-1 and PD-L1 can improve responses to 
tumour vaccines (Sierro et al. 2011), and clinical trials using the anti-PD-1 antibody CT-
011 are currently underway.  
 
Tumours also recruit other cell types which alter the tumour microenvironment into 
one which is immunosuppressive. One example of these are myeloid derived suppressor 
cells (MDSCs). MDSCs are thought to suppress T cells through their release of nitric 
oxide and arginase-1 (Nagaraj and Gabrilovich 2008). Another cell type enriched in 
many tumours is the Treg, which will be discussed below. 
 
Tregs in cancer 
Regulatory T cells pose a particular problem in cancer immunity, partly because tumour 
associated antigens normally derive from abnormally or over-expressed host proteins, 
and Tregs specific for those antigens can often be found within the T cell repertoire 
(Bonertz et al. 2009;Zou 2006). Tregs specific for other TAAs can also be induced if 
conditions are tolerogenic. It has been proposed that Tregs have a negative effect in 
cancer patients by suppressing anti-tumour T cell responses (Antony et al. 2005;Curiel 
et al. 2004;Turk et al. 2004). Indeed, depleting Tregs has been shown to increase tumour 
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rejection in mice (Onizuka et al. 1999;Shimizu et al. 1999). Elevated levels of Tregs have 
been detected in various cancers, including in the blood of pancreatic and breast cancer 
(Liyanage et al. 2002), lung cancer (Karagoz et al. 2010) and liver cancer (Feng et al. 
2011) patients. Tregs have also been found in the TIL of breast, pancreatic (Liyanage et 
al. 2002), ovarian, colon, hepatic (Kryczek et al. 2009b) and gastric (Shen et al. 2010) 
cancer. Treg numbers are also higher in the TIL from patients with metastatic 
melanoma, compared to their peripheral blood (Jandus et al. 2008). Tregs from tumour 
draining lymph nodes in pancreatic cancer patients were able to suppress CD8 and 
CD4+CD25- T cell proliferation, and IFN-γ production in vitro (Liyanage et al. 2002). 
Tregs from ovarian carcinoma tumours have also been shown to suppress tumour-
specific T cell immunity in both in vitro experiments on human cells and an in vivo 
experiment using a mouse model (Curiel et al. 2004).  
 
There is also evidence that in certain cancer settings, Tregs may actually be beneficial. 
The presence of Tregs within colorectal tumours correlates with an improved prognosis 
(Salama et al. 2009), as does increased proportions of Tregs in Hodgkin’s lymphoma 
(Alvaro et al. 2005), follicular lymphoma (Carreras et al. 2006) and head and neck 
cancer (Badoual et al. 2006). It may be that in these cancers that the reduction of 
tumour-promoting inflammation by infiltrating Tregs may have a more significant effect 
than the suppression of tumour immunity by the same cells.  
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The precise mechanism of Treg enrichment in tumours is unclear. However it may be 
due to the chemokines produced by the tumour being complementary to chemokine 
receptors expressed on Tregs, thereby recruiting or retaining Tregs at the tumour site 
(Curiel et al. 2004;Ishida et al. 2006). In addition a Treg phenotype may be induced on 
effector CD4 cells due to exposure to TGF-β within the tumour tissue (Chen et al. 2003). 
Equally, Tregs may be better able to survive the tumour environment, for example it has 
been shown that Tregs have reduced sensitivity to oxidative stress, possibly due to 
greater expression of thiol groups (Mougiakakos et al. 2009). This resistance could 
explain the enrichment of Tregs at tumour sites where oxidative stress is prevalent. 
 
1.4.3.  Immunotherapy for renal cell carcinoma 
In common with melanoma, RCC has high levels of TIL which suggests it is an 
immunogenic tumour (Bex et al. 2010;Capitanio et al. 2009;Cohen and McGovern 
2005;Patard et al. 2003). In addition, 7% of patients with advanced disease can be cured 
by IL-2 therapy (Rosenberg 2007) and 10-20% respond to IL-2 or IFN-α 
immunotherapy treatments, which are thought to work by modulating the immune 
system in favour of an anti-tumour response (Oudard et al. 2007). Rare cases of 
spontaneous regression have been described (Oya 2009), and stem cell transplants have 
occasionally resulted in a graft vs. tumour immune response (Childs et al. 1999;Childs et 
al. 2000;Takahashi et al. 2008). This evidence, combined with other studies where the 
existence of functional anti-RCC T cells has been demonstrated in vitro, suggests T cell 
immunotherapy could be a potentially effective therapy for the disease (Alexander et al. 
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1990;Belldegrun et al. 1988;Finke et al. 1990;Hanada et al. 2011;Koo et al. 
1991;Leisegang et al. 2010;Seliger et al. 2011).  
 
However, so far the successes seen in melanoma have eluded RCC patients. Clinical trials 
using ACT of TIL, tumour cell vaccines and DC vaccines have reported varying degrees of 
success (summarised in (Shablak et al. 2009), (Draube et al. 2011) and (Itsumi and 
Tatsugami 2010) but no approach has produced significant complete responses.  
 
1.4.3.1. Tumour antigens in RCC 
One of the main challenges in developing effective immunotherapy for RCC is the lack of 
a defined target antigen. Work on the therapeutic effects of stem cell transplants has 
identified epitopes from the retrovirus HERV-E as potential targets, since HERV-E viral 
proteins are expressed in as many as 76% of clear cell RCCs, as a result of VHL gene 
inactivation (Cherkasova et al. 2011). To date the only T cell clone identified is restricted 
to the relatively rare HLA-A11 MHC I allele, but further studies hope to identify 
additional HERV-E specific TCRs (Takahashi et al. 2008). Carbonic anhydrase IX (CA-IX) 
expression is also regulated by VHL and is upregulated in 99% of RCCs but absent in 
normal kidney (Genega et al. 2010;Oosterwijk et al. 1986) and could therefore be an 
attractive target for immunotherapy. Approaches using an antibody for CA-IX to induce 
ADCC have had modest success (Bleumer et al. 2004;Bleumer et al. 2006), however ACT 
of T cells with a CAR resulted in severe toxicity due to expression of CA-IX in the bile 
duct (Lamers et al. 2006). A phase III trial using the antibody is currently taking place. 
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5T4 antigen is usually expressed in the placenta but is upregulated in various cancers, 
including RCC. Vaccines using modified vaccinia Ankara (MVA) engineered to deliver the 
5T4 antigen elicit 5T4 specific antibody production and cellular responses (Hawkins et 
al. 2009), however a phase III trial (which unfortunately was terminated before all 
patients had the complete course of vaccines) found no difference in the overall survival 
of patients (with the possible exception of those with a good prognosis) (Amato et al. 
2010). Recent studies have cloned TCRs specific for multiple RCC tumours without 
reactivity against normal tissue (Engels et al. 2005;Wang et al. 2011a). One of these 
TCRs is unconventional in that it does not recognise an MHC bound peptide but instead 
sees TRAIL bound to its DR4 receptor (Hanada et al. 2011). A clinical trial using patient 
T cells engineered to express this TCR is currently in progress 
 
1.4.3.2. Immune evasion in RCC 
Unlike other malignancies, in RCC there is often good expression of the MHC I (Romero 
et al. 2006;Saenz-Lopez et al. 2009) and MHC II (Brasanac et al. 1999;Tomita et al. 1990) 
molecules needed for T cell recognition, and therefore it may be possible to promote an 
anti-tumour response if immunosuppressive mechanisms could be overcome. 
 
In RCC, as with other cancers, the tumour microenvironment appears to encourage the 
enrichment of Tregs, which can predict a worse prognosis and potentially reduce anti-
tumour responses (Griffiths et al. 2007). The tumour may also influence systemic 
immunity, as the proportion of CD4+CD25hi cells in the peripheral blood was found to be 
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higher than in the blood of healthy donors (7.5% vs. 2.24% of lymphocytes and 2.47% 
vs. 1.50% of T cells) (Cesana et al. 2006;Griffiths et al. 2007). When Tregs were 
identified by staining for Foxp3 as well as CD4 and CD25, they were found to represent 
2.02% of the peripheral blood of RCC patients compared 0.73% in healthy donors. A 
correlation between higher levels of circulating CD4+CD25high cells and a worse 
prognosis has also been demonstrated (Griffiths et al. 2007). 
 
Evidence from RCC patients show the ganglioside GM2 can be found on TIL, despite the 
fact the cells do not make GM2 synthase, indicating the GM2 is tumour-derived. Cells 
from blood of healthy donors also pick up GM2 after incubation with supernatant from 
RCC cell lines. GM2 positive cells apoptose more frequently than GM2 negative cells 
suggesting tumour GM2 release is an immunosuppressive mechanism (Biswas et al. 
2009). There is also substantial evidence that tumour cells from RCC express the 
inhibitory molecule PD-L1 (Thompson et al. 2004;Thompson et al. 2006;Thompson et al. 
2007). 
 
I have investigated markers of the functional status of RCC TIL, and examined the 
potential contribution of PD-1:PD-L1 and Tregs to immune suppression in RCC. I will 
discuss immune evasion in RCC in more detail in later chapters in the context of my own 
results. 
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1.5. T Cell migration 
A pre-requisite for effective T cell therapy is that tumour specific T cells must be able to 
home to the tumour site (Breart et al. 2008;Mukai et al. 1999;Quezada et al. 2008). High 
levels of tumour-specific T cells in the circulation will not function unless they can 
migrate to, and access, the tumour cells (Rosenberg et al. 2005). Until now the homing 
phenotype required for a T cell to migrate to RCC was not well defined. This work aims 
to identify the mechanisms by which T cells migrate into RCC to aid the development of 
more effective immunotherapies for RCC. 
 
In order for naive T cells to mount an effective immune response they must first localise 
to the lymphoid tissue where they can encounter their cognate antigen and become 
activated, after which they must migrate to the tissue where they are required. This T 
cell homing is orchestrated by a variety of ligand and receptor molecules expressed both 
on the T cell surface and the tissue itself. These molecules have to facilitate initial 
adhesion of the T cell to the tissue endothelium, arrest them further in order to retain 
them and finally aid transendothelial migration. This stepwise model is known as the 
‘adhesion cascade’ (Figure 3). 
Finally lymphocytes migrate 
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either transcellular or 
paracellular migration 
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Figure 3: The adhesion cascade 
T cells within blood vessels can form transient bonds with the vessel endothelium via selectins and their ligands. If a chemokine receptor expressed by 
the T cell binds its receptor integrins on the T cell will become activated. If they encounter their ligand the T cell will form a strong bond and be arrested 
on the endothelium. It can then migrate through the endothelium into the tissue where it is required. 
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1.5.1. The adhesion cascade 
1.5.1.1. Selectins 
The initial transient binding of the T cell to the vessel endothelium is mediated by a 
family of C-type lectins known as ‘selectins’, which bind sugar moieties on specific 
glycoproteins (Cummings and Smith 1992). Most naive and central memory T cells 
express high levels of L-selectin (CD62L) (Sallusto et al. 1999), which recognises PNAd, a 
molecule consisting of a protein backbone and a sulphated oligosaccharide. PNAd is 
present on the high endothelial venules (HEVs) of peripheral lymph nodes (PLNs), and 
therefore the PNAd:CD62L interaction is involved in capturing circulating lymphocytes 
and directing them to the PLNs where they can encounter APCs (Geoffroy and Rosen 
1989;Michie et al. 1993). MAdCAM-1 is a similar molecule, also a ligand of CD62L, and is 
present on the HEVs of Peyer’s patches and mesenteric lymph nodes (MLNs) thereby 
directing lymphocytes to those tissues (Kraal et al. 1995). Therefore the expression of 
CD62L directs cells to lymphoid organs (Gallatin et al. 1983). 
 
Two other types of selectin, P and E-selectin, are both found constitutively in the skin 
and are upregulated during inflammation (de Vries et al. 1998). It is therefore 
unsurprising that skin-homing T cells express the receptor for these selectins: cutaneous 
lymphocyte antigen (CLA) (Fuhlbrigge et al. 1997). Therefore the selectins and ligands a 
T cell expresses can start to direct its migration to a specific tissue site. 
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1.5.1.2. Integrins 
Ligand:selectin bonds are transient and due to the nature of the bonds require shear 
stress force provided by blood flowing over the endothelium to occur (Alon et al. 1995). 
However, for T cell migration through an HEV into a tissue, a strong bond between the 
cell and the endothelium is needed. Integrins are heterodimeric receptor proteins with α 
and β glycoprotein chains (Law et al. 1987;Sanchez-Madrid et al. 1983). Their first role 
in the adhesion cascade is to slow down rolling by forming stronger bonds between the 
lymphocytes and endothelium. Patterns of integrin expression are also tissue specific. T 
lymphocytes migrating to the MLNs must possess α4β7 integrins that interact with 
MAdCAM-1 present on the MLN HEVs (Berlin et al. 1993;Hamann et al. 1994). They also 
express the α1β2 integrin LFA-1, which interacts with ICAM-1 on the MLN (Bargatze et al. 
1995;Marlin and Springer 1987). Migration to PLNs also requires an LFA-1:ICAM-1 
interaction (Stein et al. 2000). Additionally an interaction occurs between the α4β1 (VLA-
4) integrin on lymphocytes and the adhesion molecule VCAM-1 on skin HEVs (Berlin-
Rufenach et al. 1999;Elices et al. 1990;Santamaria Babi et al. 1995). 
 
Integrins need to be in an active conformation to bind their ligands and form strong 
bonds. This conformational switch is mediated by signalling downstream of chemokine 
receptor:ligand interactions. 
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1.5.2. Chemokines and chemokine receptors 
1.5.2.1. Introduction 
In order to obtain complete lymphocyte arrest from rolling, chemokines and their 
receptors are necessary. Chemokines are a family of small chemoattractant proteins that 
bind to G protein-coupled receptors (GPCRs) (Kelvin et al. 1993). They are grouped by 
their amino acid composition, specifically on the position of the first two cysteine 
residues of the chemokine conserved tetra-cysteine motif, with the CC and CXC 
chemokines forming the two largest groups (Murphy et al. 2000). The molecules 
CX3CL1, XCL1 and XCL2 are also regarded as chemokines. Chemokines can be grouped 
according to whether they are “inflammatory” or “homeostatic”, that is whether they are 
produced by inflamed tissue and so recruit innate immune cells and effector T cells, or 
are constitutively produced by tissues and so maintain normal immune cell trafficking 
(Bono et al. 2007;Cyster 1999;Oppenheim et al. 1991;Schall and Bacon 1994;Yoshie et 
al. 1997a).  
 
Homeostatic chemokines and receptors function to maintain health and immune 
function. CCR7 and CXCR5 are required for secondary lymphoid homeostasis (Forster et 
al. 1999;Voigt et al. 2000), and CCR9 and CCR10 for gut and skin immunosurveillance 
(Homey et al. 2000;Zabel et al. 1999). CXCR4 has many roles including intestinal 
homeostasis (Werner et al. 2011). CCR4 and CCR6 also play some roles in immune 
surveillance and lymphoid homeostasis (Campbell et al. 1999;Cook et al. 2000), however 
they can also play a role in inflammatory disease (Katou et al. 2001;Welsh-Bacic et al. 
2011). 
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Inflammatory chemokines are produced in inflammatory settings and their receptors 
are induced on lymphocytes upon activation. Some chemokine receptors are more 
commonly induced on different subsets of T cells: type 2 T cells more commonly express 
CCR3, CCR4 and CCR8 (D'Ambrosio et al. 1998;Sallusto et al. 1998), whereas CCR5, 
CXCR3, CXCR6 and CX3CR1 are more often found on type 1 T cells (Fraticelli et al. 
2001;Kim et al. 2001a;Loetscher et al. 1998b;Sallusto et al. 1998;Unutmaz et al. 2000). 
Other receptors, CCR1, CCR2, and CCR6, are also upregulated in response to 
inflammation, but their expression patterns are less distinct (Bonecchi et al. 1998;Ebert 
and McColl 2002). 
 
As is evident from table 1, the chemokine and chemokine receptor system is complex 
with many ligands binding multiple receptors and vice versa. Therefore there is 
redundancy in the system. This is most evident for the inducible or inflammatory 
receptors and chemokines, and mouse knockouts of these receptors produce mild or 
undetectable phenotypes (Hancock et al. 2000;Unutmaz et al. 2000). In fact, humans 
with mutated CCR5 not only have no obvious phenotypic defects, but actually have a 
survival advantage as wild type CCR5 is one of the receptors used by HIV to infect cells 
(Huang et al. 1996;Samson et al. 1996). In contrast, knockouts of the homeostatic 
chemokine receptors have more severe effects, with CXCR4-/- being embryonic lethal 
(Zou et al. 1998), and CCR7 and CXCR5 knockouts displaying disrupted secondary 
lymphoid tissue architecture and impaired splenic primary follicles, respectively 
(Forster et al. 1999;Voigt et al. 2000).
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Table 1:Chemokine receptors expressed by T cells, and their ligands 
 
 
CCR1
CCR2
CCR3
CCR5
CCL2
CCL4
CCL28
CCL3
CCL13
CCL5
CCL8CCL26
CCL24
CCL11
CCR8
CXCR3
CXCR6
CXCL9
CXCL11
CXCL10
CXCL16
CCL1
CX3CR1CX3CL1
CCL7
CCR7
CCR9
CCR10
CXCR4
CXCR5
CCL19
CCL21
CCL25
CCL27
CCL28
CXCL12
CXCL13
CCR4
CCL17
CCL22
CCR6 CCL20
Inflammatory (inducible)
Inflammatory/
homeostatic Homeostatic
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1.5.2.2. Function 
The binding of chemokines to their receptors not only activates integrins to enhance 
their binding to adhesion molecules, but also mediates cell migration via a concentration 
gradient. When a chemokine binds its receptor an intracellular signalling cascade is set 
up, beginning with dissociation of G protein subunits which activate PLC. Activated PLC 
then cleaves phosphotidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) to generate inositol-
1,4,5-triphosphate (InsP3) and diacylglycerol (DAG). InsP3 then triggers an influx of Ca2+, 
which together with DAG activates guanine-nucleotide-exchange factors (GEFs) (Li et al. 
2000;Wu et al. 2000). GEFs then activate small GTPases(del Pozo et al. 1999;Vicente-
Manzanares et al. 2005). This then leads to induction of transitional integrin 
conformational changes through either the direct or indirect (via intermediate effectors) 
association of a GEF with actin-binding proteins such as talin-1. Talin-1 then stabilises 
the high-affinity integrin conformation by coming between the α and β integrin chains, 
thereby opening the ligand-binding pocket. This results in stronger integrin-ligand 
bonds that can arrest the lymphocyte from rolling (Ley et al. 2007;Sampath et al. 
1998;Wegener et al. 2007). The lymphocytes then transmigrate into the tissue where 
they are required. 
 
Chemokine receptor ligation can also lead to cell proliferation and survival. This can be a 
direct effect, activating the phosphoinositide 3-kinase (PI3K) signalling pathway, as in 
the case of CCL5 binding (Choi et al. 2007). Other chemokines that can act in this fashion 
include CCL2, CCL3, CCL21 and to a lesser extent CCL4 (Flanagan et al. 2004;Taub et al. 
1996). Chemokines can also improve T cell stimulation by APCs, thereby indirectly 
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increasing T cell proliferation. CCL2, CCL3, CCL4 and CCL5 binding to DCs increased 
expression of the co-stimulatory molecule CD80 (Taub et al. 1996).  
 
Chemokines can also affect whether an APC primes a T cell to be type 1 or type 2. 
Binding of CCL2, CCL7, CCL8 or CCL13 to a receptor on APCs decreases IL-12 production, 
thereby biasing towards a type 2 response (Braun et al. 2000;Chensue et al. 1996). All 
these ligands bind CCR2, indeed CCL2 has no other known receptor, indicating that this 
effect is mediated through CCR2. In contrast, ligation of CCR5 on APCs increases 
production of IL-12 and favours a type 1 response (Aliberti et al. 2000).  
 
Chemokines can also directly influence polarisation if present at the time of TCR 
stimulation. CCL2 induces cells that produce IL-4 and not IFN-γ, i.e. type 2 T cells. The 
presence of CCL3 (ligand for CCR1 and CCR5) on the other hand, results in Th1 T cells 
that produce IFN-γ (Karpus et al. 1997). It is likely that more ligands and receptors 
influence T cell polarisation, but they have not yet been investigated. The reason 
different chemokines result in different polarisation is unclear but it has been 
speculated that they may result in different Gi proteins being activated in the 
downstream signalling pathway (Luther and Cyster 2001). 
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1.5.3. Chemokine receptor expression 
Chemokine receptor expression is influenced by TCR stimulation. Naive T cells down-
regulate CCR7 and CXCR4 on initial stimulation, to direct them away from lymph node 
homing and allow them to migrate to peripheral tissue (Bleul et al. 1997;Gunn et al. 
1998a).  
 
The chemokine receptor expression profile of an activated T cell also depends on the 
cytokine and chemokine signals it receives (Figure 4). Exposure to IFN-α increases CCR1 
expression while decreasing CCR3 and CCR4 (Sallusto et al. 1997;Sallusto et al. 1998), 
and IL-2 increases expression of the Th1 receptors, CCR5, CXCR3 and CXCR6 (Loetscher 
et al. 1998a;Unutmaz et al. 2000). It also increases CCR6 expression (Unutmaz et al. 
2000). IL-15 has a similar effect, up-regulating CCR5, CCR6 and CXCR6 (Norii et al. 
2006;Unutmaz et al. 2000).  
 
The tissue a DC has migrated from can determine the chemokine receptor profile it will 
imprint on T cells. DCs from the gut can induce CCR9 expression and those isolated from 
skin induce the expression of E-selectin ligands. Signals from the secondary lymphoid 
tissue in which a T cell is primed also have a similar effect (Dudda et al. 2005).  
 
 
Naive T cell 
Immature DC 
Inflamed tissue 
CCL2 
CCL7 
CCL8 
CCL13 
CCL19 
CCL21 
CCL3 
Th17 
↑ IL-12 ↓ 
High IL-12 
CCL3 
IL-2 
IL-15 
Low IL-12 
CCL2 
Low IFN-α 
IL-2 
IL-15 
Th2 
Th1 
Mature DC 
Lymph node 
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Figure 4: Regulation and expression of chemokine receptors on T cell subsets 
Naive T cells express CCR7, which directs them towards the ligands CCL19 and CCL21 that are expressed in the lymph nodes. Immature DCs express tissue 
homing chemokine receptors, which interact with their ligands within the tissue. These interactions influence IL-12 production by DCs and both down-
regulate the tissue homing receptors and up-regulate CCR7. Therefore the DCs also migrate to the lymph nodes, where they can prime naive T cells. The 
chemokine and cytokine signals the T cells receive determine their chemokine receptor expression and subsequent homing capacity. 
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Regulatory T cells are also affected by their chemokine receptor repertoire. It appears 
imperative that Tregs are primed in the lymph node, and therefore naive Tregs must 
express lymph node homing molecules CCR7 and CD62L, in order for them to be 
effectively activated and subsequently suppress the immune response (Schneider et al. 
2007;Szanya et al. 2002;Taylor et al. 2004;Tosello et al. 2008). Murine studies also found 
CCR5 expression on Tregs is required to prevent GVHD and Tregs expressing CCR4 are 
required for tolerance to allografts (Lee et al. 2005;Taylor et al. 2004;Wysocki et al. 
2005). Some experiments have show the majority of peripheral blood Tregs from 
humans express CCR4, CCR6, CCR7, CCR8, CXCR4, CD62L and CLA (Hirahara et al. 
2006;Iellem et al. 2001). Activated Tregs express CXCR4, which is involved in Treg 
trafficking to bone marrow (Zou et al. 2004), where T cells can also be primed for an 
immune response (Feuerer et al. 2003). CCR4 and its ligand, CCL22, have been 
implicated in Treg trafficking both ovarian carcinoma and Hodgkin’s lymphoma (Curiel 
et al. 2004;Ishida et al. 2006). 
 
1.5.4. Tissue specific homing 
T cells need to home to the lymph node in order to encounter APCs and interact with B 
cells. T cells homing to the lymph node express the chemokine receptor CCR7, and its 
ligands, CCL19 and CCL21, have been shown to be involved in T cell recruitment to 
secondary lymph nodes (Campbell et al. 1998b;Gunn et al. 1998b;Yoshida et al. 1997).  
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The chemokine receptor homing phenotypes required for migration to cutaneous and 
mucosal/intestinal tissue have also been defined. In addition to specific selectins and 
integrins being involved in T cell recruitment to the skin, particular chemokine 
receptors and chemokines are involved. CCR4 is expressed on most CLA+ CD4 circulating 
T cells and its ligand CCL17 is constitutively expressed by skin tissue and is upregulated 
during inflammation (Campbell et al. 1999). CCR10 is also expressed by a subset of T 
cells and its ligand CCL27 is secreted by skin keratinocytes (Homey et al. 2000). The 
chemokine receptors required for intestinal homing have been similarly defined. The 
chemokine CCR9 is expressed on a group of α4β7+ T cells and its ligand CCL25 is 
constitutively secreted by the small intestine (Svensson et al. 2002). However T cells 
from CCR9 deficient mice still show a small but significant migration to the small 
intestine (Stenstad et al. 2006), highlighting the redundancy in the system and indicating 
that it is the co-expression of several molecules rather than their individual expression 
that controls T cell homing in these instances. 
 
The chemokine receptors required for homing to other tissues, particularly in the 
context of inflammatory diseases or cancer, have also been investigated. Inflammation 
up-regulates the inducible chemokines, and their receptors play varying roles in T cell 
migration to the sites of disease. CXCR3 ligands have been shown to be up-regulated in 
chronic hepatitis and infiltrating T cells show high CXCR3 expression and enhanced 
migration to their ligands (Curbishley et al. 2005).  
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T cells trafficking to bronchoalveolar (BAL) fluid in allergic asthma patients were found 
to show higher expression of CCR5, CCR6, CXCR3, and CXCR4 compared with peripheral 
blood T cells (Thomas et al. 2007). Another study on patients with various lung diseases 
found CXCR6 to show the greatest up-regulation when comparing infiltrating and 
circulating T cells, and also showed its ligand CXCL16 was highly expressed in the lung 
(Morgan et al. 2005). CXCR6 has also been demonstrated to be involved in lymphocyte 
homing to the aortic wall (Galkina et al. 2007). Although CCR4 is usually involved in T 
cell recruitment to cutaneous tissue, it also has a role in regulatory T cell trafficking to 
MLNs in inflammatory bowel disease (Yuan et al. 2007).  
 
The chemokine receptors required for homing to cancer tissue is of great interest in the 
context of improving T cell therapies. Machado et al (Machado et al. 2009) carried out 
flow cytometry analysis of peripheral blood mononuclear cells (PBMCs) and TILs from 
Hodgkin’s Lymphoma (HL) patients and found that CXCR3+ and CXCR4+ T cells were 
enriched in TIL. They also showed CXCR5 and CCR7 were expressed on at least 33% of 
TILs. 10-20% TILs showed expression of CXCR6, CCR4 and CCR5, whereas CCR1, CCR2, 
CCR3 and CCR6 were virtually absent. The adhesion molecules CD62L LFA-1, PSGL-1 
and VLA-4 were detected on the majority of TILs. By contrast, TILs from the colorectal 
cancer cases studied had higher expression of CXCR6, CCR5 and CCR6 and lower 
expression of CCR7 and CD62L. Hepatocellular carcinoma infiltrating lymphocytes also 
showed high expression levels of CXCR3 and CCR5 and the corresponding chemokine 
ligands were expressed in the tumour, suggesting that lymphocytes are recruited there 
by these chemokine interactions (Yoong et al. 1999). 
61 
 
1.5.4.1. T cell migration into renal cell carcinoma 
Integrins and their ligands are vital for T cell recruitment to RCC. An 
immunohistochemical study of 22 RCC samples and normal tissue found low levels of 
ICAM-1 and VCAM-1 expressed, and that the levels of ICAM-1 were significantly lower 
than on normal tissue (Hemmerlein et al. 2000). In contrast another study found ICAM-1 
expression to be higher on ccRCC compared to normal tissue. VCAM-1 expression was 
comparable on normal and tumour tissue, as was β1 integrin expression which could be 
an indicator of VLA-4 expression. Two studies comparing VLA-4 expression on 
metastatic and non-metastatic RCC found expression to be very low on non-metastatic 
tumours but upregulated on both the primary and metastatic tumours in patients with 
mRCC (Gilcrease et al. 1996;Tomita et al. 1995). Therefore, at least to some degree, RCC 
can express the integrin ligands required for T cell homing. 
 
In order to attract T cells via chemokine receptors, the tumour must produce 
chemokines. CXCL16 has been shown to be expressed in RCC tumours, as has CCL20, 
CXCL9, CXCL10, CCL5 and CCL4 (Gutwein et al. 2009;Kondo et al. 2004;Kondo et al. 
2006;Middel et al. 2010;Suyama et al. 2005a). 
 
It is currently thought that T cells migrate into RCC using the receptors CCR5 and CXCR3 
(Attig et al. 2009;Cozar et al. 2005;Kondo et al. 2006;Suyama et al. 2005a). However, 
previous studies have only examined the expression of a limited number of chemokine 
receptors, and did not discriminate between naive and memory T cells when comparing 
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TIL with peripheral blood mononuclear cells (PBMC), which could potentially bias the 
results as PBMC contain a much greater proportion of naive cells. In addition no study 
has investigated the homing phenotype of the distinct T cell subsets infiltrating RCC. 
This study therefore aimed to screen TIL and PBMC with a comprehensive panel of 
chemokine receptor antibodies to determine the homing mechanisms of various T cell 
subsets to RCC, selecting only memory T cells for more accurate comparison between 
TIL and PBMC.  
 
1.6. Hypotheses 
The first chapter of my thesis deals with the hypothesis that T cells are recruited into 
RCC using particular homing receptors. The second chapter concerns the hypothesis that 
the T cells in TIL have been anergised or rendered dysfunctional by the tumour, and that 
the tumour has recruited regulatory T cells in order to evade the immune system. The 
third chapter investigates the hypothesis that other T cell subsets, Th17s and Tr1s, are 
recruited into RCC tumours and play a role in tumour immunity. 
 
1.7. Aims 
The aims of this work were: 
 To investigate the mechanisms of T cell recruitment into RCC, determining which 
receptors are required and whether the same receptors are relevant for effector 
and regulatory T cell homing 
 To investigate the functional capacity of T cells that home to RCC 
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 To investigate the presence and function of regulatory T cells in the tumour, and 
to investigate how the tumour may be evading the immune response 
 To determine if other T cell subsets are present at the tumour site and how they 
may function 
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2.  Materials and Methods 
2.1. Materials 
2.1.1. Clinical material 
Samples of human RCC tissue, adjacent normal kidney tissue and 120ml heparinised 
whole blood were obtained from patients undergoing surgical resection (nephrectomy) 
at the Queen Elizabeth Hospital, Birmingham, UK. Paraffin-embedded tissue blocks were 
obtained from the department of pathology, Queen Elizabeth Hospital.  
 
Written informed patient consent and local ethical committee approval (South 
Birmingham research ethics committee LREC reference 06/Q2706/82) were obtained 
prior to sample collection. Inclusion criteria stated patients must be aged 18 years or 
over, competent to give full informed consent and have a haemoglobin level of >10g/dL. 
Patients were excluded if they were taking corticosteroids or other medication that 
suppresses the immune system. Patients were also excluded if they were known to be 
infected with HIV, HBV or HCV. 
 
2.1.2. Patient characteristics 
Heparinised blood samples and tissue biopsies used in this study were collected from 78 
RCC patients undergoing nephrectomy, of which the vast majority (80%) were clear cell, 
14% papillary, 3.4% translocation, 1.7% collecting duct and 1.7% chromophobe. 71% 
were male, and the mean age of the patients at the time of nephrectomy was 61 years. 
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According to the TNM system 5.6% of tumours were classed as stage 4, 41% were stage 
3b, 15% stage 3a, 1.9% stage 2, 20% stage 1b and 17% stage 1a. 23% of the tumours 
were Fuhrman grade 4, 28% grade 3, 46% were grade 2 and only 3.5% of tumours were 
grade 1.  
 
2.1.3. Buffers, media and solutions 
Complete medium: RPMI 1640 (Gibco) containing 10% v/v heat-inactivated foetal calf 
serum (FCS) (Invitrogen) and 100 IU/ml penicillin and 100 μg/ml streptomycin (Gibco). 
Cryopreservation media: RPMI 1640 containing 40% v/v FCS and 10% v/v dimethyl 
sulphoxide (DMSO) (Fisher scientific). 
FACs media: PBS containing 0.1% w/v bovine serum albumin (BSA) (Miltenyi biotech) 
and 0.1% v/v NaN3 (Fisher scientific). 
EDTA antigen retrieval buffer (pH8): 1mM ethylenediaminetetraacetic acid (EDTA) 
(Abcam) in distilled H20, with 0.1% Tween20 (Promega), adjusted to pH8. 
Citrate antigen retrieval buffer (pH6): 10mM citrate buffer (Abcam) in distilled H20, 
with 0.1% Tween20, adjusted to pH6. 
Migration assay medium: RPMI 1640 containing 0.1% w/v BSA and 100 UI/ml 
penicillin and 100 μg/ml streptomycin. 
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2.1.4. Antibodies 
2.1.4.1. Flow cytometry 
 
Table 2: Primary and conjugated antibodies (flow cytometry) 
Antibody Source 
Catalogue 
number 
Final concentration 
Anti-human CCR1 R&D MAB145 
1 in 100 dilution of 
stock 
Anti-human CCR2 R&D MAB150 
1 in 250 dilution of 
stock 
Anti-human CCR3 R&D MAB155 
1 in 100 dilution of 
stock 
Anti-human CCR4 BD 551121 
1 in 100 dilution of 
stock 
Anti-human CCR5 BD 555990 
1 in 500 dilution of 
stock 
Anti-human CCR6 R&D MAB195 
1 in 100 dilution of 
stock 
Anti-human CCR7 BD 552175 
1 in 250 dilution of 
stock 
Anti-human CCR8 Abcam ab1666 1 in 5 dilution of stock 
Anti-human CCR9 R&D MAB179 
1 in 100 dilution of 
stock 
Anti-human CCR10 Abcam ab3904 1 in 5 dilution of stock 
Anti-human CXCR1 R&D MAB330 
1 in 250 dilution of 
stock 
Anti-human CXCR2 R&D MAB331 1 in 80 dilution of stock 
Anti-human CXCR3 BD 557184 
1 in 500 dilution of 
stock 
Anti-human CXCR4 R&D MAB172 
1 in 500 dilution of 
stock 
Anti-human CXCR5 R&D MAB190 
1 in 250 dilution of 
stock 
Anti-human CXCR6 R&D MAB699 
1 in 250 dilution of 
stock 
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Anti-human CXCR7 R&D MAB4227 1 in 20 dilution of stock 
Anti-human XCR1 R&D AF857 1 in 20 dilution of stock 
Anti-human CX3CR1 MBL D070-3 1 in 40 dilution of stock 
PE-Cy5 conjugated anti-human 
CD3 
Beckman 
Coulter 
A07749 1 in 20 dilution of stock 
ECD cojugated anti-human CD8 
Beckman 
Coulter 
737659 1 in 20 dilution of stock 
FITC conjugated  anti-human 
CD4 
BD 555346 1 in 20 dilution of stock 
Pacific blue conjugated anti-
human CD3 
Beckman 
Coulter 
558117 1 in 50 dilution of stock 
Am-Cyan conjugated anti-
human CD8 
BD 339188 1 in 50 dilution of stock 
PerCP-Cy5.5 conjugated anti-
human CD4 
BD 332772 1 in 50 dilution of stock 
PE-Cy7 conjugated anti-human 
CD4 
BD 557852 2 in 50 dilution of stock 
PE conjugated anti-human CD3 BD 555333 1 in 50 dilution of stock 
FITC conjugated  anti-human 
CD3 
BD 555332 1 in 50 dilution of stock 
APC-Cy7 conjugated anti-human 
CD3 
BD 557832 1 in 50 dilution of stock 
AF700 conjugated anti-human 
CD45RA 
Biolegend 304120 1 in 50 dilution of stock 
FITC conjugated  anti-human 
CD107a 
BD 555800 1 in 10 dilution of stock 
PE conjugated anti-human 
CTLA-4 
BD 555853 1 in 2.5 dilution of stock 
AF700 conjugated anti-human 
HLA-DR 
BD 560743 1 in 2.5 dilution of stock 
APC conjugated anti-human 
IFN-γ 
BD 341117 
1 in 100 dilution of 
stock 
APC conjugated anti-human IL-2 BD 341116 1 in 10 dilution of stock 
APC conjugated anti-human 
TNF-α 
BD 340534 1 in 10 dilution of stock 
FITC conjugated anti-human 
CD27 
BD 555440 1 in 2.5 dilution of stock 
PE-Cy7 conjugated anti-human 
CD127 
Ebioscience 25-1278 1 in 5 dilution of stock 
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PE-Cy5 conjugated anti-human 
CD25 
BD 555433 1 in 5 dilution of stock 
PE conjugated anti-human CD25 Miltenyi 120-001-311 1 in 5 dilution of stock 
APC conjugated anti-human PD-
1 
Ebioscience 17-9969 1 in 5 dilution of stock 
PE conjugated anti-human IL-17 Ebioscience Dec-78 1 in 10 dilution of stock 
FITC conjugated anti-human 
Foxp3 
Ebioscience 11-4776 1 in 5 dilution of stock 
PerCP-Cy5.5 conjugated anti-
human Foxp3 
Ebioscience 45-4776 1 in 10 dilution of stock 
PE conjugated anti-human IL-10 Invitrogen RHCIL-1004 1 in 10 dilution of stock 
Pacific blue conjugated anti-
human CD45RA 
Biolegend 304123 1 in 50 dilution of stock 
AF700 conjugated anti-human 
Ki67 
BD 561277 1 in 10 dilution of stock 
PE-Cy7 conjugated anti-human 
IFN-γ 
BD 557643 1 in 25 dilution of stock 
AF700 conjugated anti-human 
granzyme B 
BD 561016 1 in 17 dilution of stock 
PE conjugated anti-human 
perforin 
BD 556437 1 in 10 dilution of stock 
PE conjugated anti-human IL2 BD 559334 1 in 17 dilution of stock 
 
Table 3: Isotype controls (flow cytometry) 
Antibody Source 
Catalogue 
number 
Final concentration 
mouse IgG1 negative control R&D MAB002 as appropriate 
mouse IgG2a negative control R&D MAB003 as appropriate 
mouse IgG2b negative control R&D MAB004 as appropriate 
mouse IgG3 negative control DAKO M060501 as appropriate 
rat IgG2a negative control R&D MAB006 as appropriate 
69 
 
FITC conjugated rat IgMk 
negative control 
BD 555951 as appropriate 
goat IgG negative control R&D AB-108-C as appropriate 
AF700 conjugated mouse IgG1 
negative control 
BD 557882 as appropriate 
AF700 conjugated mouse IgG2a 
negative control 
BD 557880 as appropriate 
PE conjugated mouse IgG1 
negative control 
BD 555749 as appropriate 
FITC conjugated mouse IgG1 
negative control 
BD 555748 as appropriate 
APC conjugated mouse IgG1 
negative control 
BD 554681 as appropriate 
PE conjugated rat IgG1 negative 
control 
AbD Serotec MCA1123PE as appropriate 
PE conjugated mouse IgG2a 
negative control 
BD 551438 as appropriate 
 
Table 4: Secondary antibodies and reagents (flow cytometry) 
Antibody Source 
Catalogue 
number 
Final concentration 
PE-Cy5.5 conjugated anti-mouse 
IgG1 
Invitrogen M32018 
1 in 100 dilution of 
stock 
PE conjugated anti-mouse IgG2b Invitrogen M32404 
1 in 100 dilution of 
stock 
Biotinylated goat anti-mouse 
IgG2a 
Invitrogen M32315 
1 in 100 dilution of 
stock 
Biotinylated goat anti-rat IgG Southern biotec 305208 
1 in 100 dilution of 
stock 
Biotinylated goat anti-mouse 
IgG 
Southern biotec 102008 
1 in 100 dilution of 
stock 
Biotinylated rabbit anti-goat IgG Abcam ab6740 
1 in 100 dilution of 
stock 
PE conjugated streptavidin Invitrogen SNN1007 
1 in 100 dilution of 
stock 
APC conjugated Streptavidin Invitrogen SA1005 
1 in 100 dilution of 
stock 
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2.1.4.2. Immunohistochemistry 
Table 5: Primary antibodies (IHC) 
Antibody Source 
Catalogue 
number 
Final concentration 
Anti-human CCL4 R&D AF-271 0.5μg/ml 
Anti-human CCL5 R&D AF-278 5μg/ml 
Anti-human CCL20 R&D AF360 5μg/ml 
Anti-human CXCL9 R&D AF-392 5μg/ml 
Anti-human CXCL10 R&D AF-266 5μg/ml 
Anti-human CXCL11 R&D AF-260 5μg/ml 
Anti-human CXCL16 R&D AF-976 5μg/ml 
Anti-human PD-1 Abcam ab52587 10μg/ml 
Anti-human CD3 Dako M7254 1/200 
Anti-human Foxp3 ebioscience 14-4777 2.5μg/ml 
Anti-human CCR5 Abcam ab1673 3.3μg/ml 
Anti-human CCR6 R&D MAB195 0.3μg/ml 
Anti-human CXCR3 BD 557184 2.5μg/ml 
Anti-human CXCR6 R&D MAB699 2.5μg/ml 
 
Table 6: Isotype controls (IHC) 
Antibody Source 
Catalogue 
number 
Final concentration 
Rabbit IgG negative control R&D AB-105-C as appropriate 
mouse IgG1 negative control Dako X0931 as appropriate 
mouse IgG2a negative control Dako X0943 as appropriate 
mouse IgG2b negative control Dako X0944 as appropriate 
goat IgG negative control R&D AB-108-C as appropriate 
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Table 7: Secondary antibodies (IHC) 
Antibody Source 
Catalogue 
number 
Final concentration 
ImmPRESS Universal antibody 
anti-mouse Ig/anti-rabbit Ig 
peroxidase 
Vector MP-7500 undiluted 
ImmPRESS anti-goat Ig 
peroxidase 
Vector MP-7405 undiluted 
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2.2. Methods 
2.2.1. Collection and preparation of blood and tumour tissue 
2.2.1.1. Isolation of lymphocytes from normal and tumour tissue  
Tissue was manually disaggregated using scalpels in complete medium. Necrotic or 
haemorrhagic tissue was excluded from the study. The supernatant was collected, 
passed through a 70μm filter to remove tissue aggregates, and analysed for the presence 
of lymphocytes using light microscopy. A minimum of 0.4x106 tumour-infiltrating 
lymphocytes were required in order to perform the smallest of the subsequent 
experiments, therefore samples with fewer TIL were unusable. 
 
2.2.1.2. Isolation of lymphocytes from peripheral blood 
Whole blood was mixed at a ratio of 1:1 with RPMI 1640 and layered over 
LymphoprepTM density gradient solution (Axis-Shield) at a ratio of 2:1, prior to 
centrifugation at 800 x g for 20 minutes (brake off). PBMCs were removed from the 
density gradient interface and washed by first re-suspending in RPMI 1640 and 
centrifuging at 600 x g for 10 minutes, then re-suspending in RPMI 1640 and 
centrifuging at 400 x g for 5 minutes.  
 
2.2.1.3. Cryopreservation of tissue infiltrating lymphocytes and PBMC 
Cells were cryopreserved at -180oC for long term storage. Cell suspensions were 
pelleted by centrifugation at 400 x g for 5 minutes, and resuspended in cryopreservation 
medium. Cells were frozen overnight in a Mr Frosty freezing container (Nalgene 
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labware) at -80oC, before being stored over liquid nitrogen. When required cells were 
thawed in a 370C waterbath and immediately washed twice by re-suspending in 
complete medium and centrifuging at 400 x g for 5 minutes. 
 
2.2.1.4. Preparation of tissue slides from paraffin blocks 
Formalin fixed, paraffin embedded sections of 5μm were cut from a tissue block using a 
microtome, and mounted onto X-tra® Adhesive Snowcoat slides (Surgipath). Slides 
were incubated at 60OC for 1 hour, before storage. 
 
2.2.2. Flow cytometric analysis 
Details of antibodies used are in section 2.1.4.1, p66. 
Flow cytometry was performed using a Coulter XL (for preliminary examination of 
chemokine receptor expression on TIL) or BD LSRII flow cytometer (all other flow 
assays). Antibodies were diluted in 50μl FACs media and added for 20 minutes on ice 
then washed by dilution in FACs media followed by centrifugation at 400 x g for 5 
minutes. 
 
Concentration matched isotype controls were used to confirm specific staining. 
 
Data were analysed using FlowJo software (Treestar Inc.). 
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2.2.2.1. Chemokine receptor expression on T cell subsets 
To analyse cell surface phenotype, TIL from 35 patients and matched PBMC from 12 RCC 
patients were stained. Up to 1x105 Cells were stained using individual or combinations 
of antibodies to: CCR1-10, CXCR1-7, XCR1 or CX3CR1, CD11b, CLA, CD62L, PSGL-1, VLA-
4 and BLT-1. Where appropriate, biotinylated secondary antibodies were then used: 
goat anti-mouse, goat anti-rat or rabbit anti-goat, followed by Streptavidin-PE or 
Streptavidin-APC; or goat anti-mouse IgG1-PECy5.5, goat anti-mouse IgG2b-PE and goat 
anti-mouse IgG2a-biotin.  
 
Cells were then blocked with 5% mouse serum (Invitrogen) in FACs buffer for 20 
minutes then stained with CD3-PECy5, CD8-ECD and CD4-FITC (Coulter XL analyses), or 
CD3-Pacific Blue, CD4-PerCPCy5.5/CD4-PECy7, CD8-AmCyan, CD45RA-AF700 and 
LIVE/DEAD® Fixable Red Dead Cell Stain Kit (Invitrogen) (LSRII analyses) and gated 
accordingly.  
 
To analyse Treg homing phenotype cells were also stained for CD25-PECy5 or CD25-PE 
and CD127-PECy7. They were then fixed and permeabilised using Foxp3 
Fixation/Permeabilisation Concentrate and Diluent kit (Ebioscience) then stained with 
an anti-Foxp3-FITC antibody. 
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2.2.2.2. Expression of markers of immune function and intracellular cytokine staining of T 
cells subsets 
1x105 TIL or PBMC were re-suspended in 100μl of either a stimulation mix of complete 
media containing 0.02μg/ml PMA, 2μg/ml Ionomycin, and 4μg/ml DNase IV (to prevent 
clumping due to released DNA) (all Sigma); or a no-stimulation mix of complete media 
containing 4μg/ml DNase IV. CD107a-FITC or the relevant concentration matched 
isotype control were added and the cells were incubated in the dark for 1 hour at 37oC, 
5% CO2. 100μl of complete media containing 40μg/ml Brefeldin-A, 4μl/ml GolgiStop 
(both BD) and 4μg/ml DNase IV were then added to each well and cells were incubated 
for a further 4 hours. Alternatively T cells were incubated at a 1:1 ratio with 
Dynabeads® Human T-Activator CD3/CD28 beads (Invitrogen), with Brefeldin-A, 
GolgiStop and DNase IV, for 5 hours at 37oC. 
 
Cells were then all stained for CD3-Pacific Blue/CD3-PE/CD3-FITC/CD3 APC-Cy7, CD4-
PECy7/CD4-FITC, CD8-AmCyan, CD45RA-AF700/CD45RA-Pacific Blue and LIVE/DEAD 
viability stain and gated accordingly. Cells were also stained for combinations of CD27-
FITC, CTLA-4-PE, HLA DR-AF700, CD25-PE, PD-1-APC and CD127-PECy7.  
 
Cells were then fixed and permeabilised, as before. Combinations of antibodies to IFN-γ-
APC, IL-2-APC, TNFα-APC, Foxp3-PerCPCy5.5, IL-10-PE, granzyme B-AF700, perforin-PE, 
IL-17-PE and Ki67-AF700 were then used. 
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2.2.3. Immunohistochemistry  
Details of antibodies used are in section 2.1.4.2 p70. 
Sections were deparaffinised by placing in either Xylene or Histoclear (Fisher Scientific) 
for 10 minutes, then rehydrated in industrial methylated spirit (IMS) (Fisher Scientific) 
for 10 minutes. Sections were rinsed in tap water then placed in 0.3% hydrogen 
peroxide solution (30% H202 (Sigma) dissolved in H20) to block endogenous peroxidase 
activity. Where antigen retrieval was required, sections were either placed in EDTA 
buffer or citrate buffer that had been pre-heated in a microwave for 10 minutes at 800 
Watts. The sections were then heated by microwave (800 Watts) for a further 20 
minutes. After the slides had cooled, they were washed with Tris-buffered saline (TBS). 
A blocking step was performed using 2X casein solution (10X casein solution (Vector) 
diluted in TBS) or normal horse serum (Vector).   
 
Sections were then stained with antibodies to CD3, Foxp3, PD-1, CCL4, CCL5, CCL20, 
CXCL9, CXCL10, CXCL11, CXCL16, CCR5, CCR6, CXCR3 or CXCR6, or isotype matched 
controls. EDTA antigen retrieval was used before staining for CD3, Foxp3, CCL4, CCR6, 
CXCR3 and CXCR6 for one hour at room temperature. Citrate buffer antigen retrieval 
was used before staining for PD-1 overnight at room temperature, CXCL9 and CXCL11 
overnight at 4oC, or CCR5 for 1 hour at room temperature. For CCL20 staining, slides 
were pre-treated overnight in EDTA buffer on a hot-plate stirrer at 65
o
C before staining for 1 
hour at room temperature. CCL5, CXCL10 and CXCL16 antibodies were used overnight at 
4oC.  
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Slides were then washed twice for 10 minutes on a stirring platform with TBS 
containing 0.1% Tween, and bound antibody was detected using an immunoperoxidase 
method (Vector IMPRESS anti-mouse or anti-goat kits) and visualised using DAB 
(Vector), used according to the manufacturer’s instructions. Sections were mounted 
using DPX and a coverslip and air-dried. Slides were recorded digitally using a Nikon 
Eclipse E400 microscope. 
 
The identification and tissue distribution of positively staining cells was determined 
with the help of a pathologist, Neeta Deshmukh (Department of Pathology, Queen 
Elizabeth Hospital, Birmingham, UK). 
 
2.2.4. Migration assay 
T cells (0.25-1 x 10
5
) in 75l migration assay medium were added to the top chamber of a 
3μm pore HTS-Transwell-96 (Corning) and the same medium containing recombinant CCL4, 
CCL5, CXCL16 or the CXCR3 ligands (CXCL9, CXCL10 and CXCL11) (R&D Systems), or 
combinations of ligands for multiple chemokine receptors, was added to the lower 
chamber. Where cell numbers permitted, T cells (0.25-1 x 105) in 75l migration assay 
medium were also added to wells of a 96-well plate in triplicate, and incubated under the 
same conditions, in order to have a record of the number of cells inputted into the assay. 
Transwells were incubated at 37oC for 4 hours before cells from the lower chamber 
were harvested and stained using anti-CD3-PE. Migrated cells were counted using a BD 
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LSRII flow cytometer and Flow-Count™ fluorospheres (Beckman Coulter). The number 
of cell inputted were also measured in the same way. Background migration was 
assessed using migration media alone as a stimulus. The migration index was calculated 
as the ratio of cells migrated towards ligand compared to cells migrated towards media 
alone. 
The assay was performed in triplicate. 
 
2.3. Statistical analysis 
Statistics were calculated using GraphPad Prism (GraphPad Software Inc.). The majority 
of data did not reach a normal distribution, therefore data were compared using a 
Wilcoxon signed rank test or a Wilcoxon matched pairs test. Data were not corrected for 
multiple comparisons as, due to the nature of the assays, the resulting estimates of 
significance would be quite conservative and could mask interesting trends. For 
example, if I used the Bonferroni correction for the comparison of chemokine receptor 
expression in TIL and PBMC examined in chapter 3, where 26 comparisons were made, 
only a p value of 0.0019 or less would be considered significant. In most cases, further 
investigations were undertaken to determine whether observations that had reached 
significance were important. 
Correlations were calculated using Spearman correlation tests. Details of all the 
correlation calculations performed are in Appendix A. 
In all cases p values of less than 0.05 were considered significant. 
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3. Molecular mechanisms of T cell recruitment into renal cell 
carcinoma 
3.1. Introduction 
This chapter aims to investigate the mechanisms by which T cells migrate into RCC, and 
which T cell subsets are recruited. The specific combination of receptors and ligands 
required for homing to many tissues has been well characterised, however the 
molecules required for homing to RCC are currently unknown. This information is 
important in the context of developing T cell immunotherapies for the cancer, as in 
order for an anti-tumour T cell to be effective it must be able to migrate to the tumour 
site (Mukai et al. 1999). It also allows us to block the homing of undesirable cell subsets, 
such as Tregs, to improve tumour immunity. 
 
If a particular homing receptor is involved in recruiting T cells into RCC the TIL may 
show an enrichment of that receptor compared to the corresponding population of cells 
in PBMC. Therefore to determine which receptors might contribute to T cell recruitment 
to the tumour I compared the homing phenotype of matched TIL and PBMC from RCC 
patients. I also compared the chemokine receptor expression on CD4 and CD8 effector T 
cell subsets, and on Tregs, to determine whether they were recruited by similar or 
distinct mechanisms. 
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Unless otherwise stated, throughout this chapter ‘TIL’ and ‘PBMC’ refer to the T cell 
compartment within the respective populations. All significances were calculated using 
Wilcoxon matched pairs tests. 
 
3.2. T cells infiltrate RCC 
RCC has been reported to contain a significant T cell infiltrate. I performed 
immunohistochemical analysis (IHC) of CD3+ cells in 10 RCC patient samples and 
compared the staining to isotype matched controls. I saw a clear T cell infiltrate in RCC 
tissue (Figure 5A). The majority of T cells were clustered near vascular areas, with only a 
few T cells able to penetrate the tumour nests. A similar observation was made by 
Wittnebel et al. (Wittnebel et al. 2007)  
 
I performed multi-colour flow cytometry on T cells from tumour-infiltrating 
lymphocytes (TIL) and PBMC from matched patient samples to determine their 
chemokine receptor and adhesion molecule expression profile. For the 22 TIL samples 
initially studied I was only able to use 4-colour flow cytometry, so the analysis was first 
gated on lymphocytes based on the forward:side scatter profile, and then on CD3 and 
either CD4 or CD8. Later the BD LSRII FACs machine became available, allowing a larger 
panel of antibodies to be used. In addition to allowing gating using a LIVE/DEAD stain, 
the larger antibody panel available using the LSRII meant I could gate on the CD45RA- 
(memory) fraction, which is beneficial as this constitutes the majority of T cells within 
TIL and ensured I was comparing the equivalent population in peripheral blood. 
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Excluding CD45RA+ T cells means I would not have included CD8 TEMRA cells in my 
analysis, however the low proportions of CD45RA+ T cells in TIL suggest this population 
is rare in RCC TIL. 
Previous studies have shown that >65% of TIL are T cells, and they are chiefly CD8+ 
(Kopecky et al. 2007;Kowalczyk et al. 1997;Van den Hove et al. 1997a). Other studies 
have demonstrated that even when CD8 T cells are not the predominant T cell 
population, the CD8:CD4 ratio is still higher in T cells from TIL than from PBMC (Balch et 
al. 1990;Cozar et al. 2005). In concordance with those studies the mean ratio of CD8:CD4 
T cells in my samples was significantly higher in TIL (1.13 inter-quartile range[IQR]: 
0.81-1.60) than matched blood (0.30 IQR: 0.21-0.40) (Figure 5B). Statistically CD8s 
represented a greater proportion of TIL than CD4s (p=0.0187), but the difference was 
small (median 62% IQR: 53%-70% vs. 55% IQR: 45%-70%) (Figure 5C).  
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Figure 5: T cells infiltrate RCC 
5μm paraffin sections from RCC tumours were stained with an antibody to CD3. Photos are representative 
of 10 RCC cases. Black arrows indicate tumour nests, white arrows indicate fibrous/stromal areas (A). 
Paired TIL and PBMC were stained with antibodies to CD4 and CD8, and analysed by flow cytometry to 
determine the ratio of CD8 T cells: CD4 T cells. (B) and the relative proportions of CD4 and CD8 T cells (C). 
Significance was calculated using a Wilcoxon matched pairs test. 
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3.3. Homing phenotype of TIL 
I used flow cytometry to analyse chemokine receptor and adhesion molecule expression 
on up to 22 samples of RCC TIL using the 4-colour Coulter XL ( 
Figure 6, Figure 7), and subsequently 10 samples of RCC TIL and 10 matched PBMC using 
the BD LSRII (Figure 8 and Figure 9). I stained for all 19 chemokine receptors (CCR1-10, 
CXCR1-7, XCR1 and CX3CR1) and the adhesion molecules CD11b, CLA, CD62L, LFA-1, 
PSGL-1, VLA-4 and BLT-1. Both methods of analysis gave similar results however the 
LSRII appeared more sensitive and produced results with higher percentages of homing 
marker-positive cells and higher levels of homing molecule expression, denoted by 
larger median fluorescence intensities (MFI). In addition I believe the LSRII data are a 
more accurate representation as I was able to exclude dead cells and naive T cells. 
Therefore the figures quoted in the following text are from the LSRII analysis. A table 
describing chemokine receptor expression by TIL according to the Fuhrman grade and 
RCC subtype of the sample can be found in Appendix B. 
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Figure 6: Gating strategy for defining chemokine receptor positive cells 
The figure illustrates the gating strategy used to firstly define CD3+ cells (A), then to define the CD4+ and 
CD8+ cell subsets (B), and finally to define the percentage of cells positive for a receptor (horizontal 
arrow) or the median fluorescence intensity of the positively-staining cells (dotted vertical line), using an 
isotype control to determine the level of non-specific staining (blue shaded area) (C). 
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Figure 7: Initial analysis of homing phenotype of RCC TIL using the Coulter XL cytometer 
RCC TIL samples were stained with antibodies specific for 19 chemokine receptors and 7 adhesion 
molecules. Graphs display the percentage of T cells positive for each marker and the median fluorescence 
intensity of the staining, both corrected for non-specific staining using concentration matched isotype 
controls. The number of RCC cases stained was as follows: CCR2 and CXCR4 n = 22; CCR1, 5 and CXCR3 n = 
21; CXCR1, 5, 6 n = 20; CCR4 and CCR6 n = 19; CCR7 and CXCR7 n = 18, CCR9 and CD62L n = 17; CCR3 
CXCR2, LFA-1 and PSGL-1 n = 16; CCR8, 10 and CX3CR1 n = 15; XCR1, CD11B, VLA-4 and BLT-1 n = 14; 
CLA n = 13.  
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3.3.1. Expression of adhesion molecules on RCC TIL 
Integrins and selectins play key roles in T cell recruitment into tissues. Adhesion 
molecule expression on CD45RA-CD3+ CD4 and CD8 T cells was determined by flow 
cytometry. I found LFA-1, PSGL-1 and VLA-4 were expressed on ≥50% of TIL, with LFA-1 
being expressed on a mean of 84 ± 13 % of TIL, PSGL-1 on 50 ± 22 % and VLA-4 on 53 ± 
24 %. CLA and CD62L were also expressed, on 23 ± 23 % and 16 ± 20% of TIL 
respectively (Figure 8). All adhesion molecules except for CLA were expressed at high 
levels (MFI) compared to the chemokine receptors studied (see section 3.3.2, p88). 
Adhesion molecule expression was similar on CD4 and CD8 T cells (Figure 8) 
 
Adhesion molecule expression did not correlate with RCC subtype or grade. 
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Figure 8: Adhesion molecule expression on RCC TIL: LSRII analysis  
RCC TIL were stained with antibodies to 7 adhesion molecules. Graphs display the mean percentage of T 
cells positive for each marker and the mean median fluorescence intensity of the staining (+ SD). Results 
are corrected for non-specific staining using concentration matched isotype controls.  The number of RCC 
cases stained was as follows: CD11b n = 7; CD62L and PSGL-1 n = 6; LFA-1, CLA, VLA-4 and BLT-1 n = 5.  
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3.3.2. Expression of chemokine receptors on RCC TIL 
The chemokine receptor profile of TIL gives an indication as to what mechanisms they 
used to migrate into and within the tissue, and as to whether the T cells are Th1 or Th2 
biased. Chemokine receptor expression on CD45RA-CD3+ CD4 and CD8 T cells was 
determined by flow cytometry, as before (Figure 9). 
 
Not surprisingly, the number of T cells expressing homeostatic chemokine receptors 
was low, with only CXCR4 being expressed on over 10% of T cells (37 ± 17 %), and at 
high levels (MFI 639 ± 504). CCR7, CCR9, CCR10 and CXCR5 were expressed only by 
very small populations of T cells (Figure 9). 
 
CCR4 and CCR6 can perform homeostatic functions but have also been shown to be 
involved in inflammatory scenarios (Katou et al. 2001;Welsh-Bacic et al. 2011;Yoshie et 
al. 1997b). CCR4 was expressed on very few T cells (3.1 ± 3.5 %), however a slightly 
larger T cell subset expressed CCR6 (12 ± 7.4 %), although the levels of expression were 
not high (MFI 175 ± 158). 
 
The Th1 associated inflammatory chemokine receptors were expressed on a larger 
proportion of TIL: CCR5 was on 49 ± 17 %, CXCR3 on 25 ± 18 % and CXCR6 on 21 ± 14 
%. In addition they were expressed at high levels (MFI 1778 ± 519, 639 ± 504 and 519 ± 
786) respectively. The Th2 associated receptors CCR3 and CCR8 were expressed by only 
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a minority of TIL. Very few cells expressed the remaining ‘inflammatory’ receptors, 
CCR1, CCR2, CXCR1, CXCR2, XCR1 and CX3CR1. 
 
The literature is controversial on the role and expression of CXCR7 on leukocytes 
(Berahovich et al. 2010;Hartmann et al. 2008), and I detected very few T cells in the TIL 
population expressing this receptor.  
 
Homing receptor expression was comparable on CD4 and CD8 T cells (Figure 9). 
However CCR6 was expressed more frequently (p=0.0020) and at higher levels 
(p=0.0078) on CD4 than CD8 T cells in TIL. CCR4 and CCR7 were on significantly more 
CD4 than CD8 T cells (p = 0.0488 and p = 0.0117), however they were only expressed on 
a small minority of CD4s (3.1 ± 2.2 % and 5.2 ± 4.3 %) (Figure 10). CCR7 was also 
expressed at higher levels on the CD4 subset, however the MFI was still very small (52 ± 
61).  
 
Chemokine receptor expression did not correlate with RCC subtype or grade. 
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Figure 9: Chemokine receptor expression on RCC TIL: LSRII analysis 
RCC TIL were stained with antibodies to all 19 chemokine receptors. Graphs display the mean percentage 
of T cells positive for each marker and the mean median fluorescence intensity of the staining (+ SD). 
Results are corrected for non-specific staining using concentration matched isotype controls. The number 
of RCC cases stained was as follows: CCR3, 4 5 6 7, CXCR3, 4 and 6 n = 10; CCR8 and CX3CR1 n = 8; 
CCR1, 2, 9, 10, CXCR2, 5, 7 and XCR1 n = 7; CXCR1 n = 6. 
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Figure 10: CCR4, CCR6 and CCR7 had different patterns of expression on CD4 and CD8 T cell 
subsets from TIL 
RCC TIL were stained with antibodies to all 19 chemokine receptors. Graphs display the percentage of T 
cells positive for each marker and the median fluorescence intensity of the staining. Results are corrected 
for non-specific staining using concentration matched isotype controls. Chemokine receptor staining on 
CD4 and CD8 T cells was compared and results are shown for those receptors for which the expression 
was significantly different between the subsets. Significance was calculated using a Wilcoxon matched 
pairs test. 
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3.3.3. Chemokine receptor expression on TIL compared to matched peripheral 
blood 
If a particular homing receptor is involved in recruiting T cells into RCC, the TIL may 
show an enrichment of that receptor compared to the corresponding population of cells 
in PBMC. I compared the expression of the aforementioned adhesion molecules and 
chemokine receptors on up to 16 samples of matched TIL and PBMC. There were no 
significant differences in adhesion molecule expression between TIL and PBMC (Figure 
11 and Figure 12) 
 
Compared to matched peripheral blood, CD3+ TIL had significantly higher expression 
levels of the receptors CCR1 and CCR3. CCR3 was also expressed on significantly more T 
cells. CCR5, CXCR3 and CXCR6 were also expressed more frequently in TIL than PBMC. 
These three receptors were also expressed at higher levels on TIL compared to matched 
blood (Figure 11 and Figure 12). 
 
When I compared chemokine receptor expression on CD4 and CD8 T cells in PBMC, I 
found CXCR6 was expressed on significantly more CD8 T cells than CD4 T cells in PBMC, 
and CCR5 was expressed at significantly higher levels on CD8s than CD4s. CXCR6 was 
also expressed at higher levels and CCR5 at greater frequencies on CD8s from blood than 
CD4s, but the difference was not significant (Figure 13). If CCR5 and CXCR6 do function in 
T cell migration to RCC, this may explain the enrichment of CD8 T cells within the 
tumour. 
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These data suggest CCR5, CXCR3 and CXCR6 receptors play a role in selective 
recruitment or retention of T cells in RCC tumours. Whilst they may make a significant 
contribution to the T cells that express them, CCR1 and CCR3 were expressed on such a 
small proportion of TIL that I decided not to investigate them further. Instead further 
research focussed on the receptors enriched on a larger proportion of TIL— CCR5, 
CXCR3 and CXCR6 —as these are more likely to be involved in recruiting the majority of 
TIL into the tumour. 
 
In addition, some receptors were enriched on PBMC compared to TIL. CCR4 was 
expressed on a greater percentage of T cells in PBMC than TIL (p = 0.0273), as was CCR7 
(p = 0.0293). Neither of these receptors were expressed at significantly higher levels on 
PBMC T cells than TIL, however the difference in MFI for CCR7 was approaching 
significance (Figure 11 and Figure 12). 
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Figure 11: Paired analysis of the percentage of T cells from RCC TIL and matched PBMC expressing chemokine receptors and adhesion molecules 
RCC TIL and PBMC were stained with antibodies to all 19 chemokine receptors and 7 adhesion molecules. Graphs display the percentage of viable 
CD3
+
CD45RA
-
  cells positive for each marker. Results are corrected for non-specific staining using concentration matched isotype controls. Significance 
calculated using a Wilcoxon matched pairs test. 
 
97 
 
 
 
98 
 
 
 
 
 
 
99 
 
 
 
Figure 12: Paired analysis of the median fluorescence intensity of the staining for chemokine receptors and adhesion molecules on TIL and 
matched PBMC 
RCC TIL and PBMC were stained with antibodies to all 19 chemokine receptors and 7 adhesion molecules. Graphs display the MFI of staining for each marker 
on viable CD3+CD45RA- cells. Results are corrected for non-specific staining using concentration matched isotype controls. Significance calculated using a 
Wilcoxon matched pairs test. 
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Figure 13: CCR5 and CXCR6 had different patterns of expression on CD4 and CD8 T cells from PBMC 
RCC patients’ PBMC were stained with antibodies to all 19 chemokine receptors. Graphs display the 
percentage of T cells positive for each marker and the median fluorescence intensity of the staining. 
Results are corrected for non-specific staining using concentration matched isotype controls. Chemokine 
receptor staining on CD4 and CD8 T cells was compared and results are shown for those receptors for 
which the expression was significantly different between the subsets. Significance was calculated using a 
Wilcoxon matched pairs test. 
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3.3.4. Multiple chemokine receptor expression 
The previous experiments did not allow us to determine if particular receptors were co-
expressed on the same T cell. The combinations of receptors expressed give an insight 
into whether just one type of receptor is required for homing to RCC, or whether several 
steps involving multiple receptors are involved. There may also be redundancy in the 
system, and T cells expressing just one of the three receptors of interest may have the 
capability to enter RCC tumours. 
 
Therefore I co-stained for CCR5, CXCR3 and CXCR6 on CD45RA-CD3+ lymphocytes on 6 
matched TIL and PBMC samples. This revealed 63 ± 31 % of TIL to express more than 
one of these receptors, compared to 14 ± 5.5 % in PBMC (p=0.0313) (Figure 14). In TIL 
CCR5+ cells made up the majority of single receptor positive T cells, accounting for 10 ± 
18 % CD3+ TIL. CXCR3 and CXCR6 single positive T cells were almost non-existent in TIL. 
In contrast the majority of PBMC were negative for all three receptors (71 ± 15 %), and 
there were significantly more single positive CXCR3+(8.8 ± 10 %, p = 0.0313) and 
CXCR6+ (2.0 ± 0.8 %, p = 0.0313) T cells. 
 
The proportion of CCR5+CXCR3+ and CCR5+CXCR6+ CD3+ T cells was significantly greater 
in TIL than PBMC (p = 0.0313 for both comparisons). There was also a greater frequency 
of CXCR3+CXCR6+ T cells and CCR5+CXCR3+CXCR6+ T cells in TIL than PBMC (Figure 14), 
however this did not reach significance (p values of 0.0625 and 0.0938 respectively).  
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Figure 14: Co-expression of CCR5, CXCR3 and CXCR6 on T cells from TIL and matched PBMC.  
The relative proportion of cells expressing none, one, two or all three of the chemokine receptors was 
determined using flow cytometry. Results show the mean of data from 6 cases (+ SD). Significance was 
calculated using a Wilcoxon matched pairs test (A). Representative plots for RCC TIL are also shown (B) 
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3.4. Classic Tregs are recruited into RCC 
There is evidence to suggest that regulatory T cells (Tregs) can suppress anti-tumour T 
cell responses at the tumour site. Elevated levels of Tregs have been found in the blood 
and TIL of patients with various cancers including pancreatic, breast, hepatocellular and 
ovarian cancer, and Tregs from ovarian cancer ascites, hepatocellular carcinoma and 
RCC have been demonstrated to be capable of suppressing effector T cell proliferation in 
vitro (Curiel et al. 2004;Fu et al. 2007;Liotta et al. 2010a;Liyanage et al. 2002). As Tregs 
may be suppressing anti-tumour immune responses in RCC, I sought to determine 
whether they may be selectively recruited to this tumour. 
 
Using intracellular flow cytometry I found a mean of 11 ± 6.0 % of CD4 TIL expressed 
the Treg marker Foxp3 , which is significantly greater than the 6.6 ± 4.3 % of Foxp3+ 
CD4 T cells in PBMC (p=0.0013) (Figure 15). I also used immunohistochemistry for Foxp3 
to investigate the distribution of the putative Tregs within 10 RCC tumours. Compared 
to CD3 staining, it appeared Foxp3+ cells are more evenly distributed throughout the 
tumour and do not aggregate in fibrous areas to the same extent (Figure 16). However 
the small sample size did not allow a quantitative evaluation of the differences in cell 
distribution.  
 
When I compared the percentage of Foxp3+ cells in TIL and the Fuhrman grade of the 
tumours, I found a significant positive correlation (r = 0.7096, p = 0.0097) (Figure 17). 
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Flow cytometry of lymphocytes from 6 samples of adjacent normal renal tissue showed 
that in 5 out of 6 samples, fewer than 0.5% of CD4+ CD45RA- T cells express Foxp3. In 
one sample 1.37% of CD4+ T cells were Foxp3+, however all were CD127hi, suggesting 
they are not true Tregs (Figure 18). 
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Figure 15: Foxp3+ T cells are enriched in RCC tumours 
CD4+ T cells from TIL and PBMC were stained intracellularly for Foxp3. Significance calculated using a 
Wilcoxon matched pairs test. 
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Figure 16: Immunohistochemistry for Foxp3 
5μm paraffin sections from RCC tumours were stained with an antibody to Foxp3. Photos are 
representative of 10 RCC cases. Results were compared to concentration matched isotype controls (inset 
large photo). 
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Figure 17: The percentage of Foxp3+CD4+ T cells in TIL correlates with the grade of the tumour 
A Spearman correlation coefficient was calculated to determine the correlation between the percentage of 
Foxp3+CD4+ T cells and the Fuhrman grade of the tumour. 
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Figure 18. Foxp3 expression in T cells from normal kidney tissue 
T cells isolated from normal kidney adjacent to tumour were isolated and stained for T cell markers and 
Foxp3, and analysed by flow cytometry. Cells are gated on CD3+ LIVE CD45RA- CD4+. Sample 1 is 
representative of the 5 out of the 6 samples stained in which Foxp3+ cells made up fewer than 0.5% of CD4 
T cells. Sample 2 contained some Foxp3+CD4+ T cells, however the Foxp3+ cells were CD127+ and therefore 
not true T cells.  
  
Sample 1 Sample 2
110 
 
However, Foxp3 can be upregulated transiently when T cells are activated (Ahmadzadeh 
et al. 2007;Gavin et al. 2006), so in order to further ascertain whether these cells were 
regulatory or not, I measure the surface levels of CD25 and CD127. Studies have shown 
classical Tregs have high levels of CD25 and low levels of CD127, and my data matched 
this pattern. (Figure 19). I also carried out additional phenotypic and functional studies 
on the Tregs to further demonstrate their regulatory phenotype, which are described in 
section 4.3. 
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Figure 19: Foxp3+ T cells in RCC TIL and PBMC have a classic Treg phenotype 
Levels of putative Tregs in TIL and PBL were examined by flow cytometry for co-expression of CD127 and 
CD25. CD25hiCD127lo T cells from TIL and PBMC were Foxp3+ (indicated by horizontal arrow). Data shown 
are representative of 25 RCC cases 
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3.4.1. Homing phenotype of Tregs 
I studied the homing phenotype of Foxp3+ cells in parallel with the phenotyping of the 
whole T cell population within TIL. Overall chemokine receptor and adhesion molecule 
expression on Foxp3+ cells followed a similar pattern to that on all CD3+ TIL (Figure 20, 
Figure 21). However, the frequency of cells expressing CCR6 was significantly higher 
within the Foxp3+ population than the whole CD3+ population (p = 0.0488) and the 
percentage of CXCR3+ cells among the Foxp3+ subset was significantly lower (p = 
0.0488) (Figure 22). 
 
The MFI for CCR4 expression, a marker commonly found on Tregs, was significantly 
higher on Foxp3+ cells than the total CD3+ population (p = 0.0020). This was also true for 
the receptors CCR5 (p = 0.0098), CCR6 (p = 0.0039) and CXCR6 (p = 0.0020), indicating 
Foxp3+ cells may be recruited more effectively via these receptors than other T cells 
(Figure 22). 
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Figure 20. Gating strategy for defining chemokine receptor positive Tregs 
After gating for CD4+ T cells, Foxp3 was used to define Tregs (A), the percentage of cells positive for a 
receptor (horizontal arrow) and the median fluorescence intensity of the positive cells was then 
determined, using an isotype control to determine the level of non-specific staining (blue shaded area) 
(B). 
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Figure 21: Homing phenotype of Foxp3+ TIL 
RCC TIL samples were stained with antibodies specific for 19 chemokine receptors and 7 adhesion 
molecules. Graphs display the mean percentage of T cells and the CD4+ Foxp3+ subset positive for each 
marker and the mean median fluorescence intensity of the staining (+ SD), both corrected for non-specific 
staining using concentration matched isotype controls. The number of RCC cases stained was as follows: 
CCR3, 4 5 6 7, CXCR3, 4 and 6 n = 10; CCR8 and CX3CR1 n = 8; CCR1, 2, 9, 10, CXCR2, 5, 7, XCR1 and 
CD11b  n = 7; CXCR1, CD62L and PSGL-1 n = 6; LFA-1, CLA, VLA-4 and BLT-1 n = 5. 
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Figure 22: Different patterns of chemokine receptor expression on CD4+Foxp3+ T cells and the 
whole T cell population 
RCC patients’ PBMC were stained with antibodies to all 19 chemokine receptors. Graphs display the 
percentage of T cells positive for each marker and the median fluorescence intensity of the staining. 
Results were corrected for non-specific staining using concentration matched isotype controls. Chemokine 
receptor staining on CD4+Foxp3+ and CD3+ T cells was compared and results are shown for those 
receptors for which the expression was significantly different between the subsets. Significance was 
calculated using a Wilcoxon matched pairs test.  
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3.4.2. Comparison of chemokine receptor expression on Foxp3+ T cells from TIL 
and matched peripheral blood 
Foxp3+ cells in PBMC show the conventional Treg chemokine receptor profile, with 
CCR4 and CCR7 being expressed on a greater percentage of Foxp3+ cells in PBMC than 
TIL (p = 0.0059 and p = 0.0645) (Figure 23). The Foxp3+ T cells in blood also expressed 
higher levels of CCR4 compared to matched TIL (p = 0.0316) (Figure 24).  
 
A greater proportion of putative Tregs in TIL than in PBMC expressed the receptors 
CCR1 (p = 0.0156), CXCR6 (p = 0.0137) and CXCR7 (p = 0.0156) (Figure 23). 
 
In common with the total TIL T cell population, compared to PBMC Foxp3+ TIL express 
significantly higher levels of CCR1 (p = 0.0313), CCR5 (p = <0.0001), CXCR3 (p = 0.0078) 
and CXCR6 (p = 0.0020). Interestingly they also express significantly higher levels of 
CCR6 (p = 0.0101) CXCR5 (p = 0.0313) and CX3CR1 (p = 0.0156) (Figure 24). 
 
These results showing enrichment of certain receptors on Foxp3+ TIL give an indication 
of the chemokine receptors Tregs use to enter RCC. However, as before, receptors CCR1, 
CXCR5, CXCR7 and CX3CR1 are only expressed on a very small proportion of the 
putative Tregs (Figure 23), and therefore I did not pursue these further. CCR6 was of 
particular interest as I only saw enrichment on the Foxp3+ subset of TIL and it was 
expressed by a significant proportion of cells, suggesting Tregs may have a separate 
mechanism of recruitment to the tumour via this receptor. 
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CD62L was expressed on a lower proportion of Foxp3+ TIL than Foxp3+ PBMC, which is 
unsurprising as it is a selectin usually involved in homing to lymph nodes. 
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Figure 23: Paired analysis of the percentage of CD4+Foxp3+ T cells from TIL and PBMC expressing chemokine receptors and adhesion molecules 
RCC TIL and PBMC were stained with antibodies to all 19 chemokine receptors and 7 adhesion molecules. Graphs display the percentage of viable 
CD3
+
CD45RA
-
CD4
+
Foxp3
+
 cells positive for each marker. Results are corrected for non-specific staining using concentration matched isotype controls. 
Significance calculated using a Wilcoxon matched pairs test. 
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Figure 24: Paired analysis of the median fluorescence intensity of staining of CD4+Foxp3+ T cells from TIL and PBMC for chemokine receptors and 
adhesion molecules 
RCC TIL and PBMC were stained with antibodies to all 19 chemokine receptors and 7 adhesion molecules. Graphs display the MFI of staining for each marker 
on viable CD3+CD45RA-CD4+Foxp3+  cells. Results are corrected for non-specific staining using concentration matched isotype controls. Significance 
calculated using a Wilcoxon matched pairs test. 
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3.5. Location of chemokine receptor positive lymphocytes in RCC 
I used immunohistochemistry to stain paraffin embedded RCC tissue for CCR5, CCR6, 
CXCR3 and CXCR6 to verify their expression by lymphocytes in the tumour and to 
examine the distribution of receptor positive cells. Positive staining was compared to 
concentration matched isotype controls. 
 
I found positive staining for CCR5 on lymphocytes in nine out of the ten samples studied; 
I could not identify any lymphocytes in the CCR5 negative sample. The positively stained 
lymphocytes were associated with vessels in the fibrous stroma. Interestingly some 
vessels, both in the fibrous area and within the tumour, also stained positively for CCR5, 
and tumour cells stained weakly in 6 out of 10 samples (Figure 22). 
 
CCR6 also stained a proportion of lymphocytes in all samples where lymphocytes were 
identifiably present. Again the majority of receptor positive lymphocytes were in the 
fibrous regions of the tissue, however I observed CCR6 positive lymphocytes in contact 
with tumour cells in half the samples studied. CCR6 also stained areas of tumour cells 
and some vessels in half of the samples (Figure 22). 
 
The CXCR3 antibody appeared to exclusively stain lymphocytes and a large proportion 
of lymphocytes in the stroma were CXCR3 positive. CXCR3 positive cells were also seen 
in contact with tumour cells, with the greatest levels of cell infiltration in the most 
vascularised areas (Figure 22). 
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CXCR6 also stained lymphocytes, and in common with CCR5 was most commonly seen 
on lymphocytes in the fibrous areas, with only a small minority of lymphocytes within 
the tumour staining positively. In addition the tumour cells stained weakly for the 
receptor (Figure 22) 
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Figure 25: Expression of selected chemokine receptors in RCC tissue 
5μm paraffin sections from RCC tumours were stained with antibodies to CCR5, CCR6, CXCR3 or CXCR6. 
Photos are representative of 10 RCC cases. For each receptor figures A, B, E and F show staining by 
antibodies to the chemokine receptors, and C, D, G and H show the corresponding isotype controls. 
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3.6. Chemokine expression in RCC 
In order for a T cell to home to RCC via a specific chemokine receptor, the ligand for that 
receptor must be present at the tumour site. Immunohistochemical analysis was used to 
confirm the presence of the chemokine ligands for the receptors CCR5, CCR6, CXCR3 and 
CXCR6.  
 
I stained for CCL4 and CCL5, both ligands for CCR5 and found both to be expressed by 
lymphocytes. CCL4 was expressed by lymphocytes both within the tumour and in 
fibrous stromal areas. CCL5 was only expressed by lymphocytes in fibrous areas, 
however it was also expressed occasionally on vessels in 3 of the 10 samples, both in the 
stroma and within the tumour. Tumour cells also stained positively for CCL5 (Figure 26). 
 
CCL20 is the only ligand for CCR6. Of ten samples stained for this chemokine only 3 
stained strongly, with CCL20 being expressed on lymphocytes in the stroma. In the other 
samples some staining was seen on tumour cells and vessels, however the staining was 
extremely weak (Figure 26). 
 
The ligands of CXCR3 are CXCL9, 10 and 11. I found CXCL9 to be expressed by tumour 
cells in all samples analysed. It was also expressed by lymphocytes both within the 
tumour and in fibrous regions, and by vessels in the stroma. CXCL10 was less frequently 
seen, with capillary-like cells staining within the tumour nests and occasional 
lymphocytes and tumour cells staining positively. CXCL11 was expressed most 
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frequently by tumour cells. However in half of the samples it stained vessels within the 
stroma, although vessels within the tumour were negative (Figure 26). 
 
The unique ligand for CXCR6 is CXCL16. I found CXCL16 to be expressed by tumour cells 
and vessels in the stroma. It was also seen on lymphocytes in the stroma (Figure 26). 
 
 
 
 
 
 
 
 
 
 
 
 
135 
 
 
136 
 
 
137 
 
 
 
138 
 
 
Figure 26: Expression of selected chemokines in RCC tissue 
5μm paraffin sections from RCC tumours were stained with antibodies to CCL4, CCL5, CCL20, CXCL9, CXCL10, CXCL11 or CXCL16. Photos are representative of 10 
RCC cases. For each receptor figure A shows staining by antibodies to the chemokine receptors, and B shows the corresponding isotype controls. 
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3.7. Chemokine receptors can induce migration to their ligands 
Having shown that CCR5, CXCR3 and CXCR6 are enriched on TIL compared to PBMC and 
that the corresponding ligands are expressed in the tumour tissue, I used migration 
assays to determine whether the chemokine receptors on TIL are functional. 
 
Initially I titrated the concentration of chemokine needed to induce maximal migration 
and determined 10nM to be the optimum concentration for CCL4, CCL5 and the CXCR3 
ligands (CXCL9, 10 and 11). Migratory activity with CXCL16 was greatest at 20nM. PBMC 
from healthy donors were used to determine the optimum concentration for CCL4, CCL5 
and CXCL9-11. RCC TIL were used to titrate CXCL16, as PBMC do not express the 
CXCL16 receptor, CXCR6. 
 
The CCR5 ligand CCL5 elicited the strongest migration index (2.3 ± 0.74), but 
reproducible responses were also seen to CCL4 (1.6 ± 0.67), the combination of CXCR3 
ligands CXCL9, 10 and 11 (1.7 ± 0.46) and the CXCR6 ligand CXCL16 (1.5 ±0.52) (Figure 
27). 
 
As 70% of TIL express more than one of the receptors being studied, I performed 
migration assays on 6 samples using mixtures of chemokines for multiple chemokine 
receptors, and compared levels of migration to assays using single chemokine receptor 
ligands performed in parallel. Combinations of ligands for CCR5 and CXCR6, CCR5 and 
CXCR3 and CXCR3 and CXCR6 did not significantly increase migration compared to 
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ligands to individual receptors. However combining the ligands of all three receptors of 
interest increased migration compared to using ligands of individual receptors or pairs 
of receptors (Figure 28). However, the variation in data between different experiments 
was large and therefore further study would be required to verify this result. 
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Figure 27: Functional test of CCR5, CXCR3 and CXCR6 on RCC TIL. 
Infiltrating lymphocytes isolated from RCC tissue were placed in the top chamber of a transwell filter with 
the indicated chemokine(s) or medium alone placed in the bottom chamber. Numbers of CD3+ T cells that 
migrated through the transwell were counted and a migration index measured by dividing the number of 
cells migrating in response to chemokine by the number that migrated in response to medium alone. 
Results shown represent mean migration index (+ SD) using TIL from multiple RCC cases as indicated. P 
values were calculated using the Wilcoxon signed rank test and indicate a significant increase in migratory 
activity in response to the chemokine indicated compared to media alone (A). The percentage of the cells 
inputted that migrated to chemokine or media was also calculated. Data from only 3 experiments are 
shown, as owing to low cell numbers for most samples I was not able to reserve enough cells to accurately 
measure the number of cells input Results show the median of each triplicate (+IQR) (B). 
A 
B 
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Figure 28: Migration of TIL to ligands for individual and combinations of receptors 
Infiltrating lymphocytes isolated from RCC tissue were placed in the top chamber of a transwell filter with the 
indicated chemokine(s) or medium alone placed in the bottom chamber. Numbers of CD3
+
 T cells that migrated 
through the transwell were counted and a migration index measured by dividing the number of cells migrating in 
response to chemokine by the number that migrated in response to medium alone. Results shown represent mean 
migration index of 7 RCC TIL samples (+ SD). 
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3.8. Discussion 
This chapter described an investigation into which recruitment mechanisms T cells 
utilise to home to renal cell carcinomas, and which T cell subsets are present at the 
tumour site. 
 
Whilst it has been shown that chemokine receptors can be internalised after engaging 
their ligands (Neel et al. 2005;Unutmaz et al. 2000), resulting in decreased surface 
expression of the receptor, studies investigating the roles of chemokine receptors in 
homing have demonstrated that overall, expression of a receptor required for homing to 
a tissue is enriched on cells within the tissue. In ovarian carcinoma Treg cells 
ubiquitously express CCR4, and blocking its ligand, CCL22, in in vivo models decreased 
Treg migration into tumour tissue. The Tregs also expressed CCR7 and migrated 
towards CCL19 and 21 in vitro (Curiel et al. 2004). It has also been shown that in tumour 
models where infiltrating T cells express CCR5, the addition of anti-CCR5 reduced 
accumulation of these cells in the tumours (Uekusa et al. 2002). Similar correlations 
between accumulation of receptor positive T cells and requirement of those receptors 
for homing to those tissues have been shown for the skin (Wang et al. 2010b), and gut 
(Stenstad et al. 2006). Therefore I examined differences in chemokine receptor 
expression between T cells in TIL and matched blood, as an increase in expression of 
chemokine receptors in TIL would indicate they had been recruited via those receptors. 
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It has been established in the literature (and I have also observed) that compared to RCC 
TIL, PBMC from RCC patients contain a larger proportion of naive T cells. One paper 
looked at CD45RO expression and found expression was significantly greater in TIL than 
PBMC. Another study used CD45RA and CCR7 to define memory phenotypes, and 
showed the percentage of naive cells in TIL was lower than in PBMC, for both CD4s and 
CD8s. In contrast TEMs were enriched within the TIL (Attig et al. 2009). Naive T cells are 
more likely to express CCR7 and CXCR4, and express very low levels of the inflammatory 
chemokine receptors such as CCR5, CXCR3 and CXCR6, compared to activated, memory 
T cells (Bleul et al. 1997;Campbell et al. 1998a;Gunn et al. 1998a;Qin et al. 
1998;Unutmaz et al. 2000). Therefore to ensure I was comparing equivalent 
populations, and not biasing the results, when looking at chemokine receptor expression 
in peripheral blood I only looked at the CD45RA- population. Although the memory CD8 
T cell subset TEMRA is CD45RA+ and so would be excluded from this analysis, the low 
percentage of CD45RA+ T cells in TIL suggests this T cell subset does not commonly 
infiltrate RCC. 
 
Initially the scope of my flow cytometry assays were limited by the available equipment, 
and so preliminary investigations used 4-colour flow cytometry to ascertain chemokine 
receptor and adhesion molecule expression on CD4 and CD8 T cells from RCC TIL. Later, 
the availability of the BD LSRII cytometer permitted staining for a wider range of 
markers, including CD45RA, meaning I could accurately compare TIL and matched 
PBMC samples, as I was able to exclude naive T cells from PBMC which could skew the 
results. Both methods showed T cells from TIL frequently express the chemokine 
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receptors CCR5, CXCR3, CXCR4 and CXCR6. The increased sensitivity of the LSRII also 
showed TIL express high levels of these receptors, as measured by median fluorescence 
intensity, and that CCR6 was also expressed by >10% of TIL. 
 
I found that CCR5, CXCR3 and CXCR6 were expressed on a significantly greater 
proportion of T cells from TIL than on those from PBMC. When I examined the MFI of 
chemokine receptor staining, which gives an indication of receptor density on the cell 
surface, I found CCR5, CXCR3 and CXCR6 were expressed at significantly higher levels on 
T cells from TIL than from PBMC. This suggests that the level of chemokine receptor 
expression may be significant in determining whether or not a T cell can migrate into 
RCC. There is limited evidence in the literature that the level of chemokine receptor 
expression affects trafficking. A study on monocytes showed increased CCR2 mRNA 
expression enhanced migration to CCL2 (Han et al. 1999). Another study looking at 
Jurkat cells found those expressing more CCR5 molecules migrated better to its ligand, 
and that this migration was blocked by CCR5 antibody (Desmetz et al. 2007) Also after 
CXCR6 transfection the cells with the highest levels of the receptor were most 
responsive to CXCL16, although this was measured in terms of induction of proliferation 
(Darash-Yahana et al. 2009). Increasing levels of CCR2 mRNA, in response to incubation 
of T cells with IL-2, correlated with in increased chemotaxis to CCL2. Increased levels of 
CCR1 mRNA also correlated with an increased chemotactic response to CCL5, however 
multiple chemokine receptors migrate to this ligand, which were not studied by this 
paper (Loetscher et al. 1996). 
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I also showed a significantly greater proportion of TIL expressed more than one of the 
chemokine receptors of interest compared to PBMC, and there was a reduction in the 
proportion of single positive CXCR3+ and CXCR6+ T cells in TIL compared to PBMC. This 
suggests a multi-step mechanism may be required for T cell homing to RCC, and 
expression of just one of the chemokine receptors may be insufficient for T cell 
migration into the tumour tissue. The ability of neutrophils to migrate sequentially to 
different chemokine stimuli has been demonstrated in vitro (Foxman et al. 1997), and 
more recently a multi-step mechanism of T cell recruitment has also been suggested in 
diseased liver tissue, where CXCR3 mediates recruitment through endothelium and 
CCR4 migration within the tissue to sites of inflammation (Oo et al. 2010). It is possible 
in RCC that only one or two receptors are needed for T cells to enter through vessels, 
and other receptors are involved in precise localisation or retention of the T cells within 
the tissue. As CXCL16 only mediated a low level of migration, and is a trans-membrane 
receptor, there has been suggestion of it functioning in adhesion (Shimaoka et al. 2004). 
Therefore one hypothesis could be that CXCR3 and CCR5 may play a role in cell 
migration into the tumour, and CXCR6 in cell adhesion and retention at the tumour site.  
 
Only 13 ± 8.3 % of TIL co-expressed all three receptors though, suggesting a maximum 
of two of these receptors is necessary for migration into RCC, indicating some 
redundancy in the mechanism of T cell homing. Interestingly, whilst only a negligible 
proportion of TIL expressed either CXCR3 or CXCR6 alone, 10 ± 18 % of TIL expressed 
CCR5 alone, suggesting of the three receptors CCR5 might be capable of facilitating T cell 
migration into RCC by itself. 
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I also examined the expression of adhesion molecules on TIL and PBMC, however the 
antibodies that were available to us were not conformation dependent, and so did not 
give an indication of whether the integrins investigated were activated and able to 
function. I saw no significant differences in adhesion molecule expression between TIL 
and PBMC.  
 
The predominance of CCR5, CXCR3 and CXCR6 suggests the infiltrating T cells have a 
memory, Th1 phenotype, which is desirable as there are some indications that those 
subsets are more likely to have anti-tumour activity (D'Ambrosio et al. 1998;Ito et al. 
1999;Kim et al. 2001a;Kondo et al. 2006;Loetscher et al. 1998b;Soleimani et al. 2009). 
Expression of all these receptors has been demonstrated on Th2 polarised cells in 
diseased tissue (psoriatic arthritis) (Kim et al. 2001b), however they are more common 
on Th1 cells and my cytokine staining (see section 4.2.1, p157) suggests a significant 
proportion of TIL are type 1 polarised. CXCR3 has also been demonstrated on Th17 cells, 
however my studies indicate these only constitute a tiny proportion of the TIL 
population (see section 5.2 p214).  
 
Perhaps it is unsurprising that CCR5, CXCR3 and CXCR6 are expressed together as their 
expression, along with CCR6, can be induced by the same cytokines— IL-2 and IL-15, 
and in that way they are co-ordinately regulated (Unutmaz et al. 2000). CXCR3 is also 
induced by IL-2 (Loetscher et al. 1998a). 
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When I examined which T cell subsets had infiltrated RCC, it became apparent a sizeable 
proportion of CD4 T cells had a regulatory T cell phenotype (Foxp3+CD25hiCD127lo), and 
that the proportion of Tregs present correlated with the Fuhrman grade of the tumour. 
This supports data found by other groups. One study found levels of CD4+Foxp3+ cells to 
be higher in all the RCC tissue samples they tested when compared to levels in 
peripheral blood, and that levels of Tregs in peripheral blood correlated with survival 
(Griffiths et al. 2007). Another study has also found an increase of Foxp3+CD4+CD25+ 
cells in RCC TIL compared to PBMC, and found that depletion of these cells increased the 
proliferative capacity of CD4+CD25- cells, and their ability to secrete IFN-γ following an 
MLR stimulation. Higher frequency of the Tregs correlated with grade and stage of 
disease and a higher risk of tumour recurrence (Liotta et al. 2010b). Furthermore 
studies of patients treated with IL-2 have found patients who responded to treatment 
had lower increases in Treg levels and a swifter reduction in Treg numbers post-
treatment, responded best and had better prognoses (Cesana et al. 2006;Jensen et al. 
2009).  
 
In contrast another group detected CD4+CD25+Foxp3+ cells in only a quarter of the 170 
tumours studied, at a mean of 4.1% of CD4 T cells. The presence of these cells did not 
correlate with an increased risk of death from RCC, whereas there was such a 
correlation with the number of CD4+CD25+Foxp3- cells. This T cell subset was detected 
within 84.1% of tumours studied at a mean percentage of 12.1% of CD4 T cells (Siddiqui 
et al. 2007). However these experiments were performed using immunohistochemistry 
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which may be less sensitive than flow cytometry. It is interesting to speculate that these 
Foxp3- CD4 T cells could be Tr1s which, as described earlier, also have a regulatory 
function. 
 
In light of the potential impact of these Tregs, I was interested in how they were being 
recruited into RCC. I found their homing phenotype was similar to that of the whole T 
cell population, with the addition that CCR6 was also more highly expressed on Tregs in 
TIL than in PBMC. This may explain the significant difference between CD4 and CD8 T 
cells in terms of the proportion and level of CCR6 expression, as the Tregs are within the 
CD4 subset. CCR6 has been found on PBMC Tregs in healthy donors and has been 
demonstrated to be expressed by Tregs in breast cancer and hepatocellular carcinoma 
tumours (Chen et al. 2011;Xu et al. 2010;Yamazaki et al. 2008). CCR6 is also associated 
with the pro-inflammatory Th17 cell subset (Yamazaki et al. 2008). However my 
preliminary investigations suggest only very low levels of Th17s (<1%) are present in 
RCC (see section 5.2, p214). Interestingly other chemokine receptors commonly found 
on Tregs in PBMC and other diseased tissues, such as CCR4 and CCR7 (Hirahara et al. 
2006;Iellem et al. 2001;Oo et al. 2010;Tosello et al. 2008), were absent from Tregs in TIL 
suggesting Tregs may home to RCC tumours via an RCC-specific mechanism. That is, 
they may use different chemokine receptors to migrate to RCC, compared with the 
receptors Tregs use to migrate to other sites of disease. In addition a higher proportion 
of Tregs expressed CXCR3 than the whole T cell population, and Tregs expressed higher 
levels of CCR5 and CXCR6, suggesting that while they share these receptors with effector 
T cells, they may be more efficient at migrating to their ligands. Due to restrictive cell 
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numbers and sample availability I was unable to examine co-expression of CCR6 with 
the other receptors of interest, however in common with the other receptors IL-2 and 
IL-15 increase its expression, suggesting co-expression is likely, however this has not 
been investigated in the Treg subset (Unutmaz et al. 2000). 
 
It was important to determine whether the chemokine ligands of CCR5, CCR6, CXCR3 
and CXCR6 are expressed in RCC, as without them the receptors would not function in T 
cell migration to the tumour. Ligands to all the receptors were found to be present to 
varying degrees. 
 
My results corroborate previous reports to some extent. RT-PCR studies have shown 
RNA levels for CCL4, CCL5, CXCL9, 10 and 11 are significantly higher in tumour than 
normal tissue (Kondo et al. 2004;Romero et al. 2006).  
 
The expression of CXCL9 and 11 has also been demonstrated in the literature by 
immunohistochemistry, where the former was positive on capillaries and lymphocytes 
and the latter on pericytes associated with vascular smooth muscle cells (Suyama et al. 
2005b). In contrast I saw no staining of CXCL9 or 11 on vasculature within the tumour. 
In my hands CXCL9 stained lymphocytes (in common with the published study) and 
tumour cells. CXCL11 also stained tumour cells. I did see both chemokines on vessels, 
but only those within the stroma, not within the tumour nests. The reason for these 
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differences is uncertain, however it is unclear which antigen retrieval method Suyama T 
et al. used, and in my hands EDTA buffer resulted in a very high background. Without 
this knowledge and the pictures of the corresponding isotype controls I cannot discount 
background staining accounting for some of their positive results. 
 
In agreement with my data, an immunohistochemical study of 104 RCC tumour samples 
found CXCL16 to be present in 86% of samples and it exhibited diffuse staining 
throughout the cytoplasm (Gutwein et al. 2009). CCL20 has also previously been 
demonstrated to be expressed in the cytoplasm of RCC cells (Middel et al. 2010). In my 
experiments I saw weak staining of tumour cells in 8 out of 11 samples, however the 
lymphocytes in the stroma stained more strongly. The previous study used a tyramide 
amplification system, so perhaps my assay was not sensitive enough. However the 
staining of my positive control, tonsil, was strong, suggesting at least in comparison that 
tissue expression in RCC is weak. It is also unclear how many samples the other study 
looked at. 
 
Despite CCL4 being expressed by lymphocytes within the tumour and some tumour cells 
expressing CCL5, CCR5+ T cells didn’t infiltrate the tumour nests. To my knowledge this 
is the first time the expression of CCR5 in RCC has been examined by IHC. CXCR6 
expression by tumour cells has previously been demonstrated (Gutwein et al. 2009). I 
saw weak staining of tumour cells, but also observed lymphocytes in the stromal areas 
to be positive. However despite tumour cell expression of the ligand, very few CXCR6+ T 
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cells appeared to infiltrate the tumour. CXCR3+ T cells infiltrated the tumour nests more 
effectively, perhaps due to strong expression of CXCL9 and 11 on the tumour cells, and 
the expression of CXCL10 by on some capillaries within the tumour. Previous studies 
have also shown CXCR3+ lymphocytes within RCC by IHC (Kondo et al. 2006), within the 
tumour and at peri-tumoural areas (Suyama et al. 2005a). CCR6+ T cells also infiltrated 
the tumour, despite weak expression of the CCR6 ligand, CCL20. The presence CCR6+ 
dendritic-like cells have previously been suggested within RCC tumours (Middel et al. 
2010). I observed lymphocyte-like cells to stain positively both within the tumour and in 
the fibrous regions. They appeared to have lymphocyte morphology but without dual-
staining with a T cell marker I could not definitively determine the cell type. I did not 
investigate co-expression of CCR6 with other receptors but perhaps it works in concert 
with another chemokine receptor to aid infiltration of cells despite possible low levels of 
its ligand.  
 
In addition to CXCR6, I also observed CCR5 and CCR6 expression by tumour cells. CCR6 
expression has previously been demonstrated by PCR on RCC tumour cells in short term 
culture, however the same study found no CCR5 expression (Johrer et al. 2005). 
However CCR5 expression has been suggested in oral cancer, and prostate cancer 
(Chuang et al. 2009;Vaday et al. 2006). These chemokine receptors could be involved in 
tumour metastasis. Knockdown of CCR5 inhibits the metastatic potential of breast 
cancer cells in mouse studies (Karnoub et al. 2007), and a CCR5 antagonist is currently 
being investigated to limit metastasis of prostate cancer (Zhang et al. 2010). There are 
also indications CCR6 and CCL20 mediate metastasis to the liver in colorectal cancer 
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(Ghadjar et al. 2006;Rubie et al. 2006). In contrast, knocking down CXCL16 increased 
rather than decreased migration of cells from the RCC line ACHN3. The migration 
inhibitory effect of CXCL16 is presumably carried out by the membrane bound form as 
soluble CXCL16 increased cell migration, suggesting that the soluble form of the ligand 
affects metastasis in a similar way to other chemokines (Gutwein et al. 2009). 
Unexpectedly, some vessels in RCC appeared to express CCR5 and CCR6. There is 
evidence that human endothelial cells can express some chemokine receptors, such as 
CXCR2, CXCR3 and CXCR4 (Mestas et al. 2005;Strieter et al. 2005), but literature on 
CCR5 and CCR6 expression is rare. However CCR5 expression has been reported on 
brain, coronary, appendix, mesenteric lymph node, dermal, umbilical vein and 
saphenous vein endothelia, and CCR6 on dermal, lung microvascular and saphenous 
vein endothelia, and on capillaries in normal renal tissue (Berger et al. 1999;Crola Da et 
al. 2009;Hillyer et al. 2003;Welsh-Bacic et al. 2011). The vasculature in RCC is abnormal 
which may account for aberrant expression of receptors in some samples. 
 
The predominance of lymphocyte aggregates within stroma has also been observed in 
colorectal cancer (Musha et al. 2005), seminomas (Bell et al. 1987), sertoli cell tumours 
(Henley et al. 2002) and merkel cell carcinomas (Ciudad et al. 2010). I observed that the 
vessels in the stroma expressed more chemokines that vessels within the tumour, which 
may account for T cells being able to migrate to fibrous areas. The abundance of T cells 
in the fibrous regions might also be due to successful killing of tumour cells in those 
areas, resulting in the formation of stromal areas. Presumably the surrounding tumour 
has evolved to better evade the immune response. 
154 
 
 
Previous studies on the homing receptor profile of RCC TIL are limited, with very small 
panels of receptors and T cell markers. One study investigated expression of CCR4, CCR5 
and CXCR3 by flow on 24 matched CD4+ TIL and PBMC (without stating the use of 
isotype controls), and found the frequency of CCR5 and CXCR3 to be increased in TIL 
compared to PBMC, and CCR4 expression to be decreased. Interestingly their data 
suggests the expression of CCR5 and CXCR3 decreases with tumour stage, whereas CCR4 
expression on TIL increases (Cozar et al. 2005). However looking at the whole T cell 
population I did not see a correlation between chemokine receptor and stage. Another 
study showed that in 16 out of 21 RCC samples, CXCR3 RNA was expressed, compared to 
2 out of 21 normal tissue samples. IHC demonstrated that this CXCR3 was expressed by 
lymphocytes (as well as tumour cells and macrophages) within the tumour and in the 
peri-tumoural area (Suyama et al. 2005a). A more comprehensive study of 33 RCC 
samples and 20 matched PBMC, examining expression of 4 chemokine receptors by flow 
cytometry, reported an increase in CCR5+ and CXCR3+ CD4 and CD8 T cells in TIL, 
compared to PBMC. However again isotype controls were not described and naive T 
cells were not excluded from the data (Attig et al. 2009). Finally a fourth study showed 
enrichment of CCR5+ and CXCR3+ CD8 and CD4 T cells in RCC compared to PBMC, 
however it is unclear whether the blood and TIL samples were matched and whether 
isotype controls were used (Kondo et al. 2006). Therefore my data support previous 
findings that RCC TIL express CCR5 and CXCR3, but also improve the quality of the 
evidence by examining the possibility that any of the known chemokine receptors could 
be involved in T cell recruitment to RCC. This study is also the first to avoid potential 
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bias by excluding naive cells from the analysis, which would otherwise skew the 
apparent chemokine receptor profile of PBMC. 
I was also the first to test whether the chemokine receptors on TIL are able to function 
and induce migration in response to their ligands. The transwell assay I used is artificial 
in that it only measures response to the chemokine, whereas in physiological situations 
cell migration involves interactions between molecules expressed on an HEV and 
selectins and integrins, as well as chemokine receptors. However the movement I 
measured in response to the chemokine ligands illustrates that the chemokine receptors 
are capable of inducing downstream signalling pathways resulting in cell movement, 
and therefore if the TIL encounter their ligands in vivo they are likely to migrate towards 
them. 
 
As I found the majority of T cells to express multiple chemokine receptors, I investigated 
the effect of multiple ligands on their migration. While I saw a slight increase in 
movement when using ligands for CCR5, CXCR3 and CXCR6 in the same well, the effect 
was small and there was large variation. Further work would be required to confirm this 
finding. 
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4. Function of TIL 
4.1. Introduction 
I established in chapter 3 that T cells, including those of a regulatory phenotype, 
infiltrate RCC. There is evidence to suggest RCC-specific T cells can be present in cancer 
patients, and that they can recognise and kill tumour cells in vitro as discussed in section 
1.4.3. Evidently, however, these T cells are not sufficient for eliminating the established 
tumour. Chapter 4 aims to elucidate why this might be. 
 
It is unclear precisely why T cells in cancer patients are unable to kill the tumour cells. 
The T cells may have been rendered anergic and dysfunctional by tumour-derived 
factors, or by interactions with other cells types recruited to the tumour, such as Tregs. 
 
In order to determine the degree to which effector T cells have been made unresponsive 
in situ I compared the function of TIL and matched PBMC using various parameters. I 
also further investigated the functional phenotype of infiltrating Tregs to determine 
whether they may have a role in effector T cell suppression. Finally I also performed 
some preliminary studies on the effects of the inhibitory molecule PD-1 on T cell 
function. 
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Unless otherwise stated, throughout this chapter ‘TIL’ and ‘PBMC’ refer to the T cell 
compartment within the respective populations. All significances were calculated using 
Wilcoxon matched pairs tests. 
 
4.2. Effector T cells from RCC TIL are able to function ex vivo 
I investigated the function of TIL isolated from RCC tumours, without any in vitro culture 
or expansion. I looked at both their cytokine expression in response to stimulation, and 
surface markers that give an indication of the functional status of T cells. 
 
4.2.1. Effector cytokine production by TIL 
The cytokines interleukin-2 (IL-2), interferon-gamma (IFN-γ) and tumour necrosis 
factor alpha (TNFα) are association with type 1 T cell immune responses. Therefore I 
looked at their expression by TIL post-stimulation to get an indication of whether T cells 
from TIL retained the same functional capacity as those in PBMC, or to what extent they 
had been anergised in the tumour environment. 
 
TIL and matched PBMC were stimulated with PMA/ionomycin and subsequently 
analysed by intracellular cytokine staining to determine their capacity to produce 
effector cytokines. TIL showed no defect in production of any of the three cytokines in 
comparison to PBMC (Figure 26). In fact, a significantly greater proportion of CD4+ TIL 
than CD4+ PBMC were able to produce IFN-γ (p = 0.0280) and IL-2 (p = 0.0003). As 
expected, in both TIL and PBMC CD4+ T cells were more likely to produce IL-2 than CD8+ 
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T cells (p-values of 0.0003 and 0.0008 respectively) (Croft et al. 1994). Interestingly, 
IFN-γ production by CD4 T cells was greater in TIL than PBMC, whereas CD8 T cells from 
these two sites showed the same level of IFN-γ production. The capacity of TIL to 
produce cytokines in response to stimuli suggests the cells are not irreversibly 
anergised or inherently defective and that their function can be rescued (Figure 26). A 
table describing effector cytokine production by TIL compared to the Fuhrman grade of 
the sample and subtype of RCC can be found in Appendix B 
159 
 
F
o
x
p
3
IFNg TNFaIL2 Isotype control
P
B
L
T
IL
F
o
x
p
3
IFNg TNFaIL2 Isotype control
 
 
 
 
 
 
 
  Figure 29: Gating strategy for defining effector cytokine producing cells 
TIL and PBMC were stimulated with PMA/ionomycin, and the percentage of CD4 and CD8 T cells producing effector cytokine was analysed 
by flow cytometry. The diagram indicates how isotype controls were used to define positive staining. In this representative plot the cells are 
gated on CD4. The cells have also been co-stained for Foxp3, and the same assays were used to determine cytokine production by Tregs (see 
section 4.3.2 p176) 
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Figure 30: Effector cytokine production by TIL and PBMC 
TIL and PBMC were stimulated with PMA/ionomycin, and the percentage of CD4 and CD8 T cells producing effector cytokine was analysed by flow cytometry 
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4.2.2. CD107a, a marker of degranulation, is expressed on TIL 
CD107a is mobilised to the cell surface when degranulation of T cells takes place in 
response to stimulation (Betts et al. 2003). I therefore examined its cell-surface 
expression as a surrogate to detect cytotoxic T cell effector function.  
 
CD8 T cells are more commonly cytotoxic, and in TIL significantly more CD8 T cells 
expressed CD107a than CD4 T cells. This was true both before and after PMA/Ionomycin 
stimulation, however the difference was more marked in un-stimulated cells (Figure 
31A). Un-stimulated CD8 T cells from PBMC also had a significantly greater proportion of 
CD107a+ cells than their CD4+ counterparts (Figure 31A). Un-stimulated CD107a+ CD4 T 
cells in both TIL and PBMC represented a small minority of the population, and this 
subset increased significantly upon stimulation (Figure 31A). 
 
Both CD4 and CD8 T cell subsets in un-stimulated TIL had significantly larger subsets of 
CD107a+ cells than the same subsets in un-stimulated PBMC, perhaps due to 
degranulation in response to antigen recognition at the tumour site (p = 0.0010 for CD4 
T cells and p = 0.0068 for CD8 T cells) (Figure 31B). However the MFI of the staining on 
un-stimulated cells was weak (data not shown). 
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Figure 31: CD107a expression on TIL and PBMC 
TIL and PBMC were stained for CD107a and analysed by flow cytometry. The percentage of CD4 and CD8 
T cells expressing CD107a both with and without stimulation by PMA/ionomycin was determined (A) for 
stimulated data n = 9, for un-stimulated data n = 11. Data represents the mean percentage of cells 
expressing CD107a (+SD). CD107a expression in un-stimulated CD4 and CD8 T cells from matched TIL 
and PBMC was compared (B). All significance values were calculated using a Wilcoxon matched pairs 
test. Representative plots showing CD107a staining on CD8 T cells (orange) and CD4 T cells (blue) 
compared with an isotype control (shaded red) (C). 
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4.2.3. Expression of CD27 and CTLA-4 on TIL and PBMC 
CD27 is upregulated on T cells after activation, and lost after repeated antigen 
stimulation when T cells enter a late stage of differentiation (De et al. 1992;Hintzen et al. 
1993). Therefore I investigated its expression to gain insight into the differentiation 
status of the T cells in tumour and peripheral blood. In both TIL and PBMC it was 
expressed by a mean of over 50% of all CD45RA- T cells, however the percentage of CD4 
T cells from TIL expressing the marker was significantly reduced compared to PBMC 
(Figure 32) 
There was no difference in CD27 expression between CD8 T cells from TIL and PBMC 
(data not shown) 
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Figure 32: CD27 expression by CD4 TIL and PBMC 
The expression of CD27 on CD4 T cells from TIL and PBMC was analysed by flow cytometry. Significance 
was calculated using a Wilcoxon matched pairs test (A). Representative plot showing CD27 staining on 
CD4+ T cells from PBMC (blue), TIL (yellow) compared to an isotype control (shaded red) (B).  
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CTLA-4 is also upregulated upon T cell activation, however its expression is associated 
with subsequent suppression of the immune response (Walunas et al. 1994). I looked at 
the percentage of cells expressing CTLA-4 in both un-stimulated TIL and PBMC, and in 
the same samples after incubation with the stimuli PMA/ionomycin. Post-stimulation 
there was little difference in CTLA-4 expression between CD4 and CD8 T cells, and 
between TIL and PBMC (Figure 33A). The T cells from TIL did not significantly up-
regulate CTLA-4 upon stimulation, whereas the proportion of CD4 T cells from PBMC 
expressing CTLA-4 significantly increased after stimulation (p = 0.0195). This pattern 
was also evident in the CD8 PBMC T cells (p = 0.0419) (Figure 33A). This may suggest TIL 
have already reached their maximum levels of CTLA-4 expression. 
 
Both the CD4 and CD8 un-stimulated T cells from TIL displayed a significantly higher 
frequency of CTLA-4 expression than their counterparts in matched PBMC (Figure 33B). 
This indicates they may have been activated at the tumour site. 
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Figure 33: CTLA-4 expression by TIL and PBMC 
CTLA-4 expression was measured on TIL and PBMC that were either stimulated with PMA/ionomycin, or 
left un-stimulated. Results were analysed by flow cytometry. Solid bars represent TIL, lined bars 
represent PBMC. * indicates p = <0.05, ** indicates p = <0.01 (A). CTLA-4 expression on un-stimulated 
CD4 and CD8 T cells from TIL and PBMC was compared (B). Significance was calculated using Wilcoxon 
matched pairs tests. 
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4.2.4. PD-1 is expressed more frequently on TIL than PBMC 
PD-1 is upregulated upon T cell activation, however if it then binds either PD-L1 or PD-
L2 (its ligands), T cell function becomes impaired and T cells become anergised (Barber 
et al. 2006;Freeman et al. 2000;Latchman et al. 2001). As the expression of PD-L1 has 
been reported in RCC (Blank et al. 2006;Thompson et al. 2004;Thompson et al. 2006), I 
investigated PD-1 expression on TIL and matched PBMC. 
 
In both TIL and PBMC a significantly higher proportion of CD8 T cells than CD4 T cells 
expressed PD-1 (Figure 34a). T cells from both subsets of TIL included a greater 
proportion of PD-1+ cells than those in PBMC. (Figure 34b). As with CD107a this 
difference between TIL and matched blood may be due to TIL being activated at the 
tumour site. However the expression of PD-1 may indicate an anergised phenotype 
arising from repeated antigen stimulation. I was able to confirm the expression of PD-1 
by RCC infiltrate using IHC (Figure 35). 
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Figure 34: Expression on PD-1 on TIL and PBMC 
The expression of PD-1 was compared on CD4 and CD8 T cells from both TIL and PBMC (A). Expression 
was also compared on CD4 T cells from TIL and PBMC, and CD8 T cells from TIL and PBMC (B). 
Significance was calculated using Wilcoxon matched pairs tests. 
B 
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Figure 35: PD-1 expression in RCC tissue 
5μm paraffin sections from RCC tumours were stained with an antibody to PD-1(left) or a concentration 
matched isotype control (right). Photos are representative of 10 RCC cases 
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4.2.4.1. Phenotype and function of PD-1+ T cells 
To further investigate the functional status of PD-1+ TIL I compared expression of the 
functional markers HLA-DR, CD127, CD25, CD27, Ki67, CTLA-4 and CD107a on PD-1+ 
and PD-1- memory T cells from TIL and matched PBMC. While there were no significant 
differences between the phenotypes of PD1+ cells in TIL and PBMC (data not shown), I 
did find distinctions between PD-1+ and PD-1- TIL. HLA-DR was expressed by a 
significantly larger proportion of PD-1+ cells than PD-1- cells (p = 0.0313), whereas CD25 
was found more frequently on the PD-1- subset (p = 0.0313) (). I also saw increased 
numbers of CD27+, Ki67+ and CD107a+ cells, and decreased numbers of CD127+ cells 
within the PD-1+ TIL subset, although the differences did not reach significance (Figure 
36). With the exception of CD27, PD-1+ and PD-1- PBMC followed a similar pattern (data 
not shown). 
 
To determine whether PD-1+ cells were dysfunctional in terms of cytotoxic capacity or 
effector cytokine production, cells were stimulated with anti-CD3 and anti-CD28 beads, 
before intracellular staining was carried out for IL-2, IFN-γ, perforin and granzyme B. In 
terms of cytokine production, only CD4 T cells with very high levels of PD-1 appeared to 
have an impaired ability to produce IL-2 and IFN-γ, but this did not reach significance, 
whereas CD8 T cell cytokine production did not appear to be affected by PD-1 
expression (Figure 37B). However a significantly greater proportion of PD-1hi CD4 T cells 
expressed granzyme B than their PD-1- counterparts (Figure 37C), and again this pattern 
was not mirrored in the CD8 T cell population. Expression of PD-1 by CD8 T cells did 
significantly decrease the proportion of perforin-expressing cells (Figure 37C). No 
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significant differences in perforin expression by CD4 T cells were seen but perforin 
expression by all CD4 T cells was extremely low. 
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Figure 36: Expression of various functional markers on PD-1+ and PD-1- TIL 
TIL were co-stained for PD-1 and HLA-DR, CD27, Ki67, CTLA-4, CD107a, CD25 or CD127. For HLA-DR, 
CD127, CD25 and CD27 n = 6, for Ki67n = 4 and for CD107a and CTLA-4 n = 3. Data represent the mean 
percentage of cells positive for CTLA-4 (+SD). * indicates a p = <0.05. Significant calculated using Wilcoxon 
matched pairs tests. 
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Figure 37: Cytokine production, granzyme B and perforin expression of PD-1+ and PD-1- TIL 
T cells were stimulated with αCD3 and αCD28 beads before being stained and gated on PD-1 expression 
(A). Cells were co-stained with IL-2, IFN-γ (B), granzyme B or perforin (C). Significance was calculated 
using Wilcoxon matched pairs tests. 
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4.3. Function of Foxp3+ T cells in vitro  
In section 3.4 I found that there were increased levels of Foxp3+CD4+ T cells in TIL 
compared to PBMC, and that they have the CD25hiCD127lo phenotype typical of classic 
regulatory T cells. I then sought to perform further phenotypic and functional analysis to 
confirm these cells have a regulatory role and to establish their mechanism of function 
at the tumour site. 
 
4.3.1. Attempt at proliferation assays 
The most common method of proving Treg function is to perform a proliferation assay 
and look at how Tregs affect the proliferation of responder cells. Initially I attempted to 
isolate Tregs from limited numbers of TIL using regulatory T cell isolation kits. However 
the purity and yield were insufficient to permit proliferation assays. 
 
4.3.2. Effector cytokine production by Foxp3+ T cells 
In order to investigate the function of Foxp3+ TIL, I looked at cytokine production by 
those cells compared to the general T cell cohort. Effector T cells produce IFN-γ, IL-2 and 
TNFα upon stimulation (see section 4.2.1, p157), whereas Tregs are characterised by 
their anergy and lack of cytokine production (Ahmadzadeh et al. 2008;Kryczek et al. 
2009b;Wolf et al. 2003). 
 
177 
 
Not only did a significantly smaller proportion of Tregs compared to effector CD4 T cells 
produce the cytokines IFN-γ (p = 0.0006), IL-2 (p = 0.0008) and TNFα (p = 0.0045), but 
the difference between Treg and effector T cell cytokine production was more marked in 
TIL than PBMC (Figure 38). 
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Figure 38: Effector cytokine production by Foxp3+ and Foxp3- TIL 
TIL and PBMC were stimulated with PMA/ionomycin, and the percentage of Foxp3+ (Treg) and Foxp3- (effector) CD4 TIL producing effector cytokine was 
analysed by flow cytometry. For a representative plot see Figure 29 p159. 
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4.3.3. Putative Tregs express CTLA-4 
CTLA-4 is expressed by Tregs and constitutes a mechanism by which they can suppress 
T cell function (Qureshi et al. 2011;Tivol et al. 1995;Waterhouse et al. 1995). I found the 
Foxp3+CD4 T cells in TIL contained significantly more CTLA-4+ cells and expressed the 
marker at significantly higher levels than Foxp3-CD4 T cells (Figure 39A). Comparing 
Foxp3+CD4 T cells in TIL with their counterparts in PBMC showed that CTLA-4 was 
expressed on a greater proportion of those in TIL and expression of the marker in TIL 
Tregs was increased compared to PBMC when measuring MFI. (Figure 39B). The high 
levels of CTLA-4+ on the Foxp3+ population is suggestive of a regulatory phenotype. 
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Figure 39: CTLA-4 expression on Foxp3+ and Foxp3- T cells from TIL and PBMC 
RCC TIL were stained co-stained for CTLA-4 and Foxp3. Graphs display the percentage of T cells positive 
for each marker and the median fluorescence intensity of the staining. CTLA-4 staining on Foxp3+ and 
Foxp3- T cells from TIL was compared and a representative plot gated on CD4+ T cell is shown (A). 
Staining on Foxp3+ T cells from TIL and PBMC was compared and a representative plot showing 
CD4+Foxp3+ T cells from PBMC (blue) and TIL (orange) compared to an isotype control (shaded red) is 
shown (B). Significance was calculated using a Wilcoxon matched pairs test 
A 
B 
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4.3.4. Expression of PD-1, CD107a and CD27 on Tregs in RCC 
PD-1 and CD107a expression are not generally associated with Tregs. However I saw 
expression of both PD-1 (39 ± 15 %) and CD107a (4.4 ± 3.6 %) on a proportion of 
Foxp3+ CD4 T cells from TIL. (Figure 40A and B). 
  
The percentage of Foxp3+CD4+ cells expressing PD-1 in TIL was greater than the 
proportion of Foxp3-CD4+ cells expressing this marker and it was also greater than the 
percentage of Foxp3+CD4+ cells from PBMC expressing PD-1 (Figure 40A). The putative 
Tregs from TIL were also more likely to express CD107a than those from PBMC (Figure 
40B), however there was no significant difference between CD107a expression on 
Foxp3+ and Foxp3- CD4 T cells from TIL (data not shown). The expression of these 
markers suggests additional mechanisms by which Tregs might carry out their function. 
 
The expression of CD27 varies between different functional subsets of T cells. I found a 
large proportion (79 ± 29 %) of Foxp3+ TIL expressed CD27, which was significantly 
greater than the percentage of Foxp3- TIL (50 ± 28 %) (Figure 40C). Expression of CD27 
on Foxp3+ cells from TIL and PBMC was similar (data not shown). 
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Figure 40: Expression of PD-1, CD107a and CD27 on Foxp3+ and Foxp3- T cells 
TIL and PBMC were co-stained for Foxp3 and PD-1 and the expression of PD-1 compared on Foxp3+ and 
Foxp3- T cells. Representative plot shows PD-1 staining on PBMC (blue), CD4+Foxp3- T cells (green) and 
CD4+Foxp3+ T cells (orange) compared to an isotype control (shaded red) (A). Foxp3+ T cells from TIL 
and PBMC were stained for CD107a and the proportions positive for the marker compared. The plot 
shows CD107a staining on CD4+Foxp3+ T cells from TIL (blue) and PBMC (orange) compared to an 
isotype control (shaded red) (B). Foxp3+ and Foxp3- TIL were stained for CD27 and compared. The plot 
shows CD4+Foxp3- T cells (blue) and CD4+Foxp3+ T cells (orange) from TIL compared to an isotype 
control (shaded red) (C). Significance was calculated using a Wilcoxon matched pairs test. 
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4.3.5. The ratio of the percentage of Tregs in TIL: Tregs in PBMC correlates with 
function of TIL 
I investigated whether there was a correlation between the markers of T cell function 
discussed above and the percentage of Tregs present in the TIL, to determine whether 
the Tregs were having a detectable effect on TIL function. Whereas I found no 
correlations between these markers and the proportion of Tregs in TIL, I did find that 
the ratio of Tregs in TIL: PBMC inversely correlated with effector cytokine production by 
Foxp3- T cells. For CD4+ T cells, the correlation coefficient looking at IFN-γ expression 
was -0.5679, p = 0.0272. The correlation for IL-2 approached significance: r = -0.4735, p 
= 0.0639, and for TNFα r = -0.5794, p = 0.0187 (Figure 41). For CD8+ cells the correlation 
was less clear, with IFN-γ and TNFα not quite reaching significance (r = -0.5071, p = 
0.0537 and r = -0.4571, p = 0.0867) (Figure 42) and IL-2 expression did not correlate 
(data not shown). These data suggest it is an enrichment of Tregs in TIL compared to 
PBMC that affects effector T cell function, rather than simply the proportion of Tregs 
present in the TIL. 
 
In addition, there was a inverse correlation between the level of CTLA-4 expression on 
effector T cells and the ratio of Tregs in TIL:PBMC. For CD4+ T cells the correlation 
coefficient was -0.7857, p = 0.0480, and for CD8+ T cells it was -0.8571, p = 0.0238 
(Figure 43). 
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Figure 41: Correlations between the ratio of Tregs in TIL: PBMC and CD4 T cell effector cytokine 
production 
Effector cytokine production by Foxp3- CD4 TIL was measured by intracellular cytokine staining and 
compared to the ratio of the percentage of Tregs in TIL: percentage of Tregs in PBMC. Correlation was 
calculated using the nonparametric Spearman correlation coefficient. 
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Figure 42: Correlations between the ratio of Tregs in TIL: PBMC and CD8 T cell effector cytokine 
production 
Effector cytokine production by Foxp3- CD8 TIL was measured by intracellular cytokine staining and 
compared to the ratio of the percentage of Tregs in TIL: percentage of Tregs in PBMC. Correlation was 
calculated using the nonparametric Spearman correlation coefficient. 
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Figure 43: Correlations between the ratio of Tregs in TIL: PBMC and CTLA-4 expression  
CTLA-4 expression by Foxp3- CD4 and CD8 TIL was measured by flow cytometry and compared to the 
ratio of the percentage of Tregs in TIL: percentage of Tregs in PBMC. Correlation was calculated using the 
nonparametric Spearman correlation coefficient. 
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4.4. Discussion 
In the previous chapter I confirmed the presence of T cells in RCC, and examined their 
homing receptor profile to elucidate the mechanisms of their recruitment. In this 
chapter I determined the different T cell subsets that make up the TIL population, and 
investigated their functional capacities. 
 
Although there has been some suggestion in the literature that CD8+ TIL from RCC are 
defective in function (Kudoh et al. 1997;Van den Hove et al. 1997a), my data suggest 
both CD4 and CD8 T cells from TIL are just as able, or in the case of CD4 T cells and IFN-γ 
and IL-2, more able, to produce effector cytokines, as their counterparts in peripheral 
blood. This discrepancy between TIL and PBMC could be due to the increased 
proportion of TEMs compared to TCMs in TIL as opposed to PBMC, as TEMs produce effector 
cytokine more efficiently upon stimulation (Sallusto et al. 2004). 
 
PMA/ionomycin function by bypassing the need for signalling through the TCR by 
directly increasing the concentration of Ca2+ in the cell cytoplasm and activating protein 
kinase C (Truneh et al. 1985). Since this is a strong stimulus for T cells (Kay 1991), it 
could have masked defects in TIL cytokine production. However, another group have 
looked at cytokine secretion by RCC TIL in response to stimulation with anti-CD3 and 
anti-CD28 antibodies, which more closely mimic natural T cell activation. Although the 
proportion of cells producing cytokine was smaller, the T cells again demonstrated 
equivalent or increased capacity to produce TNFα, IL-2 and IFN-γ compared to RCC 
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patients’ and healthy donors’ PBMC (Attig et al. 2009). Further evidence that cytokine 
production by RCC TIL is not compromised has been reported using ELISA (rather than 
intracellular cytokine staining) following stimulation with anti CD3 with or without PMA 
(Angevin et al. 1997;Van den Hove et al. 1997a). A study looking at mRNA expression of 
cytokines found TIL to have significantly higher levels of IFN-γ mRNA than matched 
PBMC, however the CD8+ TIL had significantly less TNFα mRNA than the PBMC 
(Elsasser-Beile et al. 2000). 
 
Animal models have shown IL-2, TNF-α and IFN-γ expression promotes an anti-tumour 
immune response (Gansbacher et al. 1990a;Gansbacher et al. 1990b;Lasek et al. 2000). 
In addition, as discussed previously (see section 3.8, p143) a type 1 immune bias within 
the tumour infiltrate is associated with a favourable immune response. Therefore these 
data suggest the TIL are capable of a Type 1 response, that should promote anti-tumour 
immunity. 
 
Both CD4 and CD8 T-cells are needed for an effective anti-tumour response (Hung et al. 
1998), however previous studies have suggested tumour-infiltrating CD8 T cells in RCC 
lack cytolytic activity (Kudoh et al. 1997;Van den Hove et al. 1997a). I found that CD8 T 
cells from TIL express CD107a, a marker of degranulation (Betts et al. 2003), suggesting 
they have degranulated prior to isolation, i.e. in vivo. There was also an enrichment of 
CD4+CD107a+ T cells in TIL compared to PBMC. This suggests a small proportion of the 
CD4 T cell subset has also degranulated. Low levels of CD4+ CTLs have been 
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demonstrated in healthy and diseased individuals and although various mechanisms of 
action have been postulated, they appear at least in some settings to work by releasing 
cytotoxic granules, and hence can be detected by looking at CD107a mobilisation (Appay 
et al. 2002;Zheng et al. 2007). Indeed, mouse models have shown that cytotoxic CD4 T 
cells can kill melanoma cells in a granzyme B-dependent manner (Quezada et al. 2010). 
Attig et al also reported CD107a expressed on both CD4+ and CD8+ RCC TIL following 
stimulation with PMA/ionomycin (Attig et al. 2009).  
 
There is some suggestion that CD107a+ T cells from TIL, such as those I have observed in 
RCC, represent a tumour antigen-specific population. One group used CD107a 
expression to accurately identify tumour-reactive T cells post vaccination in melanoma 
patients (Rubio et al. 2003). It has since been shown to be upregulated on peptide 
specific T cells in patients that responded to vaccination for chronic lymphatic 
leukaemia (Giannopoulos et al. 2010). In colon cancer a significantly higher (albeit 
small) proportion of CD8 TIL express CD107a, compared to CD8 cells from normal 
mucosa. Higher proportions of CD107a+ CD8 T cells correlated with the presence of 
tumour antigen reactive T cells in the TIL (Koch et al. 2006). Thus it is possible that the 
presence of CD107a on a significant proportion of CD8 and CD4 TIL in RCC indicates that 
these T cells are specific for antigens expressed at the tumour site and have been 
activated upon antigen encounter, yet, clearly, this has not prevented outgrowth of the 
tumour. 
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Turning to CTLA-4 expression, my data show that this increased in PBMC following 
PMA/ionomycin stimulation to a level equivalent to that of un-stimulated TIL, whereas 
TIL did not increase CTLA-4 expression post-stimulation, suggesting CTLA-4 expression 
on TIL had already reached a maximum level within the tumour environment. 
Expression of CTLA-4 is further evidence that the TIL may have seen antigen in the 
tumour as CTLA-4 is known to be up-regulated upon activation (Freeman et al. 
1992;Walunas et al. 1994). Additional evidence that tumour-infiltrating T cells have 
been activated in vivo comes from my CD27 expression studies where fewer CD4 T cells 
from TIL compared with PBMC expressed this marker. The loss of CD27 expression in 
CD45RA- CD4+ T cells is associated with chronic antigen stimulation (De et al. 1992). A 
CD27- CD45RA- CD4+ T cell phenotype also correlates with CD4 T cell cytotoxic potential 
(Appay et al. 2002;Duvall et al. 2008). Therefore it is possible that CD27- CD4+ TIL 
represent cytotoxic T cells that have repeatedly encountered their target antigen. 
Notably,  without CD27, these T cells would not be subject to apoptosis following 
encounter with CD70+ tumour cells, a proposed mechanism by which RCC evades the 
immune system (Diegmann et al. 2006). 
 
PD-1 is also upregulated on T cells post-activation and expression increases during 
chronic antigen stimulation (Barber et al. 2006). Un-stimulated T cells expressed PD-1 
ex vivo, suggesting they may have seen their antigen at the tumour site. However if PD-1 
is ligated by either of its ligands, PD-L1 or PD-L2, T cell function is attenuated and cell 
survival pathways are inhibited (Bennett et al. 2003;Chemnitz et al. 2004;Freeman et al. 
2000;Latchman et al. 2001). In RCC patients PD-1 is expressed by a greater proportion 
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of CD4 and CD8 TIL than their counterparts in PBMC. This could indicate they have been 
activated and therefore have encountered their antigen at the tumour site. In support of 
this a study in melanoma has confirmed antigen-specific cells are more likely to be PD-1+ 
(Ahmadzadeh et al. 2009). However, numerous studies have shown expression of PD-L1 
on RCC tumours, and therefore PD-1+ T cells in RCC are likely to have impaired function 
and an exhausted phenotype. One study found 66% of RCC tumours (n=196) stained 
positively for B7-H1 (PD-L1, CD274) by IHC, and in 37.2% of cases, more than 10% of 
the tumour tissue expressed this marker (Thompson et al. 2004). This is supported by a 
paper demonstrating PD-L1 expression on RCC and melanoma (Blank et al. 2006). 
Another study of 306 patients found 23.9% to have positive staining, and that these 
patients were almost four times more likely to die from RCC (univariate analysis) 
(Thompson et al. 2006). As the interaction between PD-L1 and its receptor, PD-1, is 
associated with cell exhaustion and anergy, its presence in the tumour could be a 
mechanism of immune suppression (Freeman et al. 2000;Ishida et al. 1992). In support 
of my data, a study of 136 patients using IHC found PD-1 was present on TIL in 56.6% of 
tumours. Presence of PD-1+ lymphocytes was associated with poor outcome (Thompson 
et al. 2007).  
 
When I characterised the PD-1+ T cells further I found that compared to PD-1- T cells a 
greater proportion were HLA-DR+ and CD25-. They also appeared more likely to be 
CD27+, Ki67+, CTLA4+ and CD107a+ cells, and CD127-. A similar phenotype on PD-1+ TIL 
was seen in melanoma by Ahmadzadeh et al. who found PD-1+ TIL to be HLA-DR+, 
CD127-, CTLA-4+, CD27+ and Ki67+, and suggested this is indicative of an exhausted 
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phenotype (Ahmadzadeh et al. 2009). Expression of Ki67, CTLA4 and CD107a suggest 
these cells have been activated previously and are proliferating, and the expression of 
CD107a suggests they may even have been capable of cytotoxicity (Betts et al. 
2003;Linsley et al. 1992;Malizia et al. 1985). However lack of CD127 is associated with 
impaired T cell function (Lang et al. 2005), and reduced CD25 combined with increased 
CD27 expression suggests the T cells have not been in contact with IL-2, as exposure to 
this cytokine results in the opposite phenotype (Ahmadzadeh et al. 2009;Huang et al. 
2006;Sereti et al. 2000). This is not surprising, as the presence of IL-2 can overcome PD-
1 mediated suppression and down-regulate its expression (Carter et al. 2002;Inozume et 
al. 2010), therefore high PD-1 expression is more likely where IL-2 levels are limited.   
 
Stimulated PD-1hi CD4 T cells appeared deficient in IL-2 and IFN-γ production compared 
to cells with lower levels of PD-1. However the pattern did not reach significance, and no 
effect was seen in the CD8 T cells, contrasting with results described previously looking 
at CD8 T cells in murine viral infections (Jin et al. 2010;Zelinskyy et al. 2011). This 
discrepancy could be due to the lack of sensitivity in my assay due to low overall 
cytokine production by the T cells, presumably due to the stimulation method. I have 
demonstrated that PMA/ionomycin stimulation can result in good effector cytokine 
production by TIL, however I deemed it unsuitable for use in this assay as it bypasses 
the early T cell signalling events that are thought to be important in PD-1 mediated 
inhibition (Wang et al. 2011b). Alternatively it could be that in the absence of PD-1 
ligands, which may not have been present in the TIL used, stimulation overcame 
previous PD-1 mediated suppression. 
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Previous studies have shown that blocking the PD-1:PD-L1 interaction can increase 
cytotoxicity of T cells (Lukens et al. 2008;Phares et al. 2010). Nonetheless, PD-1 
expression has been shown to positively correlate with expression of the cytotoxic 
molecule granzyme B in CD8 T cells in viral infections in mice (Jin et al. 2010;Zelinskyy 
et al. 2011). I found CD4 T cells with high expression of PD-1 to have greater expression 
of granzyme B. Cytotoxic CD4 T cells are thought to be an antigen experienced 
population and their presence is seen most frequently in chronic diseases (Appay 2004). 
Therefore it could be expected that PD-1 up-regulation and CD4 cytotoxicity would 
correlate. Perforin expression by CD8 T cells appeared impaired in PD-1 expressing 
cells, whereas granzyme B did not. Perforin is a key mediator of cytotoxicity and 
therefore this could indicate these T cells are suppressed. The presence of granzyme B 
does not necessarily contradict this hypothesis, as it has been suggested in the literature 
that high granzyme B expression can be a marker of exhaustion in CD8 T cells, and it is 
the loss of perforin which affects their cytotoxic capacity (Takamura et al. 2010;Wherry 
et al. 2007).  
 
Despite my evidence that TIL display markers of activation ex vivo and can release 
effector cytokines in response to stimulation, spontaneous regression of RCC tumours in 
the clinic is rare, indicating the immune system is not able to kill the tumour. The 
tumour could be resistant to the cytotoxic mechanisms employed by the T cells, or 
alternatively could be causing suppression of the function of the T cells. The PD-1: ligand 
interaction may account for this, however I also found enrichment of Foxp3+ Tregs 
within the TIL, which may suppress a tumour-specific immune response.  
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It has been shown that an infiltrate with a large proportion of Tregs may be detrimental 
to RCC patient survival (Griffiths et al. 2007). Treg control of the immune response has 
been shown to play roles in suppressing autoimmune and inflammatory immune 
responses (Behrens et al. 2007;Sakaguchi et al. 1995;Takahashi et al. 2006). They may 
also have a negative effect in cancer patients by suppressing anti-tumour immunity. In 
section 3.4 I found cells with a Treg-like phenotype (CD3+CD4+CD25hiCD127loFoxp3+) to 
be enriched at the tumour site compared to matched PBMC. I next wanted to investigate 
these cells’ capacity to suppress an immune response. Due to low numbers of TIL I was 
unable to perform conventional suppression assays using these cells, so instead I 
analysed their effector cytokine profile following PMA/Ionomycin stimulation; an 
approach recently demonstrated to identify Tregs in melanoma (Ahmadzadeh et al. 
2008). I found that the putative Tregs from TIL produced very little IFN-γ, IL-2 or TNFα, 
in contrast to the Foxp3- T cell population. This functional profile is consistent with that 
described for Tregs in the literature (Ahmadzadeh et al. 2008;Kryczek et al. 2009b), and 
with the Foxp3+ cells in PBMC from RCC and healthy donors, where we could also 
confirm suppressive function using conventional assays of T cell proliferation (data not 
shown). 
 
The putative Tregs expressed CTLA-4 at higher frequencies and levels than Foxp3- TIL, 
and therefore may suppress an immune response via this receptor. CTLA-4 has been 
described as an immunoregulatory molecule which is vital in preventing autoimmune 
disease (Tivol et al. 1995;Waterhouse et al. 1995), and which may contribute to 
regulatory T cell suppression of T cell function by stripping APCs of their co-stimulatory 
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molecules, CD80 and CD86 (Qureshi et al. 2011). Although all activated T cells can 
transiently express CTLA-4, Tregs constitutively express high levels of the molecule 
(Dieckmann et al. 2001;Takahashi et al. 2000;Tang et al. 2004). Therefore their 
increased CTLA-4 expression compared to Foxp3- T cells suggests the Foxp3+ TIL are 
true Tregs. If CTLA-4 is one of the main mechanisms Tregs use to suppress effector T 
cells, it may be possible to reverse this suppression using treatments currently under 
investigation. Trials using an antibody to block CTLA-4 have shown some success in a 
phase II trial with RCC patients. However, as perhaps would be expected, patients with 
better responses also suffered severe autoimmune reactions (Beck et al. 2006;Yang et al. 
2007). 
 
A higher percentage of Foxp3+ CD4 T cells expressed CD27 compared to Foxp3- CD4+ T 
cells. Previous studies have demonstrated CD27 defines a subset of Tregs with greater 
suppressive capacity and higher Foxp3 expression (Grossman et al. 2004;Ruprecht et al. 
2005), again indicating this cell subset has a regulatory function.  
 
I found over a third of Tregs in TIL expressed PD-1, and in common with studies on 
mouse models of GVHD and human melanoma and hepatitis C virus patients, I found an 
increased PD-1 expression on Tregs compared to Foxp3- cells (Franceschini et al. 
2009;Kitazawa et al. 2007;Wang et al. 2009). Using cells from melanoma patients it was 
shown that blocking PD-1 on Tregs before adding them to a suppression assay 
decreased their capacity to suppress the proliferation of melanoma-antigen-specific CD8 
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T cells, and down-regulated their Foxp3 expression (Wang et al. 2009). In addition, in 
the mouse model of GVHD, blocking PD-L1 in wild type mice increased disease levels to 
those seen in Treg-depleted mice, and adding a PD-L1 block to Treg-depleted mice did 
not further increase disease. This suggests Tregs require the PD-1:PD-L1 interaction for 
suppression of GVHD. However it is unclear whether this interaction has a direct effect 
on regulatory T cells or whether the interaction between Tregs and APCs modulates APC 
function in a PD-L1 dependent manner (Kitazawa et al. 2007). On the contrary, studies 
in hepatitis C infection have shown blocking PD-L1 during antigenic stimulation of Tregs 
increases Treg proliferation and thereby enhances Treg-mediated immune suppression 
(Franceschini et al. 2009). Further study is required to determine what effect PD-1 
expression on Tregs from RCC has on their suppressive function, as this will have 
implications for any potential therapeutic approaches that seek to block PD-1:ligand 
interactions. 
 
A subset of Tregs expressed the CD107a marker of degranulation, and although the 
proportion of CD107a+ Tregs was small, it was nonetheless significantly greater than the 
proportion of Foxp3+ cells in PBMC that expressed this marker. There is evidence in the 
literature that Tregs can mediate suppression via perforin or granzyme induced 
cytotoxicity (Grossman et al. 2004), however this would seemingly only be relevant for a 
minority of the Treg population in RCC. 
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Although it might have been anticipated that lack of effector function in TIL would 
correlate with the frequency of infiltrating Tregs, our data did not support this. 
However, we did find a correlation between both lack of effector cytokine production 
and CTLA-4 expression with an increased ratio of Tregs in TIL:Tregs in matched PBMC.  
 
The reason for this correlation is unclear, but the pattern suggests that it is a relative 
enrichment rather than simply a high proportion of Tregs that determines their effect on 
T cell function. Perhaps the enrichment is due to preferential recruitment of a more 
suppressive Treg subset by the tumour, or induction of Tregs at the tumour site which 
are more potent than nTregs. Further phenotypic analysis to determine whether there 
are any functional differences between Tregs in tumours where they are enriched 
compared to where there is no enrichment, may shed light on the mechanisms of this 
phenomenon.  
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5. Rare subsets in TIL 
In addition to the effector and regulatory CD4 and CD8 T cells already investigated in the 
previous chapters, additional T cell subsets may be present in the tumour and have the 
ability to influence tumour growth. Tr1s are another subset of regulatory CD4 T cell 
which are thought to play a role in squamous cell carcinoma of the head and neck 
(Badoual et al. 2006). Th17s, on the other hand, are pro-inflammatory cells that may 
either promote or inhibit tumour growth (Kryczek et al. 2009a). There is little in the 
literature on the relative proportions and contributions of these cell subsets in RCC, so 
this work investigated their presence within the tumours. I also observed a significant 
proportion of CD4+CD8+ T cells within a subset of RCC tumours. I therefore also explored 
their potential function in RCC, and examined their homing phenotype to gain insight 
into how they may have migrated into the tumour. 
 
Unless otherwise stated, throughout this chapter ‘TIL’ and ‘PBMC’ refer to the T cell 
compartment within the respective populations. All significances were calculated using 
Wilcoxon matched pairs tests. 
 
5.1. Double positive CD4+CD8+ T cells in TIL 
While analysing my flow cytometry data I observed that in a proportion of samples, a 
substantial population of CD4+CD8+, ‘double positive’ (DP) T cells were present. 
According to the literature DP T cells constitute 1-3% of human PBMC (Blue et al. 
1985;Patel et al. 1989), and I saw similar proportions in the PBMC samples I studied 
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from RCC patients. I therefore defined DPhi samples as those with 5% or more of their T 
cells expressing both CD4 and CD8.  
 
I found that 35% of RCC TIL samples studied were DPhi, with DPs consisting of from 
5.7%-39.7% (median 11%) of T cells, whereas in matched PBMC consistently fewer than 
5% of T cells expressed both CD4 and CD8 (Figure 44A and B). Flow cytometry showed 
the DP TIL displayed the same forward scatter as single positive (SP) T cells, and did not 
have an altered pulse width. They were therefore not an artefact of two SP T cells 
sticking together. The DP cells expressed high levels of CD8, however the MFI for CD4 
staining was lower than that of CD4 SP T cells. Therefore the DPs in RCC are 
CD4dimCD8bright (Figure 44C). 
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Figure 44: Double positive T cells are found in RCC TIL 
Double positive T cells were found in 35% of TIL samples and had a CD4dimCD8bright phenotype (A). 
Matched PBMC were not enriched with DP T cells (B). The DPs had similar pulse widths and forward 
scatter(FSC):side scatter(SSC) profiles to single positive T cells, indicating they are not doublets (C). 
Pictures representative of 18 cases. 
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5.1.1. Homing phenotype of DP TIL 
I went on to look at the homing phenotype of the DPs to determine if they use the same 
mechanisms as single positive T cells to enter the tumour, or whether they have a 
unique homing phenotype. I compared double positive T cells to single positive T cells 
from the same sample to ensure any differences were not due to variations in 
individual’s immune and tumour biology. 
 
Data analysed during both the initial screen of TIL using the Coulter XL cytometer, and 
the later LSRII analysis, were used to maximise the sample size. I did not find any 
significant differences in the homing phenotype of DP and SP T cells, suggesting they are 
recruited to the tumour via the same mechanisms (Figure 45). 
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Figure 45: Comparison of the homing phenotype of SP (CD4+CD8- and CD4-CD8+ T cells) and DP RCC 
TIL 
RCC TIL samples were stained with antibodies specific for 19 chemokine receptors. Graphs display the 
percentage of T cells positive for each marker and the median fluorescence intensity of the staining, both 
corrected for non-specific staining using concentration matched isotype controls. The number of RCC 
cases stained was as follows: CCR3, 4, 5, 6, 7, CXCR3, 4, 6, n = 6, CCR1, 2, 8, 9, CXCR1, 2, 5, 7, n = 5, CCR10, 
XCR1 and CX3CR1, n = 4. 
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5.1.2. DP effector cytokine production 
The literature on the function of double positive T cells is far from consistent, therefore 
it was unclear how the DPs in RCC TIL would function in response to stimulus. I 
stimulated the T cells with PMA/ionomycin and found that compared to SP CD4 T cells, 
production of effector cytokines was significantly lower: IFN-γ (p = 0.0456), IL-2 (p = 
0.0078) and TNFα (p = 0.0078). CD8 SP T cells expressed similar levels of cytokine to 
DPs, with only IFN-γ expression being greater in SP cells and approaching significance (p 
= 0.0625) (Figure 46).  
 
Interestingly, in samples containing DP T cells, fewer SP T cells produced cytokine, than 
SP T cells from samples without DPs (Figure 47). However the differences did not reach 
significance. 
 
These data suggest DPs are most similar to CD8 SP T cells in their effector cytokine 
profile. They also indicate that samples with high levels of DPs have TIL that are less 
functional. 
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Figure 46: Effector cytokine production by SP and DP TIL 
DP and SP TIL were stimulated with PMA/ionomycin for 5 hours, and the percentage of cells producing effector cytokines was measured using intracellular 
cytokine staining. 
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Figure 47: Effector cytokine production by SP cells from DPhi and DPlo samples 
The effector cytokine production by single positive CD4 or CD8 T cells from samples with <5% T cells with 
a DP phenotype (filled circles) or >5% T cells with a DP phenotype (open circles), was measured by 
intracellular cytokine staining. 
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5.1.3. CD107a expression by DP TIL 
To investigate whether the DP T cells were cytotoxic and had previously undergone 
degranulation, I looked at their CD107a expression ex vivo. The DP T cells had similar 
expression of CD107a to single positive CD8 T cells, but a greater proportion of DP 
compared to CD4 SP T cells were CD107a+ (30 ± 23 % vs. 5.2 ± 4.9 %) (Figure 48). 
However, this did not reach significance (p = 0.0625), probably due to the small sample 
size (n = 5). Therefore the DPs appear to have a similar cytotoxic capacity to CD8 SP T 
cells. 
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Figure 48: CD107a expression by SP and DP TIL 
TIL were stained with an antibody to CD107a and the percentage of cells expressing the marker was 
analysed using flow cytometry. 
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5.1.4. PD-1 and CTLA-4 expression by DP TIL 
As the double positive T cells were CD107a+, I inferred they may have been activated in 
vivo prior to isolation. If so, I would also expect them to express PD-1 and CTLA-4. 
 
The vast majority of DP T cells expressed PD-1 (87 ± 12 %), and the mean proportion of 
PD-1+ cells was greater in the DP subset than in both the single positive CD8 subset (69 
± 18 %) and the single positive CD4 subset (38 ± 14 %) (Figure 49A and C). Neither of the 
differences reached significance (the p-value was 0.0625 for both comparisons) but 
again, this could be due to the small sample size (n = 5). Again, the DP T cells appear 
most similar to CD8 rather than CD4 SP cells. 
 
Intriguingly, SP CD8 T cells from DPhi samples contained a significantly greater 
proportion of PD-1+ cells than CD8 T cells from samples without a double positive T cell 
population (Figure 49B). This also indicates DPhi samples are more immunosuppressed. 
 
DP T cells expressed slightly higher levels of CTLA-4 than single positive T cells (Figure 
49D), which may indicate a greater degree of activation. 
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CD4+CD8- CD4-CD8+ CD4+CD8+
16% 57% 86%
Figure 49: Comparison of PD-1 and CTLA-4 expression on SP and DP TIL 
TIL were stained with antibodies to PD-1 and expression on SP and DP subsets was compared using flow 
cytometry (A). PD-1 expression on single positive T cells from samples with <5% T cells with a DP 
phenotype (filled circles) or >5% T cells with a DP phenotype (open circles), was analysed. Significance 
was calculated using a Wilcoxon matched pairs test (B). The proportion of PD-1+ DPs was higher than 
that for CD4 and CD8 SP cells (C) Expression of CTLA-4 on SP and DP TIL was measured by flow 
cytometry (D).  
 and CTLA-4, and the percentage of cells expressing the marker was analysed using flow cytometry. 
Significance was calculated using a Wilcoxon signed rank test. 
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5.1.5. CD27 expression by DP TIL 
As discussed in chapter 4, CD27 expression gives an insight into the differentiation 
status of T cells. DP T cells from TIL expressed similar levels of CD27 to single positive T 
cells (Figure 50) 
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Figure 50: CD27 expression by SP and DP TIL 
TIL were stained with an antibody to CD27 and expression on SP and DP TIL was analysed by flow 
cytometry. 
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5.2. Th17s do not represent a significant proportion of TIL 
Th17 T cells are a subset of CD4 T cells characterized by their expression of the cytokine 
IL-17. Their function and contribution in tumour immunology is currently the subject of 
much debate.  
 
Using intracellular cytokine staining I looked at IL-17 production by TIL and PBMC 
subsets with and without stimulation by PMA/ionomycin. There were no significant 
differences between any of the subsets tested, and only small proportions of T cells 
expressed the cytokine (Figure 51), with the highest mean expression for any subset 
being 3.6 ± 5.9 % (stimulated Tregs from PBMC), and even for this T cell population, half 
the RCC samples tested contained no IL-17-producing cells. Due to the low numbers of 
IL-17 producing cells in my samples, further study of these cells was impossible. 
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Figure 51: IL-17 expression by T cell subsets in TIL and PBMC, before and after stimulation 
IL-17 expression was measured on both TIL and PBMC that had either been stimulated with 
PMA/ionomycin, or left un-stimulated. Results were analysed by flow cytometry. solid bars represent TIL, 
lined bars represent PBMC. For stimulated CD4 TIL, n = 11, for stimulated CD8 TIL and un-stimulated CD4 
TIL, n = 8, for all other populations, n = 6. Results show mean percentage of cells expression IL-17 (+SD). 
(A). Flow plots show IL-17 staining on stimulated CD4 (blue) CD8 (green) and regulatory (orange) T cells 
compared to an isotype control (shaded red). 
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5.3. IL-10-producing T cells in RCC 
IL-10 is an immunosuppressive cytokine which can inhibit the function of immune cells, 
including T cells. Foxp3+ Tregs in the intestine produce IL-10 and this appears to be a 
mechanism by which they suppress effector responses (Maynard et al. 2007). However 
there are other CD4+ suppressor T cells, known as Tr1s, that also produce IL10 but do 
not express Foxp3 (Groux et al. 1997;Levings et al. 2005). CD8 T cells can also be 
suppressive, and it has been shown that CD8 Tregs can act in an IL-10 dependent 
manner (Filaci et al. 2007). We therefore investigated IL-10 expression by the T cells 
infiltrating RCC. 
 
I found that un-stimulated Tregs contain significantly more IL-10 producing cells than 
Foxp3- CD4 T cells (p = 0.0313), however the mean percentage of Tregs producing IL-10 
was only 5.3 ± 4.2 %, therefore it is unlikely this is the dominant mechanism of 
suppression (Figure 52A).  
 
Considering the Foxp3- population, a minority of CD4 and CD8 TIL also produced IL-10 
(Figure 52B). CD4 TIL were the only subset which showed an increase in the proportion 
of cells producing IL-10 after stimulation, which approached significance (p = 0.0547). 
These CD4+Foxp3-IL-10+ T cells do not express high levels of CD25 or IL-2, which is 
consistent with them being Tr1 cells (Groux et al. 1997;Levings et al. 2005) (Figure 52C). 
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Figure 52: IL-10 expression by TIL subsets 
IL-10 expression by subsets of TIL was measured by intracellular cytokine staining. IL-10 expression 
by Foxp3- and Foxp3+ CD4 TIL was compared (A) and significance calculated using a Wilcoxon 
matched pairs test. IL-10 expression was also analysed in Foxp3- TIL before and after stimulation with 
PMA/ionomycin (B). The majority of IL-10 expressing cells were Foxp3-, CD25- and IL-2- (C), plot is 
representative of 5 experiments. 
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5.4. Discussion  
While studying the properties of the TIL population I observed a third of RCC TIL 
samples contained a significant proportion of CD4+CD8+ double positive T cells. This 
chapter described my investigation of their recruitment and function. I also looked for 
the presence of other subsets of T cells in TIL, namely Th17s and IL-10 producing T cells. 
 
Double positive lymphocytes make up around 1-3% of human peripheral blood T cells 
(Blue et al. 1985;Patel et al. 1989;Prince et al. 1994). The levels of DP cells in peripheral 
blood increase with age(Laux et al. 2000), although this only occurs in a proportion of 
the elderly (Ghia et al. 2007). I found a third of RCC TIL samples had high levels of DP T 
cells (>5% T cells), whereas levels in matched PBMC were consistently below 5%, 
suggesting the increased numbers in TIL were not due to the age of my patients. My data 
indicates the cells are not doublets, and others have demonstrated mRNA for both CD4 
and CD8 in DP T cells from healthy donors (Sullivan et al. 2001). 
 
In rare cases double positive T cells can be significantly increased in people with normal 
health (Kay et al. 1990;Tonutti et al. 1994). More frequently they have been reported to 
be elevated in certain diseases. Patients with multiple sclerosis, atopic dermatitis and 
systemic sclerosis have higher proportions of DP T cells in their peripheral blood or site 
of disease (Bang et al. 2001;Munschauer et al. 1993;Parel et al. 2007). In vitro infection 
of T cells with HTLV-1 induces a DP phenotype, transient increases in some infectious 
mononucleosis patients have been observed, and DPs specific for HIV in AIDs patients 
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have also been reported (Howe et al. 2009;Macchi et al. 1993;Ortolani et al. 1993). 
Elevated levels DP T cells have also been reported in nodular lymphocyte predominant 
Hodgkin lymphoma, T cell large granular lymphocyte leukaemia, melanoma and breast 
cancer (Desfrancois et al. 2009;Desfrancois et al. 2010;Karasawa et al. 
2003;Rahemtullah et al. 2006). 
 
Increased levels of DPs have also been reported in RCC. Porta et al. found a significant 
increase in the number of circulating DPs in RCC patients compared to age and gender 
matched healthy controls (Porta et al. 2007), and Van den Hove et al. reported the 
presence of DPs in RCC TIL (Van den Hove et al. 1997b).  
 
The role of double positive T cells in health and disease is unclear. Studies where 
phenotyping has been performed found DPs to be memory T cells (Bang et al. 
2001;Desfrancois et al. 2009;Nascimbeni et al. 2004;Prince et al. 1994;Rahemtullah et al. 
2006;Tonutti et al. 1994;Van den Hove et al. 1997b;Weiss et al. 1998) and to express the 
α and β TCR chains rather than the γδ TCR (Bang et al. 2001;Desfrancois et al. 
2009;Ortolani et al. 1993;Prince et al. 1994;Tonutti et al. 1994;Van den Hove et al. 
1997b;Weiss et al. 1998). I examined the cytokine production of DP TIL in response to 
PMA/ionomycin stimulation and found DPs to be similar to CD8 SP T cells in their 
cytokine profile, with the exception that they may be less able to produce IFN-γ. DPs 
appeared deficient in effector cytokine production compared to CD4 SP T cells. I do not 
know whether the DP positive T cells arise from CD8 SPs gaining CD4, or vice versa, 
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although the DPs had more phenotypic similarities with CD8 SP T cells than CD4s. My 
cytokine data contrasts with that on DP cytokine production in healthy donors, breast 
cancer and an HIV case study, which all reported no reduction in ability to produce IFN-
γ and TNFα compared to SP CD4 and CD8 T cells (Desfrancois et al. 2009;Nascimbeni et 
al. 2004;Weiss et al. 1998), however my data are in agreement with the only other study 
to address this in RCC where van den Hove et al. reported preliminary data indicating 
reduced cytokine production by DP cells (Van den Hove et al. 1997b). Interestingly the 
study on healthy donors and an HIV patient found CD4brightCD8dim DPs, which may have a 
different functional profile. The DPs studied in melanoma and breast cancer were, like 
the ones observed in my experiments, CD4dimCD8bright, however they had been expanded 
by phytohaemagglutinin (PHA) treatment prior to their use in functional assays. PHA 
has been shown to induce CD4 expression on CD8 T cells, and therefore the cells they 
were studying may have been an artefact of the culture conditions (Sullivan et al. 2001). 
 
Van den Hove’s analysis of DPs in RCC TIL found CD4dimCD8bright DPs to be present in 
15/27 RCC samples studied (all the positive samples were clear cell) and CD4brightCD8dim 
in 8/27 samples. They were also able to show the CD4dimCD8bright cells express both the 
CD8 α and β chains. The antibody I used only binds the α chain of CD8, but Van den 
Hove’s results suggest the DPs in my TIL samples are likely to be CD8αβ. 
 
To further examine these cells’ function I investigated their expression of CD107a, PD-1, 
CTLA-4 and CD27. There were no differences in CTLA-4 and CD27 expression between 
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SP and DP T cells, the latter in contrast to the DPs in Nascimbeni et al.’s study which 
found reduced CD27 on DPs compared to SPs (Nascimbeni et al. 2004). The CD107a 
expression on DP TIL ex vivo was similar to that of CD8 SP T cells, suggesting they are 
just as able to degranulate. This result suggests in terms of cytoxicity, the DPs behave 
similarly to those reported in breast cancer (Desfrancois et al. 2009), where CD107a, 
perforin and granzyme expression were demonstrated to be at similar levels to those 
seen in SP CD8 T cells. To my knowledge there is no literature on PD-1 expression by DP 
T cells. In RCC TIL the majority of DP T cells express PD-1, and the proportion of PD-1+ 
cells was greater than that in both SP subsets.  
 
Combined, these data suggest the DP T cells in RCC have been activated to the same 
degree as SP T cells, as they express similar or higher levels of CTLA-4, PD-1 and CD27. 
The CD107a and cytokine data suggests they have a similar function to CD8 SP T cells. 
The literature indicates CD4dimCD8bright DPs arise from stimulated CD8 T cells, and 
therefore in RCC TIL may be an indication that a T cell response has taken place at the 
tumour site (Sullivan et al. 2001). 
 
As levels of DP T cells increase with age, are more likely to be have a restricted 
repertoire of T cell receptor beta variable regions (TRBV) and therefore be clonal, and in 
healthy donors have been shown to be frequently specific for viral antigens, it could be 
hypothesised that they arise from chronic antigen stimulation (Ghia et al. 2007;Laux et 
al. 2000;Nascimbeni et al. 2004). I found that in DPhi samples, a higher percentage of SP 
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CD8 T cells expressed PD-1 than in DPlo samples. I could speculate that DPs occur in 
samples where T cells have repeatedly come into contact with antigen, and hence would 
be found in samples with a greater number of PD-1+ T cells. The DPs themselves also had 
increased PD-1 expression compared to SP T cells, suggesting they have had greater 
chronic exposure to antigen and may therefore be exhausted. This may also explain their 
lack of effector cytokine production, compared to DPs isolated from other patient types 
described in the literature. 
 
I investigated the homing phenotype of DP T cells to determine if they could migrate into 
RCC by a unique mechanism. I didn’t find any significant differences between SP and DP 
cells’ homing phenotype, suggesting they are recruited via the same receptors. It has 
been reported that in healthy donors greater proportions of DPs express CXCR3 
compared to SP T cells (Nascimbeni et al. 2004), but I did not see this in my assays. 
 
Th17s, a CD4 T cell subset characterised by expression of IL-17, play a role in 
inflammatory disease. However, as discussed in section 1.3.6.4 p31, their contribution to 
anti-tumour immunity is controversial. 
 
The contribution of Th17s to anti-tumour immunity in RCC is equally unclear. My 
studies indicate that pre- and post-stimulation levels of Th17s were extremely low in 
RCC. There are very few published studies on Th17s in RCC, but one study reported that 
IL-17 released from Th17-like T cells caused RCC lines to increase IL-8 secretion. 
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Preliminary data also suggested that RCC tumours with higher levels of IL-17-producing 
T cells have greater levels of IL-8 mRNA expression, therefore Th17s within the tumour 
may alter the immune response (Inozume et al. 2009). In agreement with our data, the 
paper found levels of IL-17 producing cells to be around 1-3.5% of total CD3+ TIL after 
PMA/ionomycin stimulation. Another paper reported very low numbers of IL-17 
producing CD4+ TIL, but not an enrichment of IL-17 producing cells compared to PBMC 
(Attig et al. 2009). While I cannot exclude them having an effect on tumour immunity, 
the numbers of Th17s in RCC precluded further study on the phenotype and function of 
this cell subset. 
 
IL-10 is a cytokine that can suppress immune responses by inhibiting T cell proliferation 
and cytokine release (Del et al. 1993;Groux et al. 1997). Foxp3+ IL-10 producing Tregs 
have been described in bowel disease and head and neck squamous cell carcinoma 
(Maynard et al. 2007;Strauss et al. 2007;Uhlig et al. 2006). However, a study of TIL from 
six other types of solid cancers, including RCC, concluded neither Foxp3+ Tregs, nor 
Foxp3- Tr1 cells from TIL produce IL-10 ex vivo (Kryczek et al. 2009b). While I did find 
very small percentages of CD4+Foxp3+, CD4+Foxp3- and CD8+ T cells produce IL-10, in 
common with other studies (Attig et al. 2009;Kryczek et al. 2009b), the percentages 
were very small and therefore these cells are unlikely to be dominant suppressive 
populations in TIL.  
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6. Concluding Discussion 
Harnessing the power of T cells shows promise as a treatment for renal cell carcinoma, 
but to date significant clinical responses have eluded scientists and clinicians. One 
reason for this may be insufficient tumour infiltration by anti-tumour T cells and so this 
study aimed to elucidate the receptors required for T cell migration into RCC. Another 
possibility is that immunosuppressive mechanisms within the tumour environment 
prevent anti-tumour T cell function. Therefore the study also examined the suppressive 
Treg subset within RCC and the functional capacity of TIL within this tumour. 
 
Previous studies have found RCC TIL express CCR5 and CXCR3 (Attig et al. 2009;Cozar et 
al. 2005;Kondo et al. 2006;Suyama et al. 2005a). We expanded current knowledge by 
examining the expression of the entire repertoire of chemokine receptors on TIL and 
matched PBMC. Furthermore, since TIL are almost entirely CD45RA- memory cells, in 
contrast to previous studies we restricted our analysis to CD45RA- memory cells in both 
the tumour and blood. In this way we avoided any bias due to the large proportion of 
naive T cells carried in the blood that are known to display a different chemokine 
receptor phenotype to memory T cells. Our work confirmed expression of CCR5 and 
CXCR3 by infiltrating CD4 and CD8 T cells, and also found CXCR6 to be enriched on these 
populations. We also examined the homing phenotype of two additional T cell subsets 
which make up a significant proportion of TIL: Tregs and double positive T cells. The 
homing phenotype of these cells was similar to that of the whole T cell population, 
suggesting they are recruited via similar mechanisms. However Tregs also expressed 
CCR6, which may represent a unique homing mechanism for these cells.  
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Data on the chemokine receptors required for T cell homing to RCC will aid the 
development of T cell therapies for RCC. For example, it should help determine whether 
anti-tumour T cells generated through vaccination carry an appropriate tumour-
targeting phenotype. Also, using cytokines such as IL-2 and IL-15, it should be possible 
to induce this homing phenotype in vitro on T cells used for adoptive therapy (Loetscher 
et al. 1998a;Unutmaz et al. 2000). Alternatively it may be desirable to block receptor 
function to prevent the infiltration of Tregs. Blocking CCR5, CXCR3 or CXCR6, may block 
the infiltration of beneficial effector T cells, so the most advantageous strategy would be 
to block the CCR6:CCL20 interaction.  
 
The work described in this thesis to analyse T cell homing into tumours is an important 
first step to fully characterising the mechanisms involved. However, there are 
limitations to the approach. Most notably it is not possible to fully determine whether T 
cells used these receptors to migrate into the tumour, whether the receptors function in 
retaining the T cells at the site, or whether their expression is in fact induced at the 
tumour site. Nevertheless, demonstrating the ability of infiltrating T cells to migrate in 
response to the relevant ligands suggests that these cells at least have the capacity to be 
recruited via those receptors. We were also able to demonstrate the presence of the 
appropriate ligands within RCC tissue which is consistent with a role for CCR5, CCR6, 
CXCR3 and CXCR6 in T cell recruitment. Although cytokines could have upregulated 
expression of these chemokine receptors in the tumour microenvironment, the CD25-
CD27+PD-1+ phenotype that we observed for many TIL suggests IL-2 is limited 
(Ahmadzadeh et al. 2009), so the chemokine receptors are not likely to be induced via 
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IL-2 stimulation. Studies of mRNA present in RCC also suggest there is little IL-2 present 
(Olive et al. 1998;Wang et al. 1995). IL-15 can induce expression of Th1 chemokine 
receptors, however in RCC it has only been demonstrated to be expressed in its 
membrane bound form (Wittnebel et al. 2007), and it is unclear whether this form is 
capable of inducing chemokine receptor expression. In addition, E. Maher’s work using a 
microarray found IL-2 and IL-15 are not up-regulated in RCC compared to normal 
kidney tissue (personal communication, 2010) Now that we can hypothesise which 
receptors are relevant, studies in animals such as the RENCA model (Murphy and 
Hrushesky 1973) could confirm their role in T cell recruitment to RCC.  
 
Of all the chemokines studied, CXCL9 was expressed most consistently by tumour cells, 
and may therefore explain the increased tumour infiltration of CXCR3+ T cells. 
Nevertheless most T cells were seen on the periphery of the tumour rather than within 
tumour nests suggesting that T cell migration into the tumour tissue may be restricted. 
This might be explained by the observation that although many of the relevant 
chemokines were expressed on vessels within the fibrous areas, they were generally not 
expressed on vessels within the tumour nests. A very recent paper described the 
nitration of the chemokine CCL2 by the reactive nitrogen species that are present in 
many human tumours, and the inverse correlation between nitration of proteins in 
tumours and T cell infiltration. In vitro and in vivo work also demonstrated T cells have 
reduced ability to migrate to nitrated CCL2, and that blocking CCL2 nitration increased T 
cell infiltration into tumours (Molon et al. 2011). If this is applicable to RCC tumours and 
other chemokines, it could be hypothesised that chemokine nitration accounts for the 
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lack of T cell migration into the tumour nests. The inability of most T cells to infiltrate 
the tumour nests is relevant for immune therapy since T cell-mediated lysis of the 
malignant cells is likely to require cell-cell contact.  
 
In contrast to other T cell subsets, our preliminary observations suggested that Foxp3+ 
Tregs are capable of infiltrating the tumour nests, although a larger number of samples 
would be required to confirm this. This could be due to their additional expression of 
CCR6. DCs expressing CCR6 also infiltrate tumour nests, whereas CCR6- DCs are found at 
the tumour edge (Middel et al. 2010). Another possibility is that CD4 effector cells 
differentiate into a Treg phenotype upon migration into the tumour nest. However 
recent work has shown that at least in RCC patients’ PBMC, Foxp3+ cells co-express the 
transcription factor Helios, which is thought to be a marker of nTregs (Elkord et al. 
2011).  
 
The receptors CCR5, CCR6, CXCR3 and CXCR6 are frequently associated with trafficking 
to areas of inflammation (Luster et al. 2005), and therefore it appears RCC is mimicking 
an inflammatory disease. Tumours often up-regulate inflammatory cytokines and 
chemokines as the resulting signalling facilitates cell proliferation and survival. It is 
possible that the TIL themselves promote this inflammatory environment. Both their 
chemokine receptor profile and effector cytokine production on stimulation suggest 
they are type 1 T cells. Therefore if they are stimulated within the tumour they will 
release IFN-γ, which will in turn up-regulate the chemokines CXCL9, 10 and 11, thereby 
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recruiting more type 1 T cells and promoting further inflammation. This would be 
advantageous to the patient if the T cells were able to function and destroy the tumour, 
but in RCC this does not appear to be the case.  
 
There have been reports that T cells in cancer are often dysfunctional and that in RCC 
CD8 T cells in particular in RCC are defective (Kudoh et al. 1997;Van den Hove et al. 
1997a). However we found that, at least in response to a strong stimulus, the infiltrating 
T cells were capable of producing effector cytokines. Staining TIL ex vivo also showed 
they had upregulated CD107a, CTLA-4 and PD-1, all associated with antigen recognition 
and activation. Thus it appears that T cells entering the tumour are partly activated, 
possibly through antigen recognition, yet clearly they are incapable of completely 
destroying the malignant cells. In other disease settings, if the target antigen persists, T 
cells eventually become exhausted, possibly to prevent uncontrolled T cell stimulation 
resulting in massive lymphoproliferation and immune pathology by cytotoxicity. In the 
context of cancer, however, this exhaustion would allow the tumour to escape immune 
control. The levels of PD-1 seen on CD8 and DP TIL were high, consistent with an 
exhausted phenotype. PD-1 ligands are expressed at the tumour site (Thompson et al. 
2006) and are therefore likely to suppress the function of PD-1+ T cells. Although in RCC 
TIL PD-1 only appeared to negatively affect perforin expression, these assays were not 
done in the presence of a defined amount of PD-1 ligands, without which T cell function 
could have been rescued by the stimulus. Therefore further work is necessary to 
determine the true extent of PD-1 mediated suppression in RCC. Overall our data 
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suggest one of the ways the malignant cells in RCC escape immune-mediated destruction 
is by suppressing T cell function and inducing an exhausted phenotype. 
 
The expression of PD-1, as with the expression of CTLA-4 by non-Tregs, also suggests 
there may be antigen-specific T cells amongst the infiltrate. Not all the T cells will be 
antigen specific as the activation of T cells can release chemokines that attract other 
effector memories T cells. It is unclear as to what antigen these cells may recognise, but 
by isolating T cells based on their PD-1 or CTLA-4 expression, could potential enrich for 
an anti-tumour population. The enrichment of PD-1 on double positive T cells also 
suggests double positive high samples potentially have more antigen-specific cells. 
Therefore if further study confirms PD-1hi cells are more likely to be antigen specific, the 
presence of double positive T cells could  be used as a prognositic or predictive marker, 
for patients more likely to benefit from an immune-boosting therapy. 
 
Therefore therapies aimed at restoring the function of such exhausted cells (for example 
the use of PD1-blocking antibodies (Barber et al. 2006)) may be beneficial in this 
disease. Encouragingly, a phase II study using MDX-1106 (an anti-PD-1 antibody) to 
treat patients with treatment-refractory solid tumours, including RCC, found it had 
clinical efficacy against RCC and melanoma. One patient with RCC achieved a partial 
response that lasted at least five months (Brahmer et al. 2009). Further trials are 
planned, but my data supports the rationale for pursuing this line of treatment. 
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Interestingly the administration of IL-2 to RCC patients is the only therapy that can cure 
late stage disseminated disease. IL-2 has been shown to counteract PD-1-mediated 
exhaustion (Inozume et al. 2009). It can also substitute for insufficient help from CD4 T 
cells (Fearon et al. 1990) thereby improving the cytotoxic response. It could also offset 
the IL-2-depleting effects of Tregs which are thought to act as an IL-2 sink (Pandiyan et 
al. 2007). Therefore it is unsurprising that therapeutic treatment with IL-2, which has 
the potential to reverse all these inhibitory effects, can produce good results. Finally, IL-
2 can up-regulate the chemokine receptors that our data indicate are important for T 
cell recruitment to RCC (Loetscher et al. 1998a;Unutmaz et al. 2000), thereby improving 
T cell infiltration into the tumour. 
 
However, IL-2 therapy only works in a small subset of patients. Work is now being done 
on the use of IL-21 instead of IL-2. IL-21 is from the same family of cytokines as IL-2 and 
uses the same common γ chain receptor subunit. Encouragingly, in a study on a mouse 
model of thymoma IL-21 was more effective at producing a long-lasting CD8 T cell 
response resulting in tumour-free survival (Moroz et al. 2004). IL-21 has already gone 
through a phase I trial in RCC where it produced some objective responses and stable 
disease (Thompson et al. 2008). 
 
Another reason for the inability of TIL to clear the tumour could be additional 
suppressive mechanisms employed by Tregs. We and others have found Tregs to be 
enriched in RCC, and we have demonstrated their numbers correlate with tumour grade. 
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Furthermore, others have shown their presence predicts a worse prognosis (Griffiths et 
al. 2007). We found that a greater enrichment of Tregs in TIL compared to PBMC 
correlated with both decreased cytokine production by infiltrating T cells upon 
stimulation in vitro and decreased expression ex vivo of CTLA-4 (a marker normally up-
regulated on effector T cells following antigen recognition). In contrast, CTLA-4 was 
expressed at high levels on the infiltrating Tregs, where it may impair T cell priming by 
inhibiting co-stimulation by DCs (Qureshi et al. 2011). Infiltrating Tregs also express PD-
1 which may interact with its ligand on DCs, further suppressing their capacity to 
stimulate T cells (Kitazawa et al. 2007).  
 
IL-10 is produced by gut-resident Tregs (Annacker et al. 2003) and can induce an 
exhausted or Tr1 T cell phenotype (Brooks et al. 2006;Levings et al. 2005). We only 
detected expression of IL-10 by a small proportion of infiltrating RCC Tregs and Tr1 
cells. However IL-10 is detectable in RCC tumours (Knoefel et al. 1997), and therefore its 
production by Tregs, Tr1s or another cell type may yet be influencing T cell function. 
 
The results described above suggest there may be multiple mechanisms by which the 
tumour prevents immune function. Therefore a combination of therapies may be 
beneficial. The use of tumour specific TIL with the correct homing phenotype might be 
more beneficial if combined with an approach to increase T cell migration into the 
tumour nests. Further work is needed to determine why T cells remain on the periphery 
of the tumour, but the abnormal vasculature seen in RCC may be having an effect. TKIs 
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have been shown to normalise vasculature, which could improve T cell infiltration as 
other anti-angiogenic agents have been shown to increase adhesion molecule expression 
on endothelium and enhance T cell infiltration in a mouse melanoma model (Dirkx et al. 
2006;Shrimali et al. 2010). Therefore combining ACT or other immunotherapy with TKI 
administration may improve response rates. However even if the T cells infiltrate the 
tumour, expression of PD-L1 and the presence of Tregs that we have seen in RCC may 
suppress a response. Early investigations using anti-CTLA-4 in RCC suggest this may aid 
tumour regression (Beck et al. 2006;Yang et al. 2007), and anti-PD-1/PD-L1 improves 
responses in mouse models of melanoma (Sierro et al. 2011). Our data supports the 
rationale for using these agents. 
 
The presence of double positive T cells in RCC was unexpected and the current literature 
is unclear on their precise function. Our data suggest that in RCC they have an exhausted 
phenotype, with very high levels of PD-1 expression and reduced effector cytokine 
production. Notably single positive T cells from samples with high levels of DPs are also 
deficient in function. DP T cells are known to arise in chronic diseases, and this 
combined with their exhausted phenotype supports the hypothesis that RCC is 
mimicking a chronic inflammatory disease or viral infection. Therefore modulating the 
immune system to reactivate exhausted T cells may be all that is required for tumour 
regression, as the expression of activation markers on T cells directly ex vivo, combined 
with evidence from previous studies, suggest that tumour specific TIL do exist. 
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In conclusion we have found effector (CD4 and CD8), regulatory and double positive T 
cell subsets within RCC tissue. All the subsets appear to use the chemokine receptors 
CCR5, CXCR3 and CXCR6 to migrate into the tumour, with Tregs using an additional 
receptor, CCR6. Despite the effector T cells having the ability to produce effector 
cytokines ex vivo, they do not kill the tumour in RCC patients. Our results suggest the 
enrichment of Tregs at the tumour site and engagement of PD-1 ligands by effector T 
cells, may account for the lack of an anti-tumour response in vivo. 
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7. Future work 
We have shown CCR5, CCR6 CXCR3 and CXCR6 are enriched on subsets of TIL. Further 
work is necessary to fully elucidate their roles in T cell homing. Due to low cell numbers 
we were unable to use migration assays to determine whether Tregs could migrate 
towards the CCR6 ligand CCL20. Larger samples may permit this and confirm the CCR6 
receptor is capable of functioning when expressed by Tregs. Flow based assays looking 
at adhesion and transmigration of cells across an endothelial layer would be beneficial 
as they more accurately mimic in vivo cell recruitment. Selective blocking of receptors 
and adhesion molecules would show whether the chemokine receptors are involved in 
integrin-mediated adhesion and transmigration, or potentially have another role such as 
guiding T cells once they are within the tissue, or functioning as adhesion molecules in 
their own right. 
 
In order to definitively prove the receptors are capable of facilitating T cell migration to 
RCC an in vivo model would be required. RENCA is a mouse renal cell carcinoma which 
has frequently been used as an in vivo model of RCC. In common with human RCC 
RENCA has infiltrating T cells and responds to IL-2 therapy. Studies on the mechanisms 
by which cytokines cause tumour regression have already shown that CXCR3-/- mice do 
not respond to IL-2 therapy. IL-2 increases CXCR3 expression on T cells, and their 
infiltration into the tumour is enhanced when CXCL9 is injected intra-tumourally (Pan et 
al. 2006). In addition tumour regression in the RENCA model caused by IL-12 
administration is dependent on CXCL9 and CXCL10 and blocking these chemokines 
reduced T cell infiltration of the tumour (Tannenbaum et al. 1998). It is likely that, at 
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least in terms of the CXCR3:ligand axis, RENCA mimics human tumours, as patients 
treated with IL-12 also have increased levels of CXCL9 and CXCL10 and increased T cell 
infiltration of their tumours (Bukowski et al. 1999). These experiments demonstrate the 
involvement of CXCR3 and its ligands in T cell recruitment to RCC in vivo. RENCA lung 
metastases have been shown to express CCL3 and CCL4 and T cells expressing CCR5 
have been shown to infiltrate them (Wu et al. 2008). Assuming the metastases have a 
similar profile to the primary tumour, this again suggests a strong similarity between 
murine and human RCC and may allow studies in RENCA to confirm the involvement of 
CCR5 in T cell trafficking. Experiments in RENCA using blocking antibodies and intra-
tumour ligand injection, or chemokine and chemokine receptor knockout mice, could 
confirm the involvement of other chemokine receptors, especially as it is possible to 
track infused cells in this model. 
 
Another approach could be to use a xenograft, as these have been shown to maintain a 
similar morphology to the tumours in RCC patients (Wang et al. 2010a). In addition 
patient T cells can then be used in the mouse model to study their function. 
 
These experiments are particularly desirable in the light of the limitation of our assays 
in that we could not use the Bonferroni correction on our data due to the large number 
of comparisons that were being made. This work has already gone some way to test the 
hypotheses regarding which receptors are involved in T cell infiltration of RCC by 
examining tumour tissue for the relevant ligands and demonstrating the infiltration of 
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receptor positive lymphocytes by IHC. However in vivo work would give further proof of 
the involvement of these receptors migration to the tumour. 
 
Ultimately however, the most relevant setting in which to study T cell migration into 
RCC is within the context of an adoptive T cell therapy trial, where T cells prepared for 
infusion could be analysed for their homing phenotype (or be manipulated to express a 
given phenotype), labelled (for example with Indium111 (Meidenbauer et al. 2003)) and 
then tracked in vivo. If tumour biopsy material is then taken post-infusion, it would be 
possible to check for the presence of the infused cells at this site, as well as determining 
their functional status. 
 
It would be interesting to further investigate the involvement of Tregs within RCC. If 
further samples corroborated the preliminary data that Tregs infiltrate tumour nests 
more effectively than effector T cells, elucidating the mechanisms by which they do this 
could help both block Treg recruitment and enhance the infiltration of beneficial T cells.  
 
Further studies using blocking antibodies and transwells could determine which 
mechanisms the Tregs are using in immune suppression and whether they involve cell-
cell contact. These observations could also be confirmed using animal models. Blocking 
the PD-1:ligand interaction when stimulating TIL in the presence of PD-L1 expressing 
RCC cells could also more accurately determine the degree of T cell suppression or 
exhaustion conferred by a PD-1:PD-L1 interaction in the tumour. 
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Of course, it is not only T cells that infiltrate RCC and have an effect on the tumour 
environment. NK cells are enriched in RCC TIL compared to RCC patients’ PBMC, and 
compared to TIL from colorectal and breast cancer (Cozar et al. 2005), and have 
cytotoxic potential in freshly isolated TIL (Schleypen et al. 2003). However their 
mechanism of homing to RCC is unknown and understanding how to improve their 
infiltration and anti-tumour activity could benefit patients. Macrophages and myeloid 
derived suppressor cells (MDSCs) also migrate to RCC and have a deleterious effect as 
they inhibit effector T cell function (Daurkin et al. 2011;Ochoa et al. 2007). Therefore 
preventing their recruitment could augment the anti-tumour response. Dendritic cells 
also infiltrate the tumour, however they are thought to be unable to mature properly at 
the tumour site (Figel et al. 2011;Gigante et al. 2009;Middel et al. 2010). Improving DC 
maturation and function may inhibit the down-regulation of effector T cell function seen 
when immature DCs interact with T cells. 
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Appendix A. Correlation calculations performed 
Table 1. Correlation of the percentage of TIL expressing chemokine receptors and adhesion molecules, with the Fuhrman grade of the tumour 
 
CCR1 CCR2 CCR3 CCR4 CCR5 CCR6 CCR7 CCR8 CCR9 CCR10 CXCR1 CXCR2 CXCR3 CXCR4 CXCR5 CXCR6 CXCR7 XCR1 CX3CR1 
r 
0.359 0.549 -0.234 -0.176 0.480 0.337 0.091 0.271 -0.090 -0.075 -0.579 -0.692 0.143 0.078 0.310 0.247 -0.392 -0.099 -0.496 
p-
value 0.430 0.259 0.516 0.627 0.160 0.341 0.802 0.516 0.847 0.874 0.228 0.085 0.694 0.831 0.499 0.492 0.385 0.833 0.212 
 
 
cd11B/MAC1 CLA CD62L LFA-1 PSGL-1 VLA-4 BL-1 
r 
0.179 -0.894 0.123 -0.112 0.031 0.738 0.000 
p-value 
0.701 0.061 0.816 0.858 0.954 0.155 1.000 
 
Table 2. Correlation calculations performed looking at the correlation between TIL phenotype and clinical characteristics, percentage of Tregs infiltrating 
tumour samples and the ratio of the percentage of Tregs in TIL: percentage of Tregs in PBMC 
Correlation with Fuhrman Grade, r (p-value) 
 
Correlation with % Tregs, r (p-value) 
 
Correlation with ratio % Tregs in TIL: % Tregs in PBMC, 
 r (p-value) 
% DPs -0.2849 (0.2678) 
 
CD107a CD8 0.03571 (0.9635) 
 
CD107a CD4 0.0 (1.0365) 
% Tregs 0.7096 (0.0097) 
 
CD27 CD4 0.7748 (0.0480) 
 
CD107a CD8 -0.2143 (0.6615) 
CCR5 0.3233 (0.0761) 
 
CD27 CD8 0.5943 (0.1667) 
 
CD27 CD4 0.2523 (0.5943) 
CCR6 -0.03945 (0.8360) 
 
CTLA-4 CD4 0.7208 (0.0881) 
 
CD27 CD8 0.1802(0.7131) 
CD107a CD4 0.2058 (0.6615) 
 
CTLA-4 CD8 0.3964 (0.3956) 
 
CTLA-4 CD4 -0.7857 (0.0480) 
CD107a CD8 0.05614 (0.9063) 
 
CTLA-4 Treg 0.3964 (0.3956) 
 
CTLA-4 CD8 -0.8571 (0.0238) 
CD27 CD4 0.7094 (0.0576) 
 
IFNg CD4 -0.174 (0.0520) 
 
CTLA-4 Treg 0.5946 (0.1667) 
CD27 CD8 0.2518 (0.5364) 
 
IFNg CD8 -0.1794 (0.5061) 
 
IFNg CD4 -0.5679 (0.0272) 
CD27 Treg 0.1147 (0.9500) 
 
IL-2 CD4 0.03922 (0.8812) 
 
IFNg CD8 -0.5017 (0.0537) 
CTLA-4 CD4 0.4619 (0.1786) 
 
IL-2 CD8 0.009804 (0.9702) 
 
IL-2 CD4 -0.4735 (0.0639) 
CTLA-4 CD8 -0.1530 (0.6821) 
 
PD-1 CD4 -0.6571 (0.1750) 
 
IL-2 CD8 -0.3412 (0.1959) 
CTLA-4 Treg 0.0 (1.0000) 
 
PD-1 CD8 -0.5429 (0.2972) 
 
PD-1 CD4 -0.3143 (0.5639) 
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Correlation with Fuhrman Grade, r (p-value) 
 
Correlation with % Tregs, r (p-value) 
 
Correlation with ratio % Tregs in TIL: % Tregs in PBMC, 
 r (p-value) 
CXCR3 0.3265 (0.0682) 
 
PD-1 Treg -0.4286 (0.4194) 
 
PD-1 CD8 -0.1429 (0.8028) 
CXCR6 0.4560 (0.4103) 
 
TNFa CD4 -0.2206 (0.3949) 
 
PD-1 Treg -0.5429 (0.2972) 
IFNg CD4 0.122 (0.706) 
 
TNFa CD8 -0.2824 (0.2893) 
 
TNFa CD4 -0.5794 (0.0187) 
IFNg CD8 0.118 (0.714) 
    
TNFa CD8 -0.4571 (0.0867) 
IL-2 CD4 0.2994 (0.3445) 
      
IL-2 CD8 0.3991 (0.1987) 
      
PD-1 CD4 0.09356  (0.8397) 
      
PD-1 CD8 -0.1684 (0.7131) 
      
PD-1 Treg -0.775 (0.333) 
      
TNFa CD4 -0.02217 (0.9455) 
      
TNFa CD8 -0.2439 (0.4449) 
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Appendix B. Correlation of lab findings with grade. 
Table 1. Chemokine receptor expression on T cells from RCC TIL samples, and clinical characteristics 
Sample characteristics Percentage of CD45RA
-
LIVE T cells expression chemokine receptor, corrected for non-specific staining using concentration matched isotype controls 
Grade Tumour type CCR1 CCR2 CCR3 CCR4 CCR5 CCR6 CCR7 CCR8 CCR9 CCR10 CXCR1 CXCR2 CXCR3 CXCR4 CXCR5 CXCR6 CXCR7 XCR1 CX3CR1 
2 Clear cell 9.3% 3.0% 12.1% 0.7% 28.8% 9.4% 4.8% 2.4% -0.1% 9.7%   1.5% 6.0% 44.4% 4.1% 14.5% -0.5% 4.3% 2.0% 
2 clear cell 7.3% 8.7% 5.3% 2.0% 46.1% 11.3% 6.0% -0.8% 12.8% 0.1% 21.7% 14.2% 0.7% 18.2% 6.8% 9.5% 9.8% -0.2% 4.9% 
2 Clear Cell 5.3% 0.7% 10.5% 3.0% 44.2% 7.6% 13.9% 6.5% -0.3% 4.6% 4.3% -0.3% 44.3% 21.8% 1.3% 14.1% 0.1% 3.2% 3.3% 
2 Clear cell 2.5% -2.1% 4.2% 2.4% 52.7% 9.2% -0.5% -0.7% 1.7% -3.1% 1.5% 1.1% 28.2% 44.4% -1.2% 28.5% 0.7% -0.7% 7.0% 
2 Clear cell         26.63               44.2     33.07       
2 Clear cell         39.87               63.68     66.45       
3 Chromophobe         66.21               21.98     28.192       
3 Clear cell 9.6% 4.6% 5.4% -0.8% 35.3% 7.1% 3.9% -5.2% 13.5% 9.6% 7.6% 3.3% 11.5% 36.2% 12.4% 35.8% 12.3% 14.3% 7.1% 
3 Clear cell     25.8% 3.5% 81.0% 19.3% 10.1%           55.8% 58.8%   23.4%       
3 Clear cell     3.5% 11.9% 56.8% 19.0% 5.2% 1.9%         36.9% 45.2%   21.4%     12.1% 
3 Clear cell         6427.0%               6529.0%     2314.0%       
3 Clear cell         4340.0%               4508.0%     4005.0%       
3 nd 2.3% 0.9% 3.1% 1.3% 27.6% 3.5% 1.7% -0.7% 0.5% -1.0% -0.4% -0.7% 4.6% 19.6% 0.8% -1.0% -0.7% -0.8% 8.6% 
4 Clear cell     13.7% 5.2% 68.5% 27.6% 11.9%           34.4% 63.2%   46.3%       
4 Papillary         28.72               12.37     27.53       
4 translocation 0.0572 0.0267 0.0116 0.0139 0.4408 0.0764 0.0436 -0.0083 -0.0066 -0.0189 0.0194 -0.0141 0.03 0.03 0.02 0.159 -0.0051 -0.0097 0.0359 
 
Sample characteristics Median fluorescence intensity of chemokine receptor expression, corrected for non-specific staining using concentration matched isotype controls 
Grade   CCR1 CCR2 CCR3 CCR4 CCR5 CCR6 CCR7 CCR8 CCR9 CCR10 CXCR1 CXCR2 CXCR3 CXCR4 CXCR5 CXCR6 CXCR7 XCR1 CX3CR1 
2 Clear cell 157 0 30 108 1920 0 0 0 4 544 
 
172 469 1195 0 3 59 217 155 
2 clear cell 114 133 133 104 987 185 142 0 255 0 379 207 56 371 121 218 249 0 212 
2 Clear Cell 110 76 50 86 1529 275 69 0 0 0 55 0 906 510 24 277 15 9 43 
2 Clear cell 65 0 200 76 1962 183 0 0 98 0 150 105 727 1519 0 639 96 0 275 
2 Clear cell         591               1717     321       
2 Clear cell         3491               4640     611       
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Sample characteristics Median fluorescence intensity of chemokine receptor expression, corrected for non-specific staining using concentration matched isotype controls 
3 Chromophobe         4275               1919     419       
3 Clear cell 647 143 81 447 2346 319 17 0 599 422 245 0 1762 2647 642 2567 399 607 109 
3 Clear cell 
  
278 19 1809 85 39 
     
838 799 
 
80 
   
3 Clear cell 
  
11 32 847 30 10 8 
    
139 327 
 
48 
  
77 
3 Clear cell         487               1143     63       
3 Clear cell         167               174     77       
3 nd 0 
 
25 43 1881 10 9 0 15 0 0 0 115 397 0 0 0 0 87 
4 Clear cell 
  
183 98 2371 458 120 
     
622 1428 
 
992 
   
4 Papillary         1260               1425     340       
4 translocation 198.54 126.8 0 86.08 2131.03 256.78 2.92 0 0 0 0 0 759.17 622.41 47.97 371.16 0 0 51.85 
Cells are shaded according to the proportion of chemokine receptor positive cells or degree of staining as determined by median fluorescence intensity. 
White shading indicates the lowest levels of staining, red, the highest. 
Table 2. Effector cytokine production by T cells from RCC TIL samples as measured by intracellular cytokine staining after 5 hours stimulation with PMA and 
ionomycin, and clinical characteristics 
Sample characteristics 
Mean percentage of T cells producing effector cytokines, corrected for non-specific staining using concentration 
matched isotype controls 
Grade 
ratio % Tregs in TIL: % 
Tregs in PBMC All cytokine production IFNγ production IL-2 production TNF-α production 
2 2.08 14.96 2.38 3.94 38.57 
2 ND 12.05 5.12 1.09 29.94 
2 1.05 56.92 64.73 33.84 72.21 
2 43.13 1.00 0.33 1.15 1.53 
2 2.35 7.28 ND 4.42 11.75 
2 0.67 33.97 35.74 25.25 40.94 
2 0.73 32.19 31.06 5.52 60.01 
2 1.19 38.19 55.52 15.17 49.58 
3 5.49 2.46 1.57 1.54 4.28 
3 1.12 2.71 3.14 1.44 3.57 
3 3.16 26.03 34.81 10.52 32.76 
3 1.65 6.55 8.99 0.95 9.70 
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Sample characteristics 
Mean percentage of T cells producing effector cytokines, corrected for non-specific staining using concentration 
matched isotype controls 
4 1.80 44.75 33.35 32.19 68.73 
4 0.96 22.38 22.85 15.89 28.41 
4 1.57 51.07 58.26 25.71 69.23 
4 3.30 12.78 13.73 4.53 20.08 
4 1.40 14.41 12.42 9.23 21.58 
4 4.40 23.40 22.46 15.39 32.35 
ND, no data. Cells are shaded according to the proportion of cytokine-producing T cells. White shading indicates the lowest levels of staining, red, the highest. 
 
 
